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Minimally invasive procedures for prostate cancer diagnosis and treatment, including
biopsy and brachytherapy, rely on medical imaging such as two-dimensional (2D) and
three-dimensional (3D) transrectal ultrasound (TRUS) and magnetic resonance imaging
(MRI) for critical tasks such as target definition and diagnosis, treatment guidance, and
treatment planning. Use of these imaging modalities introduces challenges including timeconsuming manual prostate segmentation, poor needle tip visualization, and variable MRUS cognitive fusion. The objective of this thesis was to develop, validate, and implement
software- and hardware-based tools specifically designed for minimally invasive prostate
cancer procedures to overcome these challenges.
First, a deep learning-based automatic 3D TRUS prostate segmentation algorithm
was developed and evaluated using a diverse dataset of clinical images acquired during
prostate biopsy and brachytherapy procedures. The algorithm significantly outperformed
state-of-the-art fully 3D CNNs trained using the same dataset while a segmentation time
of 0.62 s demonstrated a significant reduction compared to manual segmentation. Next, the
impact of dataset size, image quality, and image type on segmentation performance using
this algorithm was examined. Using smaller training datasets, segmentation accuracy was
shown to plateau with as little as 1000 training images, supporting the use of deep learning
approaches even when data is scarce. The development of an image quality grading scale
specific to 3D TRUS images will allow for easier comparison between algorithms trained
using different datasets. Third, a power Doppler (PD) US-based needle tip localization
method was developed and validated in both phantom and clinical cases, demonstrating
reduced tip error and variation for obstructed needles compared to conventional US.
Finally, a surface-based MRI-3D TRUS deformable image registration algorithm was
developed and implemented clinically, demonstrating improved registration accuracy
compared to manual rigid registration and reduced variation compared to the current
clinical standard of physician cognitive fusion. These generalizable and easy-to-implement
tools have the potential to improve workflow efficiency and accuracy for minimally
invasive prostate procedures.
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La A die ce

Prostate cancer is the most common non-skin cancer in Canadian men. The management
of prostate cancer often includes the use of needles, such as in diagnosis to extract tissue
samples and test for the presence of cancer, known as biopsy, and in treatment to deliver
radiation from inside the body, known as brachytherapy. These procedures rely on medical
imaging for critical tasks including target definition, creating patient-specific treatment
plans, and accurately guiding needles into the body. This also introduces challenges as
time-consuming and difficult manual tasks must be completed in the operating room such
as accurately identifying the prostate and needle tip locations and mentally combining
information from multiple imaging types. This thesis is focused on developing innovative
software and hardware solutions to overcome these challenges and improve treatment
efficiency and accuracy.
First, artificial intelligence was used to train an algorithm to locate the prostate
boundary (or segment ) in three-dimensional ultrasound images in under 1 second,
demonstrating equal segmentation accuracy and greatly reducing time compared to manual
segmentation, which can take up to 10 minutes. Next, this same algorithm was tested using
smaller datasets, demonstrating equivalent performance with as little as 7% of the full
dataset, potentially increasing access to artificial intelligence methods even if data is
scarce. Third, an alternative ultrasound technique known as power Doppler ultrasound was
used to improve needle tip visibility during the live brachytherapy procedure,
demonstrating reduced variability compared to standard ultrasound. Finally, an automated
image registration algorithm was developed to overlay magnetic resonance images on
ultrasound images, facilitating the targeting of the previously invisible tumour in the
operating room.
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This thesis is an integration of four original research articles which are either published in
peer-reviewed scientific journals or are submitted and under peer-review. As the first
author of each of these manuscripts, I had a significant role in all aspects of the work
including the proposal of research questions, experimental design, data acquisition, data
analysis, statistics, manuscript drafting, and manuscript revision. All authors contributed
editorial feedback prior to manuscript submission. The specific contributions of all coauthors for each manuscript are described below.
Chapter 2 is an original research article entitled Automatic prostate segmentation
using deep learning on clinically diverse 3D transrectal ultrasound images which was
published in Medical Physics in 2020. This manuscript was co-first authored by Nathan
Orlando and Derek J. Gillies with co-authorship from Igor Gyacskov, Cesare Romagnoli,
David D Souza, and Aaron Fenster. Derek Gillies and I equally split contributions for
experimental design, data collection and curation, development of image analysis software,
3D CNN implementation (model training, optimization, validation, and testing), data
analysis, interpretation, and statistics, and manuscript drafting, editing, and revising. Igor
Gyacskov completed all manual prostate segmentations and was responsible for the 2D UNet implementation (model training, optimization, validation, and testing) and 3D
reconstruction algorithm development. Cesare Romagnoli (now deceased) and David
D Souza were the Radiologist and Radiation Oncologist, respectively, who assisted with
clinical 3D TRUS image acquisition. Aaron Fenster contributed to the conception and
design of the study and supervised the data interpretation and manuscript drafting and
revision.
Chapter 3 is an original research article entitled Effect of dataset size, image quality,
and image type on deep learning-based automatic prostate segmentation in 3D ultrasound
which was published in Physics in Medicine & Biology in 2022. This manuscript was coauthored by Nathan Orlando, Igor Gyacskov, Derek J. Gillies, Fumin Guo, Cesare
Romagnoli, David D Souza, Derek W. Cool, Douglas A. Hoover, and Aaron Fenster. My
contributions included experimental design, dataset collection and curation, image and data
iv

analysis, data interpretation and statistics, and manuscript drafting and revision, in addition
to assisting with the U-Net++ implementation. Igor Gyacskov was responsible for 2D
neural network implementation and 3D reconstruction algorithm development. Derek J.
Gillies assisted in the development of segmentation evaluation software. Fumin Guo
provided the U-Net++ python code and assisted with implementation. Cesare Romagnoli
(now deceased) and David D Souza were the Radiologist and Radiation Oncologist,
respectively, who assisted with clinical 3D TRUS image acquisition. Derek W. Cool was
the interventional radiologist who developed the 3D TRUS image quality grading scale
and subsequently graded the testing dataset images. Douglas A. Hoover and Aaron Fenster
contributed to the conception and design of the study and supervised the data interpretation
and manuscript drafting and revision.
Chapter 4 is an original research article entitled A power Doppler ultrasound method
for improving intraoperative needle tip localization in interstitial prostate brachytherapy ,
which was submitted for publication in Medical Physics on March 28, 2022 and is currently
under peer-review. This manuscript was co-authored by Nathan Orlando, Jonatan Snir,
Kevin Barker, David D Souza, Vikram Velker, Lucas C. Mendez, Aaron Fenster, and
Douglas A. Hoover. My specific responsibilities included contributing to the initial
conception of the power Doppler (PD) US method and oscillator design in addition to
experimental design, phantom construction and image acquisition, computed tomographyUS rigid registration and evaluation, oscillator operation and needle tip localization in
phantom and clinical brachytherapy procedures, data analysis, interpretation, and statistics,
and manuscript drafting. Jonatan Snir contributed to the initial conception of the PD US
method and oscillator design. Kevin Barker was responsible for the wireless oscillator
design and manufacture. David D Souza, Vikram Velker, and Lucas C. Mendez were
physicians who operated the mechanical oscillator as part of the prospective feasibility
clinical trial in addition to grading needle tip visibility. Aaron Fenster and Douglas A.
Hoover contributed to the conception and design of the study and supervised the data
interpretation and manuscript drafting. In addition, Douglas A. Hoover assisted with
phantom experimentation and clinical validation including needle tip localization, clinical
software operation, and needle tip visibility grading.
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Chapter 5 is an original research article entitled Validation of a surface-based
deformable MRI-3D ultrasound image registration algorithm towards clinical
implementation for interstitial prostate brachytherapy , which was submitted for
publication in Brachytherapy on June 15, 2022. This manuscript is co-authored by Nathan
Orlando, Chandima Edirisinghe, Igor Gyacskov, Jason Vickress, Robin Sachdeva, Jose A.
Gomez, David D Souza, Vikram Velker, Lucas C. Mendez, Glenn Bauman, Aaron Fenster,
and Douglas A. Hoover. My contributions included phantom image acquisition and
retrospective clinical data collection and curation. I was responsible for the validation and
operation of the deformable image registration algorithm, including intraoperative
implementation, as well as for image analysis to assess registration accuracy, organ
contouring in phantom, manual landmark localization, data analysis, interpretation, and
statistics, and manuscript drafting. Chandima Edirisinghe was responsible for the
registration algorithm development and implementation. Igor Gyacskov assisted with the
initial design of the registration algorithm. Jason Vickress assisted with study design
registration accuracy evaluation strategy. Robin Sachdeva was a part of the clinical team
which facilitated implementation of our algorithm in a prospective clinical trial. Jose A.
Gomez was the pathologist who completed histological evaluation of the targeted biopsy
tissue sample. David D Souza, Vikram Velker, and Lucas C. Mendez were the physicians
who completed the manual MR-US cognitive fusions as part of the retrospective clinical
validation. In addition, Lucas C. Mendez completed all contouring for the retrospective
and prospective clinical cases, and was the co-principal investigator along with Glenn
Bauman for the prospective clinical trial that used our algorithm was implemented in.
Aaron Fenster and Douglas A. Hoover contributed to the conception and design of the
study and supervised the data interpretation and manuscript drafting. In addition, Douglas
A. Hoover completed manual rigid registrations and assisted with clinical implementation.
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Prostate cancer is the third highest cause of cancer death among Canadian men.1 Prostate
cancer management, including diagnosis and treatment, commonly utilizes minimally
invasive procedures such as biopsy and brachytherapy. These procedures rely on medical
imaging, particularly ultrasound and magnetic resonance imaging, for target definition and
diagnosis, treatment guidance, and treatment planning. Use of these imaging methods for
minimally invasive procedures also introduces challenges including time-consuming
manual prostate segmentation, difficulty localizing implanted needle tips, and variable
cognitive fusion of magnetic resonance and ultrasound images. This thesis is focused on
overcoming these challenges through the development, validation, and implementation of
software- and hardware-based tools designed specifically for minimally invasive prostate
cancer procedures.
Chapter 1 provides foundational background knowledge including a description of
prostate cancer epidemiology (1.1), an overview of current prostate cancer diagnosis (1.2)
and treatment (1.3) techniques, and a description of how medical imaging is used in
prostate cancer disease management (1.4). The remaining sections motivate the work in
Chapters 2-5 through a description of current challenges in minimally invasive prostate
procedures (1.5) and an outline of the thesis including specific objectives for each study
(1.6).

1.1

P
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Prostate cancer is the most commonly diagnosed non-cutaneous cancer in Canadian men,
with 24,000 cases or 20.3% of all new cancer cases in men projected for 2021.1 This
corresponds to 1 in 8 Canadian males expected to be diagnosed with prostate cancer in
their lifetime.1 Worldwide, the incidence of prostate cancer is second only to lung cancer
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accounting for 13.5% of new cancer cases in men and an estimated 1.3 million cases in
2018.2 Prostate cancer incidence increases as age increases with an average age of 66 years
at initial diagnosis.3
In contrast to the high incidence rate of prostate cancer, the mortality rate is
considerably lower with only 1 in 29 Canadian men expected to die from the disease.
Prostate cancer is the third highest cause of cancer death in Canadian men with an estimated
10.1% of total cancer deaths behind only lung and colorectal cancer.1 Prostate cancer
represents an even lower share of mortality rate due to cancer in men worldwide at only
6.7% in 2018.2 Reduced mortality rates may be due to earlier detection with the prevalence
of prostate specific antigen (PSA) testing and improved management of the disease after
detection.4 Ultimately, men diagnosed with prostate cancer will most likely die of other
causes.5
The prostate is an accessory gland in the male reproductive system that lies inferior
to the bladder and anterior to the rectum, with the urethra passing through it.6 The prostate
has been defined using a zonal structure,7 with an anterior nonglandular zone, transitional
zone surrounding the urethra, central zone surrounding the ejaculatory ducts, and a large
peripheral zone, collectively composed of 30 to 40 individual glands lined with epithelial
cells.6 Secretions from the prostate and neighbouring seminal vesicles contribute to the
formation of semen, with the prostate contributing nutrients, enzymes, and buffers.6,8 Due
to its glandular structure, most prostate tumours are adenocarcinomas, occurring primarily
in the peripheral zone, while benign prostatic hyperplasia (BPH) or nonmalignant
overgrowth occurs primarily in the transitional zone.9 The presence of prostate cancer may
cause adverse symptoms including blood in the urine, frequent urination, and pain.10
As the prostate is a non-vital accessory gland, the 5-year survival rate for men
diagnosed with prostate cancer is high at approximately 98% in the USA,11 with the
outcome of prostate cancer driven largely by metastases, or the spread of cancer to nearby
organs.12 The most common sites for prostate cancer metastasis include bone, lung, liver,
pleura, and adrenals, with more than 30% of prostate cancer patients expected to harbour
metastatic tumours at the time of death.12 This stresses the importance of early detection
for prostate cancer prognosis and the facilitation of safe increases in treatment
aggressiveness for high-risk disease.
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Prostate cancer diagnosis and staging are required prior to deciding on a course of
treatment. The diagnosis pathway includes initial screening (1.2.1), definitive diagnosis
with biopsy (1.2.2), and disease staging (1.2.3).

1.2.1

Initial Screening Methods

Initial prostate cancer screening is typically completed using two techniques in
combination: digital rectal examination (DRE) and prostate specific antigen (PSA) blood
test.13
The DRE procedure involves the physician palpating the prostate through the rectal
wall using a finger inserted into the patient s rectum. A tumorous prostate may feel hard
or asymmetric relative to healthy prostate and lumps may be present on the prostate surface,
all of which may be felt by the physician during a DRE.6 The efficacy of DRE has not been
definitively demonstrated, with Schröder et al. showing that DRE alone could detect 55.8%
of confirmed cancers and was strongly dependent on PSA level with low performance in
low PSA ranges (< 4.0 ng/mL).14 As such, an abnormal DRE examination is typically
paired with in subsequent PSA blood testing as well as a potential biopsy.
A blood test to determine PSA levels is a common screening technique for prostate
cancer. PSA is a protein produced exclusively by epithelial cells in the prostate and can be
detected in a blood sample.15 PSA is produced in both healthy and cancerous prostates,
with elevated concentrations of PSA observed in 25 to 92% of prostate cancer patients
depending on prostate size.16 PSA is typically measured in nanograms (ng) per millilitre
(mL), with PSA concentration above 4.0 ng/mL traditionally indicating suspicions of
prostate cancer.17 One of the difficulties with PSA screening is the elevated levels of PSA
observed in non-cancerous prostate conditions, such as in 30 to 50% of benign prostatic
hyperplasia patients, limiting the specificity of the test.16 While PSA testing is currently
the most sensitive biomarker for monitoring prostate cancer, its utility in screening and
diagnosis is not clear. In particular, the intensification of PSA testing has led to a dramatic
increase in the diagnosis of prostate cancer since its introduction, peaking in 1993 in
Canada,1 resulting in the identification of low-risk cancer that may not pose a risk to the
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patient. This has led to the overdiagnosis and overtreatment of prostate cancer, exposing
patients to the adverse side effects of biopsy or radical treatment without clearly defined
benefit. To combat the trend of overdiagnosis in prostate cancer, the US Preventive
Services Task Force advised against PSA screening for men over 65 and since 2014, PSA
screening is no longer suggested for asymptomatic men of any age, with Canada adopting
similar guidelines in 2014.18,19
Currently, the decision to use asymptomatic PSA screening is an individual choice
based on discussion with a physician. Screening is typically used in men suspected of
having prostate cancer, with optimal results obtained using a combination of DRE and PSA
testing, with transrectal ultrasound imaging to detect hyperechoic lesions included in
certain cases as well.14,16 Abnormal DRE, abnormal ultrasound imaging results, PSA levels
greater than 4.0 ng/mL, and clinical suspicion of prostate cancer are indications for prostate
biopsy to definitively confirm the presence of cancer.
PSA testing is also routinely employed after therapy to assess treatment outcome,
specifically looking for rising PSA levels, known as biochemical recurrence, which may
be a predictor of subsequent cancer recurrence and/or metastasis.20 Biochemical diseasefree survival is a common metric reported for prostate cancer treatment assessment in
clinical trials, defined as patient survival time with little to no rise in PSA levels and no
evidence of local recurrence or global metastasis.

1.2.2

Prostate Biopsy

Prostate biopsy is the gold standard for definitive diagnosis of prostate cancer after
suspicions arise during screening.21 Core needle biopsy procedures involve the removal of
small samples, or so-called cores, of prostate tissue throughout the gland using a hollow
needle inserted into through the rectum or perineum. Core samples are stained and analyzed
under microscope by a pathologist to determine if cancer cells are present. Biopsy needle
insertion is typically guided by transrectal ultrasound (TRUS) imaging, offering
visualization of the needle as its inserted into the prostate. The selection of core location
and number of cores is variable between biopsy techniques.
The original gold standard prostate biopsy method used the sextant technique, a
systematic approach where six cores were extracted from the base, middle, and apex of the
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prostate.22 Levine et al. demonstrated that the systematic sextant technique had false
negative rates of approximately 30%, meaning patients with prostate cancer were
improperly diagnosed as cancer-free in 30% of biopsies.23 To address this limitation and
decrease the false negative rate, increasing the number of biopsy cores to 8 or 11 was
proposed, demonstrating increased detection rates.24,25 The completion of two consecutive
sextant biopsies in the same procedure was also shown to increase the number of cancer
detected by 30%.23 Due to the increase number of core samples removed from the prostate,
these approaches also increased the patient burden. Alternative approaches have proposed
targeted biopsies using imaging. TRUS approaches targeting hyperechoic or hypoechoic
regions in addition to the standard sextant biopsy locations demonstrated increased
sensitivity.26 More recently, magnetic resonance imaging (MRI) targeted biopsy methods
have been proposed,27 and will be described in further detail in section 1.4.3.
Regardless of the biopsy technique used, the pathology report generated based on
the extracted samples is required for prostate cancer staging.

1.2.3

Prostate Cancer Staging

As prostate cancer is a heterogenous disease,9 prostate cancer staging to determine the
cancer extent and aggressiveness is required to determine the appropriate treatment
response. Prostate cancer staging and risk assessment most commonly includes
consideration of Gleason score,28 PSA level,16 and TNM-stage.29
Gleason score is determined based on the histologic arrangement of cancer cells in
H&E stained prostate tissue slides assessed under light microscopy.28,30 The Gleason
grading system defines five grades, labelled 1 through 5, based on the differentiation in the
pattern of growth of the tumour compared to healthy prostate cells. Prostate cancer cells
are less differentiated than healthy prostate cells, and this differentiation scales with cancer
aggressiveness. The Gleason score is then reported as the most common or primary pattern
grade plus the second most common pattern grade, thus ranging from 2-10. If only one
pattern is present, the grade is multiplied by two to give the Gleason score. For example, if
the predominant grade was 3 with a second most common grade of 4, the Gleason score
would be 7, alternatively reported as 3+4.
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PSA concentration in the patient s blood, as described in section 1.2.1, is also
included in assessment of risk level. PSA levels less than 10 ng/mL are considered low
risk, PSA levels between 10 and 20 ng/mL are considered intermediate risk, and PSA levels
above 20 ng/mL are considered high risk.31
The TNM system for cancer staging, published by the Union for International
Cancer Control, is one of the most common systems for classification of malignant
tumours.29 This system characterizes the extent of the cancer in three categories. First, the
extent of the primary tumour (T), second, whether the cancer has spread to nearby lymph
nodes (N), and third, whether the cancer has metastasized to other parts of the body (M).
The T-category ranges from 1 to 4 as primary tumour extent increases, while N- and Tcategory are yes or no categories, presented as 1 or 0, respectively. TNM characterization
along with Gleason grade and PSA level are also used to define the overall stage of prostate
cancer, ranging from I through IV, with the higher stage denoting higher spread of cancer.29
Overall risk assessment of prostate cancer considers all available diagnostic
information including Gleason score, PSA level, and TNM-stage, as defined by the
National Comprehensive Cancer Network (NCCN).32 The defined risk levels stratify
patients into either very low risk, low risk, intermediate risk, or high risk based on cancer
aggressiveness and risk of early mortality. Optimal treatment courses differ depending on
risk level assessment for each patient, making cancer staging a critical component of the
treatment process. Treatment options will be described in detail in the following section.

1.3
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As described in section 1.2.3, prostate cancer risk level plays a critical role in deciding the
optimal course of treatment. This may include a combination of surgery (1.3.1), systemic
treatments (1.3.2), radiation therapy (1.3.3), or focal therapy (1.3.4), all of which are
described in detail in this section. The widespread use of PSA testing has led to increased
prostate cancer diagnosis rates, and thus overtreatment of patients where the cancer poses
little risk to early mortality.33
Corresponding to the need to reduce overtreatment of prostate cancer, the
witholding of radical treatment is a common method of disease management for many low-
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risk cases, so-called active surveillance.34,35 This allows patients to avoid the adverse side
effects of radical therapy until the potential benefits of treatment outweigh the side effects.
Active surveillance involves the careful monitoring of prostate cancer patients using
diagnostic tests such as imaging, PSA testing, and biopsies, deferring treatment until the
first signs of higher-risk disease.35 This relies on the asumption that the time between initial
diagnosis and disease progression is long for low-risk disease.36 Criteria for active
surveillance is variable, but commonly includes patients with Gleason score less than 6,
clinical stage less than T2a, and PSA levels less than 10 ng/mL.34 Based on this criteria, up
to 36% of men diagnosed with prostate cancer may be suitable for active surveillance.34 At
the first signs of higher-risk disease, radical treatment can be initiated using techniques
described in sections 1.3.1-1.3.4. In contrast, for elder men diagnosed with prostate cancer,
so-called watchful waiting is common, where treatment is deferred without diagnostic
monitoring until symptoms develop at which point palliative treatment is initiated.35

1.3.1

Surgery

Surgery in the form of radical prostatectomy (RP) is a common treatment approach for
clinically organ-confined prostate cancer.37 RP involves the complete removal of the
prostate gland, and may include the removal of lymph nodes around the prostate gland if
there is suspicion of cancer spreading to the nodes. Retropubic RP, an open surgical
approach where an incision is made in the lower abdomen is the most common technique.38
Advances in RP surgical technique have since focused on increased nerve-sparing to
preserve patient urinary and erectile function.37
Laparoscopic RP has been proposed, demonstrating reduced operative and
postoperative morbidity as well as equivalent short-term outcomes compared to standard
retropubic RP.39 The difficulty of laparoscopic surgeries for inexperienced physicians has
prompted the development of robot-assisted laparoscopic surgeries utilizing high degreeof-freedom robots such as the da Vinci system that can mimic hand movements with high
accuracy.40 Although laparoscopic and robot-assisted RP may reduce blood loss resulting
from surgery, there is no evidence of the superiority of any surgical approach in terms of
oncologic outcome.37
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Survival outcomes following RP are good, with 5-year biochemical disease-free
survival of up to 92% for low-risk prostate cancer and 35% for high-risk prostate cancer.41
Severe toxicities associated with RP including erectile disfunction and incontinence can
result in decreased quality of life.42 Recent advances in radiotherapy have improved
oncologic outcome to levels comparable to radical prostatectomy for organ-confined
cancer, often with decreased severity of toxicities.43 As such, the treatment of localized
prostate cancer has shifted focus to radiation therapy and focal therapy approaches,
described in sections 1.3.3-1.3.4.

1.3.2

Systemic Treatments

Systemic therapy targeting the whole body is another prostate cancer treatment technique,
most commonly in the form of androgen deprivation therapy (ADT)44 or chemotherapy,45
often employed for advanced prostate cancer that has metastasized to other organs.
Androgens such as testosterone and dihydrotestosterone are made primarily by the
testicles and excess production can stimulate prostate cancer cells to grow. ADT aims to
lower androgen levels, depriving the prostate cancer cells which can cause the prostate
cancers to shrink or grow more slowly.46 Orchiectomy, the surgical removal of the testicles,
was the most common form of ADT, but was shown to have a large psychological burden
and thus has been rejected in favor of medical castration in recent years.47 Medical
castration involves the delivery of hormonal agents such as estrogens, antiandrogens, and
luteinizing hormone-releasing hormone (LHRH) agonists.47 While ADT is an effective
palliative treatment, it has several adverse side effects including decreased libido,
impotence, hot flashes, metabolic alterations, and changes in cognition and mood.46 Not all
cancers respond the same to ADT, so treatment of hormone-resistant prostate cancer is an
active area of study.48 In addition to palliative treatment for patients with advanced prostate
cancer, ADT has also been proposed as a neo-adjuvant therapy prior to radiation therapy
to shrink the cancer or after therapy if PSA levels rise.44
Chemotherapy involves the delivery of cytotoxic agents to kill cancer cells,
stopping further growth and preventing cell division. For the management of prostate
cancer, chemotherapy is commonly employed for palliative care of hormone-resistant
disease.45 The use of chemotherapy as an adjuvant and neoadjuvant treatment modality has
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been proposed.45 As with ADT, chemotherapy has several adverse side effects including
hair loss, loss of appetite, nausea, vomiting, diarrhea, and fatigue.

1.3.3

Radiation Therapy

Radiation therapy, also known as radiotherapy, relies on the delivery of high energy
photons or particles to destroy cancer cells. For photon-based radiation therapy, so-called
indirectly ionizing radiation, the incoming photons first interact with atoms in the patient s
body to produce charged particles, which can then damage the cancer cell s
deoxyribonucleic acid (DNA).49 In contrast, for particle-based or directly-ionizing
radiation therapy, charged particles such as electrons or protons are delivered, damaging
the DNA without requiring prior interactions. Charged particles damage DNA through
either direct action, where the charged particle interacts directly with the path of DNA to
damage the strands or base pairs, or indirect action, where the charged particles break down
water molecules near the DNA, producing free radicals which diffuse toward the DNA and
damage the strands or base pairs.49 DNA damage can be in the form of base damage or
strand breaks. Single-strand breaks in the sugar/phosphate DNA backbone due to damage
from charged particles can combine with single-strand breaks on the opposite side of the
DNA molecule, leading to double-strand breaks. The majority of DNA damage is repaired
by the cell but misrepair or incomplete repair can lead to chromosome aberrations, which
have been shown to correlate directly with cell survival.50
Radiotherapy treatment is typically fractionated, thus delivered over numerous
doses or fractions. The outcome of fractionated radiotherapy treatment is influenced by
five factors: cell repair of sublethal damage, redistribution through the cell cycle,
repopulation between fractions, reoxygenation of the tumour, and the inherent
radiosensitivity of the tissue in question, the so-called 5 R s of radiotherapy.51 Cell survival
after fractionated radiotherapy can be described using a linear quadratic model.52 The linear
alpha term represents the susceptibility to single-track damage, or the sensitivity at low
dose. The quadratic beta term represents the sensitivity to dual-track damage, which is
affected by dose rate and interim chromosome repair. The effectiveness of the fractionation
scheme can thus be evaluated using the tumour s alpha over beta ( / ) ratio, which
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describes the tissue susceptibility to different types of cell damage.53 The / ratio, with
units of Gy, is the dose at which the two cell killing effects, single-track and dual-track
damage, are equal, thus making it a measure of insensitivity to dose fractionation scheme.
Cells with a large / ratio are less sensitive to the effects of fractionation. Most healthy
tissue is classified as late reacting with / ratio on the order of 3 Gy, while most human
tumours are classified as early reacting tissue with / ratio on the order of 10 Gy.53 In this
case where the

/ ratio of the tumour is much larger than the healthy tissue, dose

hyperfractionation offers greater healthy tissue sparing and a high therapeutic index as the
tumour response is higher than the normal tissue response for a given dose. Prostate cancer
is unique as it has an estimated

/ ratio of 1.2-1.5 Gy, making it very sensitive to

fractionation.53 Thus, for prostate cancer treatment, since the / ratio of the tumour is
lower than the healthy tissue, hyperfractionation is not ideal as it spares the tumour more
than healthy tissue. This suggests that decreased fractionation, so-called hypofractionated
radiotherapy, may offer an improved therapeutic index for prostate cancer.
Radiotherapy is commonly classified into two approaches: external beam radiation
therapy and brachytherapy, described in detail in the following sections. Radiotherapy can
be delivered as a monotherapy but is commonly included as a follow-up to or concurrent
with other treatment modalities described in previous sections such as ADT.

1.3.3.1

External Beam Radiation Therapy

External beam radiation therapy (EBRT) involves the delivery of ionizing radiation from
a source outside of the body. Most commonly, the ionizing radiation source is high energy
(6 MV or higher) x-rays generated using a linear accelerator (linac). Linac-based EBRT
delivery utilizes several techniques to deliver dose to the prostate while limiting exposure
for nearby organs at risk (OAR) such as the rectum and bladder. This includes a rotating
gantry allowing radiation beams to enter the patient from different angles to reduce entry
dose as well as collimation in the form of moveable perpendicular jaws and highly
controllable multileaf collimators (MLCs) to ensure dose is conformal to the prostate. In
the pursuit of reducing dose delivered outside of the prostate, EBRT techniques for prostate
cancer treatment have progressed from three-dimensional conformal radiation therapy
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(3DCRT),54 where multiple stationary, shaped beams deliver radiation, to intensity
modulated radiation therapy (IMRT),55 with dynamic radiation beams that vary in intensity,
to volumetric modulated arc therapy (VMAT),56 where the MLC, gantry speed, and dose
rate are simultaneously varied while the linac gantry moves in a continuous arc. These
delivery techniques in addition to advances such as image-guided radiotherapy and
implanted target fiducials allow for highly conformal radiation treatment plans and have
helped limit dose to healthy tissue, reducing treatment toxicities.57 Traditionally, EBRT
dose fractionation for prostate cancer treatment involved the delivery of conventional 2 Gy
fractions for a total of 70-80 Gy dose, delivered five days per week over several weeks,
with higher total dose corresponding to superior disease control but also increased
toxicity.57 The standard of care has recently shifted towards the use of moderate
hypofractionation with 2.5-3 Gy fractions after several large randomized phase 3 trials
demonstrated similar efficacy and toxicity compared to conventional fractionation. 58

60

Acute adverse side effects following radiotherapy include urinary symptoms such as
increased urination frequency and nocturia in 28-50% of patients, and bowel symptoms
such as increased bowel movement frequency and loose stools in 9-26% of patients,
relative to baseline function.61 Survival outcomes following EBRT approximately match
or exceed survival following radical prostatectomy, with 5-year biochemical disease-free
survival of up to 90% for low-risk prostate cancer and 55% for high-risk prostate cancer.41
Radiotherapy, including EBRT is a recommended treatment option for localized
intermediate- and high-risk disease based on The American Society of Clinical Oncology
(ASCO) clinical practice guidelines.62 EBRT can be delivered as a monotherapy, but the
inclusion of concurrent ADT is suggested by the ASCO, in particular for high-risk
disease.62 Radiotherapy delivery to the prostatic bed after radical prostatectomy has been
shown to reduce the risk of cancer recurrence in patients with aggressive prostate cancer,
while also resulting in increased adverse side effects.63
As described in the previous section, the standard 2 Gy fractionation scheme may
not be optimal for prostate cancer treatment due to the low

/ ratio. Hypofractionated

EBRT has been suggested and may offer an improved therapeutic index. Hypofractionated
EBRT includes moderate fractionation with fraction size between 2.4-3.4 Gy and ultrahypofractionation, also known as stereotactic body radiation therapy (SBRT), with fraction
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size greater than 5 Gy.64 Several phase 3 trials have shown that moderate hypofractionation
offers similar efficacy and toxicity compared to standard fractionation.58,59 Results of the
phase 3 HYPO-RT-PC trial comparing SBRT (42.7 Gy total with 6.1 Gy/fraction) to
standard fractionation (78 Gy total with 2 Gy/fraction) demonstrated non-inferiority for the
ultra-hypofractionated approach.64 These results along with the reduced patient burden and
treatment time make hypofractionated EBRT a promising treatment method for localized
prostate cancer.
Proton-based EBRT has recently been proposed for prostate cancer treatment,
taking advantage of the unique properties of protons including increased biological
effectiveness in cell killing compared to photons and sharp peak in the depth dose profile
allowing for the creation of highly conformal treatment plans.57 Proton-based EBRT has
been to shown to allow increased whole-gland dose to the prostate compared to photonbased EBRT.65 However, the lack of evidence for improved outcomes compared to photonbased approaches and the high cost of a initiating and maintaining a proton therapy facility
has limited widespread adoption for prostate cancer.

1.3.3.2

Brachytherapy

Brachytherapy (BT) involves the delivery of ionizing radiation from a radioactive source
or sources placed temporarily or permanently inside or adjacent to the treatment target.
This close proximity to the treatment target allows for highly conformal treatment plans
that can deliver a high dose to the target while limiting dose to the surrounding healthy
tissue.65 BT can be delivered as a monotherapy or in conjunction with EBRT.66,67 BT
treatments can be separated into low-dose-rate permanent implant BT and high-dose-rate
temporary implant BT and are described in detail in the following sections.

High-Dose-Rate Brachytherapy
High-dose-rate (HDR)-BT for prostate cancer treatment is the primary focus of this thesis.
In this treatment, approximately 12-20 hollow needle applicators are inserted into the
prostate through the perineum, guided by a needle template. The needle template is a rigid
grid of evenly spaced holes, typically 5 mm apart, helping to ensure spacing between the
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needles and aid in insertion into the prostate. In addition, the needle template can lock the
needle position in place either individually or collectively to ensure there is no movement
prior to treatment delivery. Needle insertion is typically guided using transrectal
ultrasound, described in detail in section 1.4.2. Using the needle template and
intraoperative ultrasound imaging, the needles are inserted throughout the prostate to
maximize radiation coverage while avoiding dose hotspots at the urethra. Following needle
insertion, a single high-activity radioactive source is moved through the inserted needles
by a remote afterloader to irradiate the prostate. HDR-BT procedures typically utilize
iridium-192 (192Ir), which has a half-life of 73.8 days and decays by

decay 95% of the

time, leading to numerous gamma emissions from 0.11 to 1.378 MeV as well as electrons
with energy up to 1.377 MeV.68 The mean photon energy from 192Ir decay is approximately
0.3 MeV, capable of delivering more than 100 Gy per hour. Treatment follows a
personalized radiation plan, which specifies how long the radioactive source will remain
in specific dwell positions, known as the dwell time. These specific source dwell positions
are based on needle tip locations identified using imaging during the procedure. An
example transrectal ultrasound image with highlighted dwell positions overlaid on an
inserted needle is shown in Fig. 1.1. The treatment plan is created based on the prostate
and OAR anatomy (rectum, urethra, bladder) as defined using intraoperative medical
imaging to ensure the prescription dose is delivered to the entire prostate while limiting
dose to the defined OARs.
An example axial transrectal ultrasound image and the corresponding radiation
treatment plan for a clinical high-dose-rate prostate brachytherapy procedure is shown in
Fig. 1.2. Isodose levels are provided in the legend, showing the hotspots surrounding each
needle as well as the dose avoidance for the urethra. As described in the previous
paragraph, the treatment plan is defined such that the 100% isodose line in red
corresponding to 15 Gy covers the whole prostate.
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Figure 1.1: Example sagittal brightness-mode transrectal ultrasound image showing three
inserted needles in a clinical high-dose-rate prostate brachytherapy procedure. On the
needle closest to the ultrasound transducer, the dwell positions are shown, which are the
locations where the radioactive source will sit for specific amounts of time.
HDR-BT is commonly delivered as a 15 Gy boost dose in conjunction with EBRT for
treating intermediate to high-risk prostate cancer patients.69 In a large study of more than
500 patients, 5-year freedom from biochemical failure was 91% for intermediate-risk
prostate cancer patients.69 HDR-BT as a monotherapy for treating intermediate to high-risk
prostate cancer patients has been proposed.67,70,71 HDR-BT monotherapy dose
prescriptions range from seven 6.5 Gy fractions67 to two 13.5 Gy fractions,71 with
biochemical disease-free survival at 5 years ranging from 81% for high-risk patients67 to
93-98.6% for intermediate-risk patients.67,70,71 The demonstrated disease-free survival for
HDR-BT monotherapy as well as the reduction in patient burden due to greatly reduced
treatment time make this a promising option for treating localized intermediate to high-risk
prostate cancer. In addition, the hypofractionated nature of HDR-BT takes advantage of
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the low / ratio for prostate cancer. Compared to other radiotherapy treatment options,
HDR-BT is able to deliver a prescribed whole-gland dose with decreased dose to
surrounding healthy tissue compared to intensity-modulated radiation therapy, proton
therapy, and LDR-BT.65

Figure 1.2: Example axial brightness-mode transrectal ultrasound image and
corresponding radiation treatment plan isodose line overlay for a clinical high-dose-rate
prostate brachytherapy procedure. The prostate was contoured and shaded in purple and
the urethra is shown as the yellow circle. Isodose line dose levels are provided in the legend.
Each implanted needle is shown as a small horizontal line.

Low-Dose-Rate Brachytherapy
Low-dose-rate (LDR)-BT involves the permanent implantation of numerous low activity
radioactive sources within the prostate through inserted hollow needle catheters. Similar to
the HDR-BT procedure, needles are typically inserted through a needle template while
guidance is completed with transrectal ultrasound. Commonly used LDR radioactive
sources include iodine-125 (125I) and palladium-103 (103Pd), which have half-lives of 59.4
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days and 17 days and decay by electron capture with energy of approximately 28 keV and
21 keV, respectively.72 Whole gland prescription dose is 144 Gy and 115-120 Gy for LDRBT monotherapy and 100-110 Gy and 80-90 Gy for LDR-BT boost following EBRT
according to the American Brachytherapy Society (ABS) guidelines for

125

I and

103

Pd,

respectively, typically requiring 50-125 radioactive seeds.73 LDR-BT is commonly used as
a monotherapy for low-risk prostate cancer patients, with 5-year biochemical disease-free
survival of up to 94%.41 LDR-BT has also been demonstrated to improve disease control
in intermediate- and high-risk prostate cancer patients when delivered as a boost dose
following EBRT.74 Treatment planning simulations have shown that HDR-BT can deliver
more conformal plans compared to LDR-BT, making it favored for intermediate to highrisk localized prostate cancer treatment.65 Furthermore, the constant irradiation delivered
in LDR-BT treatments does not take advantage of low / ratio for prostate cancer.

Tumour-Targeted Brachytherapy
As described in the previous section, conventional BT aims to deliver a uniform dose to
the whole gland. The maximum deliverable dose is limited by the surrounding OARs,
including the rectum, bladder, and urethra, with the frequency of grade 3 toxicities
increasing for whole-gland HDR-BT dose escalation beyond the standard 15 Gy.75
Previous studies have shown that the site of local recurrence following radiation therapy is
often the dominant intraprostatic lesion (DIL), which is the site of highest cancer burden
prior to treatment.76

79

To take advantage of this, tumour-targeted HDR-BT has been

proposed to escalate dose to the DIL while maintaining the conventional whole-gland dose,
which may lead to improved tumour control while maintaining acceptable rates of toxicity.
With standard TRUS-guided BT, however, the DIL is not visible, necessitating the use of
a supplementary imaging modality to localize the DIL, such as MRI or positron emission
tomography (PET). These alternative imaging modalities are described in sections 1.4.3
and 1.4.4, respectively, including discussion of the registration methods required to
integrate this supplementary information into the intraoperative US imaging. By
maintaining the conventional whole-gland dose, the risk of delivering reduced dose to the
cancer not identified using imaging is minimized. Boosted dose to the DIL can be achieved
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with EBRT approaches as well as both HDR- and LDR-BT approaches, allowing strategic
placement of hotspots to overlap with the defined DIL.80,81 In HDR-BT focal boost
procedures, elevated dose to the DIL can be achieved by increasing the dwell times for
specific dwell positions near the DIL, or additional needles can be inserted, directly
targeting the identified DIL. Combined HDR- and LDR-BT dose escalation, utilizing
whole-gland HDR-BT followed by targeted DIL boost with LDR-BT seed implantation
has been proposed in the DELIGHT trial which began recruiting at Sunnybrook Health
Sciences Centre and is now recruiting at the London Regional Cancer Program
(NCT03323879). The level of dose boost to the DIL is highly variable depending on the
treatment centre and clinical trial with no current accepted standard.80,81 Limitations
include lack of standardized procedures for DIL localization and selection of dose boost
level as well as a lack of randomized trials demonstrating efficacy, suggesting that focal
boosting cannot be considered the standard of care at this time.80

1.3.4

Focal Therapy

In contrast with tumour-targeted BT, focal therapy is used to exclusively treat the
tumour(s), thus sparing all surrounding healthy prostate tissue and potentially reducing
morbidity while maintaining cancer control.82 For focal therapies, a supplementary
imaging modality is once again required to identify the tumour/DIL, such as MRI or PET.
The most common focal therapy techniques include cryotherapy, high-intensity focused
ultrasound, and thermal ablation.82 Focal therapy approaches rely on accurate identification
and localization of the tumour(s) using imaging, as any missed cancer will not be treated
in a focal approach. As such, current ASCO guidelines do not recommend focal therapy
for high-risk cancer.62 While focal therapy is a viable treatment option for intermediaterisk disease, it is not standard care as the comparative outcome evidence is lacking relative
to surgery or whole-gland radiotherapy, leaving focal therapy to be most common in the
salvage setting outside of a clinical trial.62
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Medical imaging plays a critical role in nearly all steps of prostate cancer management.
This includes the use of imaging for initial disease detection and diagnosis, cancer grading,
treatment planning and target definition, intraoperative treatment guidance, and assessing
treatment response. The most common medical imaging modalities used in prostate cancer
diagnosis and treatment planning are x-ray computed tomography (CT) (1.4.1), US (1.4.2),
MRI (1.4.3), and nuclear imaging (1.4.4), all of which are described in further detail in this
section.

1.4.1

X-ray Computed Tomography (CT)

In CT imaging, a low energy (70-150 keV) x-ray source is directed toward the patient,
typically in a fan beam geometry. In line with the x-ray source on the opposing side of the
patient, an array of detectors is arranged to detect the transmitted photons. By rotating the
x-ray source and detector array around the patient, x-ray images at different angles can be
acquired and reconstructed to form a 3D CT image. The difference in the photon
attenuation of materials within the body determines the number of photons reaching the
detector, thus providing image contrast to distinguish different anatomy in the image.
Although the use of CT has limitations for cancer detection,83 it is commonly used in
prostate cancer treatment, specifically for treatment planning in EBRT84 and in some cases
for treatment guidance and planning in BT.85
The most common use of CT imaging is for treatment planning in EBRT. At
megavoltage energies typically used for EBRT treatment, Compton scatter is the dominant
photon interaction with photon attenuation directly influenced by electron density.
Hounsfield units obtained from a CT image are related to electron density allowing for
accurate modelling of megavoltage beam dose, necessary for treatment planning.84 In
addition, the CT image is required for the contouring of both target organs and organs-atrisk. Prior to the delivery of EBRT, on-board cone-beam CT (CBCT) imaging is typically
used to ensure accurate and consistent patient positioning relative to the planning CT.86
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CT imaging can also be utilized for both LDR and HDR-BT treatment guidance,
needle position verification, and dose planning.85,87,88 For LDR-BT, CT is the standard-ofcare technique to visualize implanted radioactive seeds.87 HDR-BT treatments employing
CT-based workflows typically require post-implant imaging outside of the operating room
to verify needle positions and identify organs-at-risk, necessitating patient movement that
has been shown to cause needle shifts.89 Intraoperative imaging required for needle
guidance is difficult and costly with CT as it requires a specialized operating suite with an
integrated in-room CT. In addition, CT suffers from a lack of real-time imaging.
Furthermore, soft tissue contrast is poor in CT imaging due to the similarity in electron
density between different tissue types, making prostate and tumour delineation difficult. 83
CT imaging also utilizes ionizing radiation, adding to the patient dose.

1.4.2

Two-Dimensional Ultrasound (US)

Conventional brightness (B)-mode US imaging involves the propagation and detection of
ultrasonic (> 20 kHz) sound waves that pass through the body and reflect at an interface
between materials to produce 2D images of internal structures. Sound wave propagation
speed through a medium depends on the medium tissue properties such as density and
stiffness. Computing the time between sound wave emission and reflection back to the
transducer, which differs based on the medium, provides information on the location of the
reflecting interface. The mechanical, longitudinal sound waves typically used in clinical
US imaging range from 2 MHz to 15 MHz, with higher frequency resulting in increased
axial resolution and decreased penetration. For prostate cancer imaging, transrectal
ultrasound (TRUS) imaging is typically used, where the US transducer is inserted in the
patient s rectum. TRUS transducers include end-fire and side-fire geometries, with modern
iterations of the latter employing a bi-plane transducer with both axial and sagittal planes.
TRUS imaging is primarily used intraoperatively in interventional procedures for prostate
cancer diagnosis (biopsy) and treatment, where advantages over CT imaging include realtime imaging for needle insertion guidance, high portability, accessibility, cost
effectiveness, and the lack of ionizing radiation. Specifically, TRUS is utilized in prostate
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biopsy targeting and needle guidance26 and in prostate brachytherapy needle guidance and
treatment planning.90,91
TRUS imaging has been proposed as a tool for cancer screening via the detection
of hypoechoic or hyperechoic lesions and abnormalities, but lack of sensitivity compared
to imaging modalities such as MRI limits the clinical utility.16 For prostate biopsy, TRUS
is commonly used for guiding needle placement intraoperatively, including the use of
TRUS to target hyperechoic or hypoechoic regions in addition to the standard sextant
biopsy locations.26 In prostate BT, TRUS imaging is the standard of care for guiding needle
insertion intraoperatively.90,91 Conventional TRUS imaging limitations include small fieldof-view, operator dependence, and confinement to 2D image acquisition. This requires the
physician to mentally relate each 2D image to the inherently 3D anatomy, further
increasing operator dependence. Furthermore, conventional TRUS has poor ability to
detect and localize cancer within the prostate.92

1.4.2.1

Doppler Ultrasound

Doppler US is an alternative US imaging technique that displays a visual representation of
motion in the plane of the US image, presented as a coloured overlay on the conventional
B-mode image. This relies on the Doppler shift or variation in the frequency of sound as a
result of motion between the US source and receiver, with greater velocities resulting in
greater frequency shifts. Doppler US techniques vary based on the method used to calculate
and present the Doppler shift, with two common techniques being colour Doppler (CD)
and power Doppler (PD).93 CD can display the direction of motion in the US plane by
coding Doppler shifts into different colours that are then superimposed on the B-mode
image. PD provides no directionality, displaying the total integrated Doppler signal power,
and thus demonstrating increased sensitivity compared to CD.93 Doppler US can be
improved with the addition of contrast agents that improve blood flow visibility.94
In the management of prostate cancer, Doppler US imaging has been proposed for
use in cancer detection92,94,95 as well as biopsy targeting.96 Contrast-enhanced Doppler US
imaging has shown promise in localizing prostate cancer by visualizing microvessels,
which have increased density in malignant tissue.94 Although there is promise, Doppler US
cannot replace biopsies for the early detection of prostate cancer, and is currently not used
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as a standard-of-care imaging technique in prostate cancer diagnosis. Contrast-enhanced
CD US has also been proposed for use in targeted biopsy.96 By targeting hypervascular
regions intraoperatively, the CD-targeted biopsy approach demonstrated significantly
increased detection rate compared to systematic biopsy.96 Conventional Doppler US is still
limited to 2D acquisitions, however.

1.4.2.2

Three-Dimensional Ultrasound

To overcome the limitations of conventional 2D TRUS imaging, 3D TRUS techniques
have been proposed.97

100

These techniques provide a 3D view of the internal anatomy,

removing the need for physicians to mentally relate each 2D slice to the underlying 3D
anatomy, thus reducing operator dependence. In addition, these techniques remove the
need for a sonographer to manually manipulate the US transducer, further reducing
operator dependence. While matrix array 3D US transducers exist, mechanical 3D scanning
approaches, which involve the tracking and manipulation of a conventional 2D transducer
through a series of angles or steps to reconstruct a 3D image are typically used due to
increased field-of-view and resolution. There are numerous mechanical 3D US scanning
approaches, but axially reconstructed step-back, sagittally reconstructed side-fire, and endfire 3D TRUS imaging techniques are most commonly used in prostate cancer imaging.
An example of each 3D TRUS image acquisition is shown in Fig. 1.3.

Figure 1.3: Example (a) axially reconstructed step-back, (b) sagittally reconstructed sidefire, and (c) end-fire three-dimensional transrectal ultrasound images. The dotted lines in
each image represent the original ultrasound acquisition planes that compose the 3D image.
Arrows represent the direction of transducer motion during 3D acquisition.
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In end-fire and side-fire 3D TRUS imaging, a TRUS transducer is mechanically
rotated about its long axis. 2D TRUS images are acquired at set angular intervals, which
are then reconstructed to generate 3D TRUS images. End-fire 3D TRUS, commonly used
for prostate biopsy, utilizes an end-fire transducer that is rotated 180° while 2D TRUS
images are acquired at 1.0° intervals and reconstructed into a 3D volume.99 In contrast,
sagittally reconstructed side-fire 3D TRUS imaging, commonly used for prostate
brachytherapy, utilizes the sagittal plane on the bi-plane transducer.98,100,101 By rotating the
transducer 140° while 2D TRUS images are acquired at 0.5° intervals, a fan-shaped 3D
TRUS image can be reconstructed. Axially reconstructed step-back 3D TRUS images, also
used for prostate brachytherapy, utilize the axial plane on the bi-plane transducer. A series
of axial 2D US images is acquired by translating the transducer in steps inferiorly, allowing
for 3D image reconstruction.90,102,103
3D TRUS imaging is used in both biopsy and brachytherapy procedures. For
prostate biopsy, 3D TRUS imaging is used in MRI-3D TRUS fusion-guided biopsy,
demonstrating improved tumour sampling compared to 2D TRUS guidance alone by
combining the high soft-tissue contrast of MRI with real-time needle guidance capabilities
of TRUS.104 For prostate brachytherapy, axially reconstructed step-back 3D TRUS
imaging is most commonly employed.90,102,103 Intraoperative 3D TRUS imaging allows for
the visualization and localization of the prostate as well as nearby organs-at-risk including
the rectum, urethra, and bladder, providing improved spatial context compared to 2D
TRUS. In addition, 3D TRUS allows for the verification of implanted needle positions.
Through visualization of both anatomy and implanted needles, 3D TRUS imaging
facilitates accurate treatment planning without the need for additional modalities such as
CT. Sagittally reconstructed side-fire 3D TRUS imaging has also been proposed for
prostate brachytherapy, improving needle tip identification accuracy compared to stepback 3D TRUS imaging due to increased resolution in the insertion direction.101 3D TRUSguided brachytherapy procedures allow for all aspects of the treatment workflow to occur
in the operating room, including intraoperative needle guidance and treatment planning,
allowing the patient to remain stationary.90,91 TRUS is a widely available and low-cost
modality, offering real-time imaging and comparable needle tip identification accuracy to
CT,90 making it the preferred method for prostate HDR-BT guidance at many centers. 3D
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TRUS imaging is still limited in its ability to detect and localize cancer within the prostate,
so supplemental imaging modalities such as MRI and nuclear imaging are required to
facilitate lesion-targeted biopsy and treatment.92

1.4.3

Magnetic Resonance (MR) Imaging

MR imaging uses magnetic fields and radiofrequency waves to manipulate and measure
changes in the alignment of hydrogen nuclei (protons) within the patient s body to generate
signals and produce 3D images of the internal anatomy. MR images have very high soft
tissue contrast compared to other modalities such as CT and TRUS imaging, making them
invaluable for both organ contouring and tumour identification and localization.105

107

MRI

in prostate cancer largely uses magnetic field strengths of 1.5T and 3T, with either a phased
array surface coil or an endorectal coil.83,107 Endorectal coils offer a significant increase in
signal-to-noise ratio when used with 1.5T MR scanners, however they are expensive,
uncomfortable for the patient, and can deform the prostate.83 The benefit of endorectal coils
compared to phased array body coils at 3T magnetic field strength is still debated, but
image resolution is higher with either coil compared to 1.5T MR.83,107 Conventional
anatomical MR imaging for prostate cancer commonly uses T2-weighted and T1-weighted
images.83,107 While T1-weighted images can be used to detect post-biopsy hemorrhage, T2weighted images are the most common pulse sequence for lesion detection as it offers
improved soft tissue resolution including depiction of zonal anatomy.83 In T2-weighted
images, tumours commonly appear hypointense compared to healthy prostate tissue due to
tissue density differences.108 To improve lesion detection and localization, functional MR
imaging techniques such as MR spectroscopy (MRS), dynamic contrast-enhanced MRI
(DCE-MRI), and diffusion-weighted imaging (DWI) can be used.105,106,109 The
combination of anatomical T2-weighted MR imaging with the functional imaging
techniques listed above is known as multiparametric MRI (mpMRI). mpMRI offers higher
cancer detection rates compared to any one MR technique alone according to histological
validation, demonstrating detection rates greater than 90% for moderate to high risk
tumours.105,106
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The Prostate Imaging

Reporting and Data System (PI-RADS) was developed to

globally standardize the acquisition, interpretation, and reporting of prostate mpMRI
examination for prostate cancer diagnosis.108 The PI-RADS system establishes mpMRI
acquisition guidelines and provides assessment categories to report the risk of clinically
significant prostate cancer for each suspicious location.108 PI-RADS assessment categories
range from one to five, with a higher number denoting increased likelihood of clinically
significant cancer.108
As the high soft tissue contrast of MRI allows for accurate tumour localization, MR
imaging is typically used to target the tumour for prostate cancer diagnosis and treatment.
In prostate biopsy, MR imaging can be added in an MRI-3D TRUS fusion guided biopsy
approach.104 By combining the superior soft tissue contrast of MR with the real-time needle
guidance of TRUS imaging, improved tumour sampling can be achieved compared to
conventional TRUS-guided biopsy.104 In prostate cancer treatment, MR imaging can
facilitate tumour-targeted treatment in the form of dose escalation or focal therapy,
reducing dose to nearby organs-at-risk while increasing dose to the most likely site of
cancer recurrence.82,106 MRI can also visualize sensitive organs-at-risk such as the
neurovascular bundles (NVB), which are not typically visible on CT or TRUS images,
allowing for dose sparing and thus reduced probability of adverse side effects.83 An
example US and 1.5T MRI with corresponding physician contours is shown in Fig. 1.4. In
all the described use cases, the MRI information is obtained from a pre-procedural MRI
scan, necessitating MRI-to-US image registration techniques to integrate this information
into the operating room environment where TRUS imaging is typically used. MR-only
brachytherapy workflows have been proposed, utilizing MR imaging for both needle
guidance and treatment planning.110

112

MR-only workflows are limited by the lack of

intraoperative real-time imaging if the MR scanner is not located in the operating room,
necessitating patient movement post-implant, which may cause needle shifts.89 Dedicated
MR operating room suites are available, but require specialized BT tools and procedures,
resulting in an expensive and challenging procedure. The prohibitive cost of MRI systems
is still a barrier to widespread use, even in developed countries such as Canada, resulting
in TRUS and CT-guided BT to still be the standard of care.
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Figure 1.4: Example (a) three-dimensional transrectal ultrasound image and corresponding
prostate contour in the axial plane and (b) axial T2-weighted 1.5T magnetic resonance
image with physician-drawn prostate, urethra, clinical target volume (CTV), and
neurovascular bundle (NVB) contours.

1.4.4

Nuclear Imaging

Nuclear imaging in the form of PET is an alternative functional imaging technique which
allows for visualization of the tumour location within the prostate.83 PET imaging involves
the injection of a positron emitting radiotracer, which collects in organs with increased
metabolic activity, such as cancerous tissue, emitting radiation which can be subsequently
detected and used to produce an image characterizing the tracer location. Historically,
fluorodeoxyglucose (18F-FDG) is the most common PET radiotracer, as it serves as a
marker for glucose uptake in tissue, which is correlated with cell metabolism that is
typically higher in cancer cells.113,114 Recently, prostate specific membrane antigen
(PSMA)-PET has been proposed, demonstrating increased specificity and sensitivity in
prostate cancer detection compared to alternative imaging modalities.115 Gallium-based
PSMA radiotracers attach to PSMA proteins that are often overexpressed in prostate cancer
tissue allowing for highly specific tumour localization. Although PSMA is highly specific
to prostate cancer, up to 10% of prostate cancers do not overexpress PSMA.116 PSMA-PET
can be utilized alone or in combination with MRI, which has shown to increase cancer
detection rate.115 Aside from its utility in the initial diagnosis and monitoring of prostate
cancer, PSMA-PET imaging has also been proposed as an alternative to MRI for use in
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targeted biopsy as well as lesion-targeted dose escalation in HDR-BT.117 Limitations of
PET include low spatial resolution, lack of structural information necessitating registration
with another modality such as CT or MRI, and the increased cost and challenges involved
in producing, handling, and administering radiotracers. Recently developed hybrid PETMR scanners aim to overcome the first two limitations, offering simultaneous co-registered
PET and MR image acquisition.116

1.5

Challe ge i Mi i all I

a i eP

a e P ced e

Ultrasound-guided minimally invasive prostate procedures such as biopsy and HDR-BT
offer several advantages in terms of detection and treatment accuracy, respectively;
however, there are still numerous challenges involved in these procedures. In both
procedure types, imaging is required to guide needles to precise locations within the
prostate, so accurate identification of the needle and the target in the image is critical. A
common challenge across procedures is that these steps are commonly completed manually
during the procedure in the operating room, lengthening the procedure time as well as
adding observer variability. Specific challenges are described in sections 1.5.1-1.5.4 with
description of the motivation, previous work, and unmet need for each case.

1.5.1

Prostate Segmentation in Three-Dimensional Ultrasound
Images

Motivation
3D US imaging is a valuable tool in both prostate biopsy and prostate BT, allowing for
improved needle insertion accuracy and target definition as well as facilitating the
integration of other 3D imaging modalities such as MRI intraoperatively. To effectively
utilize 3D TRUS images, segmentation of the prostate gland in 3D is required. In HDRBT, the prostate is the treatment target, so accurate segmentation is critical for target
visualization during needle insertion, for glandular volume measurements,118,119 and for
dose-volume calculations during treatment planning.120 In 3D TRUS-MRI fusion-guided
biopsy and tumour-targeted HDR-BT, accurate prostate segmentation is required for use in
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surface-based registration approaches.121,122 These segmentations are typically performed
manually by the physician during the clinical procedure while the patient is under sedation
or anesthetic. Manual segmentation in 3D TRUS images is time-consuming as the
physician must segment the 3D volume slice-by-slice which can take up to 15 minutes,
extending procedure times and increasing patient risk due to anesthesia exposure.123 This
is compounded by the fact that variation in image quality can make prostate segmentation
a difficult task. Fig. 1.5 shows an example high quality 3D TRUS with a clearly visible
prostate boundary and an example poor quality image where image artifacts limit the
visibility of the prostate boundary making segmentation difficult. Manual segmentation
also leads to intra- and inter-observer variability which has been shown to have a volume
percent difference of 5.4% and 11.4%, respectively, for side-fire 3D TRUS imaging.124
Investigation into automated segmentation approaches that may decrease procedure time
and reduce operator dependence is thus critical.

Figure 1.5: Example transrectal ultrasound images highlighting the variability in image
quality and prostate boundary visibility which can make manual prostate segmentation time
consuming and difficult. (A) Example high quality image with a clearly defined prostate
boundary. (B) Example poor quality image with severe shadowing artifacts that limit the
prostate boundary visibility.

Previous Work
Automated or semi-automated 3D TRUS prostate segmentation approaches using
conventional image processing techniques have been previously investigated;125

128
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however, these techniques have lacked clinical translation due to difficult generalizing to
diverse datasets and limitations related to computational complexity and computation time.
Deep learning, specifically convolutional neural networks (CNNs), have been widely
investigated for use in image processing tasks, including image segmentation, promising
fast and accurate automated segmentation. Prostate segmentation in both 2D TRUS129 and
3D TRUS130,131 using CNN-based approaches have been proposed. While the reported
segmentation accuracy was high, key limitations include a lack of generalizability due to
use of image datasets obtained using a single US system with matched voxel dimensions
and sizes. Furthermore, the proposed approaches investigated segmentation of only one 3D
TRUS image type, further limiting generalizability and necessitating the use of multiple
networks for different procedure types. The proposed approaches have also relied on crossvalidation where information bleeding could influence the reported segmentation
performance.132,133

Unmet Need
While deep learning-based prostate segmentation in 3D TRUS images have been
investigated, there is an unmet need for clinically translatable segmentation techniques that
are generalizable and robust to diverse clinical data obtained using different US systems.
In addition, the use of different 3D TRUS acquisition methods across different minimally
invasive ultrasound-guided procedures leaves the unmet need to develop a consolidated
segmentation approach that is generalizable to different 3D TRUS acquisition methods.

1.5.2

Variability in Dataset Size, Quality, and Diversity for Deep
Learning Segmentation Applications

Motivation
Deep learning approaches for automated image segmentation tasks have been widely
proposed; however, the segmentation performance and generalizability of these approaches
rely heavily on the quality of the training dataset. For 3D TRUS prostate segmentation in
particular, the dataset size, image quality, and diversity in terms of 3D TRUS acquisition
type and US system may influence the segmentation performance and clinical translation
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potential. The generation of large clinical datasets is both time-consuming and costly,
making access to such datasets rare, especially for ultrasound. This is a major limitation
for the widespread clinical translation of deep learning approaches, especially for smaller
hospitals where data may be scarce. As described in section 1.5.1, different minimally
invasive ultrasound-guided procedures utilize different TRUS acquisition methods.
Datasets and segmentation methods that are effective for multiple TRUS acquisition
methods would increase clinical translation efficiency and reduce the duplication of work.
Finally, image quality, although critical for prostate segmentation, is highly variable based
on acquisition type, presence of artifacts, and prostate visibility. These differences also
make comparison of segmentation performance for methods trained and tested using
different datasets challenging. Investigation into the effect of these dataset considerations
on segmentation performance and generalizability may increase the clinical translation
potential of deep learning segmentation approaches in addition to improving transparency
in reporting and comparing segmentation results across methods and datasets.

Previous Work
Proposed deep learning-based segmentation approaches have utilized small datasets
ranging in size from 40 to 109 3D TRUS images;129

131,134,135

however, these methods are

still limited to one TRUS acquisition type, typically acquired using one US system, which
reduces the potential clinical translation. There is also no investigation of how performance
varies as the dataset size changes. Although image quality is critical to segmentation
performance, there is currently no grading scale to quantify 3D TRUS image quality.

Unmet Need
While deep learning segmentation approaches show great promise, there is an unmet need
to rigorously evaluate the impact of the training dataset in terms of size, image type, and
image quality. Understanding of how these factors influence segmentation performance
could improve the clinical translation potential of deep learning segmentation methods. In
addition, a segmentation method that is generalizable to different 3D TRUS acquisition
types and able to maintain performance while utilizing small training datasets may be
suitable for widespread use even if data is scarce. There is also an unmet need for a method
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to quantitatively grade the image quality of 3D TRUS images to assess the impact on
segmentation performance as well as improve the ability to compare segmentation
performance for methods trained using different datasets.

1.5.3

Intraoperative

Needle

Tip

Localization

in

Transrectal

Ultrasound
Motivation
HDR-BT involves the irradiation of the prostate by passing a high-activity radioactive
source through multiple hollow needles inserted into the prostate under TRUS guidance.90
Intraoperative needle tip localization is critical for safe and effective HDR-BT treatment,
as it directly influences the radiation treatment plan.102,136,137 As shown in Fig. 1.1, the
location of the dwell positions are set based on the identified tip location, so any error in
needle tip localization could lead to radiation delivery that deviates from the planned dose,
potentially exposing the patient to increased radiation or underdosing the tumour. Needle tip
localization error is a primary component of uncertainty in HDR-BT setup, with errors
greater than 3 mm potentially leading to adverse outcomes.136 In TRUS-guided HDR-BT
procedures, needle tip localization is completed using standard B-mode US; however, image
artifacts including shadowing and reverberation artifacts have been shown to limit needle
visibility intraoperatively.138 Investigation into approaches to improve intraoperative needle
tip visualization are critical for improving HDR-BT treatment accuracy and safety.

Previous Work
Software-based automated needle tip localization methods using both conventional image
processing techniques139

142

and deep learning143,144 have been proposed; however, these

approaches are still limited by their use of B-mode US images, and are thus sensitive to
image artifacts that may limit needle visibility.
Doppler US has been proposed as an alternative imaging approach to improve
surgical instrument visibility intraoperatively.99-110 As described in section 1.4.2.1, Doppler
US displays the motion in the US plane as a coloured overlay on the B-mode image, so by
perturbating a surgical instrument, motion is generated that can then be imaged using
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Doppler US. Previously published Doppler US-based visualization approaches include
applications in biopsy, pericardiocentesis, and radiofrequency ablation, with none
considering BT. Furthermore, these approaches are often cumbersome, requiring
modifications or additions to the standard clinical equipment including the use of vibrating
devices clipped onto the needle,145

147,153

the attachment of piezoelectric crystals,148,150,156

or electromagnetic actuation of small permanent magnets inside the needle.155 In HDR-BT
where more than 10 needles are typically required, these approaches are not suitable. There
is also no evidence of Doppler US-based needle visualization in clinical HDR-BT
procedures.

Unmet Need
While Doppler US-based needle visualization has been proposed in the past, there is an
unmet need for a perturbation technique designed specifically for BT applications and
requiring minimal modifications or additions to the operating room and the standard
clinical equipment. In addition, there is an unmet need to validate Doppler US as a needle
visualization tool intraoperatively in clinical HDR-BT procedures. Validation of a Doppler
US technique may improve needle visualization intraoperatively, potentially improving
both patient safety and treatment accuracy in HDR-BT and could be applied to other
minimally invasive procedures where similar challenges with intraoperative needle
visibility are prevalent, for example gynecologic interstitial BT or radiofrequency ablation.

1.5.4

Deformable

Magnetic

Resonance

Imaging

to

Three-

Dimensional Ultrasound Image Registration
Motivation
As the DIL is the most likely site of prostate cancer recurrence following radiotherapy,
tumour-targeted BT featuring escalation of dose to the DIL may lead to improved tumour
control while maintaining low dose to healthy tissues.76 Since the DIL is not easily visible
in TRUS images, the addition of supplementary imaging capable of visualizing the DIL,
such as MRI, is required, necessitating 3D TRUS-MRI image registration. Currently,
translation of targets identified in the MR image to the intraoperative TRUS image is
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typically done manually by the physician using cognitive fusion or rigid registration,
introducing inter- and intra-observer variability. Accurate registration is critical for
effective targeting of the DIL, so automated registration methods may reduce observer
dependence while also reducing registration time. Furthermore, registration of
radiosensitive organs-at-risk visible in MR imaging into the 3D TRUS image, such as the
neurovascular bundles, may allow dose avoidance during treatment planning which could
reduce acute side effects following radiotherapy.

Previous Work
Deformable image registration methods have been proposed, commonly focusing on MRTRUS fusion-guided biopsy.157

162

As described in section 1.4.2.2, TRUS-guided prostate

biopsy typically utilizes end-fire 3D TRUS imaging which uses a different acquisition
technique compared to axially reconstructed step-back 3D TRUS commonly used in
prostate BT. As such, validation of registration approaches seeking to translate MR-defined
treatment targets such as the DIL or anatomical structures to avoid during therapy into the
intraoperative step-back 3D TRUS images is required. Furthermore, prospective clinical
integration in tumour-targeted BT procedures is limited.

Unmet Need
While deformable 3D TRUS-MR image registration approaches have been proposed, there
is an unmet need for the development and validation of a registration algorithm designed
for tumour-targeted BT, including avoidance of radiosensitive anatomy such as the
neurovascular bundle. There is also an unmet need for prospective clinical validation and
workflow efficiency assessment in prostate BT procedures.

1.6

The i Objec i e a d O li e

The central objective of the research described in this thesis was to improve the efficiency
and accuracy of minimally invasive procedures for prostate cancer diagnosis and treatment,
including image-guided biopsy and brachytherapy, through the development and validation
of software- and hardware-based tools. The focus is on reducing lengthy procedure times,

33

improving treatment accuracy compared to standard-of-care techniques, and reducing
manual operator variability. This objective is motivated by the time-consuming and
difficult manual intraoperative work required in minimally invasive prostate procedures,
including prostate segmentation, needle tip identification, and image registration. From the
perspective of software development, we hypothesize that the integration of a generalizable
deep learning-based prostate segmentation algorithm in prostate biopsy or brachytherapy
procedures would allow for reduced procedure time, while the integration of a deformable
image registration algorithm would allow for safe and effective targeting of MR-defined
tumours as well as avoidance of MR-defined organs-at-risk, decreasing variation due to
manual registration. From the perspective of hardware-based solutions, we hypothesize
that a PD-based needle localization method utilizing needle perturbation from a mechanical
oscillator may allow for improved needle tip visualization compared to the standard of care
B-mode US, potentially improving treatment accuracy. We propose the tools in this thesis
with the aim of providing easy-to-implement, generalizable solutions to common problems
plaguing minimally invasive prostate cancer procedures with the end goal of improving
care for men with prostate cancer through reduced procedure time and improved treatment
accuracy.
The specific objectives of this thesis are to:
1. Develop an accurate and generalizable deep learning-based automatic prostate
segmentation algorithm for 3D TRUS images, trained using a clinically diverse
dataset of images from prostate biopsy and brachytherapy procedures.
2. Examine the effect of dataset size, image quality, and image type on deep learningbased automatic prostate segmentation in 3D TRUS images through the use of
smaller training datasets and the development of an image quality grading scale.
3. Develop a novel wireless mechanical oscillator for use in a power Doppler-based
needles tip localization method to improve intraoperative needle visualization in
interstitial prostate brachytherapy.
4. Develop and clinically validate a surface-based deformable MR-3D TRUS image
registration algorithm for interstitial prostate brachytherapy.
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1.6.1

Thesis Outline

The overarching goal of this thesis is to address these specific objectives in four
manuscripts (Chapters 2 to 5), briefly described in the following thesis outline.
Chapter 2: Automatic prostate segmentation using deep learning on clinically diverse
3D transrectal ultrasound images
Minimally invasive procedures for diagnosing and treating prostate cancer, such as biopsy
and brachytherapy, have incorporated 3D TRUS imaging to improve needle guidance and
target definition as well as for registration to other modalities such as MRI. To effectively
utilize these images, manual segmentations of the prostate are required, which can be timeconsuming and difficult, often occurring while the patient is under sedation or anesthetic.
This chapter describes our work to develop a novel deep learning-based automatic prostate
segmentation algorithm. Our algorithm utilized 2D prediction with a modified version of
the U-Net architecture163 on 12 2D US slices sampled radially about the approximate
central axis of the prostate before reconstruction into a 3D surface, exploiting the
symmetrical nature of the prostate. The algorithm was trained using a diverse dataset of
clinical images from clinical biopsy and brachytherapy procedures acquired using end-fire
and side-fire 3D TRUS acquisition geometries, respectively.
Our radial 2D plus 3D reconstruction method significantly outperformed a fully 3D
network trained using the same dataset as well as state-of-the-art algorithms published in
the literature. This work was the first deep learning algorithm to successfully segment the
prostate in multiple TRUS acquisition geometries. Prostate segmentation was fast and
accurate, with demonstrated generalizability and robustness to different ultrasound systems
and acquisition types. This method has the potential to decrease procedure time and reduce
operator dependence in minimally invasive procedures for prostate cancer diagnosis and
treatment.
Chapter 3: Effect of dataset size, image quality, and image type on deep learningbased automatic prostate segmentation in 3D ultrasound
Deep learning-based segmentation approaches offer the potential for fast and accurate
segmentation results. However, these approaches are sensitive to the training dataset used,
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and as large clinical datasets are rare, widespread adoption of deep learning-based
automatic segmentation has been limited. Using the 2D radial plus 3D reconstruction
segmentation method described in Chapter 2, the effect of dataset size, image quality, and
image type on segmentation accuracy was examined. Smaller training datasets were
achieved by splitting the complete dataset into different image types and subsequently
reducing the number of images in steps. For this work, a modified version of the U-Net
architecture163 as well as a U-Net++ architecture were used, as the latter has been shown
to perform well with small datasets.164,165 To assess image quality, a 3D TRUS image
quality grading scale with three factors (acquisition quality, artifact severity, and prostate
boundary visibility) was developed, the first of its kind to our knowledge.
For training datasets split based on acquisition geometry, the U-Net++ significantly
improved performance compared to the modified U-Net, while for smaller datasets, the UNet++ offered equivalent performance down to as small as 500 training images. For our
dataset of TRUS images, image quality did not have a significant impact on segmentation
performance for end-fire images, while boundary visibility grade has a significant effect
for side-fire images. The image quality grading scale provides a quantitative tool for
assessing segmentation performance while allowing for easier comparison between
networks trained using different datasets. High performance of our approach with small
training datasets supports the potential for widespread use of deep learning for
segmentation tasks, even if data is scarce.
Chapter 4: A power Doppler ultrasound method for improving intraoperative needle
tip localization in interstitial prostate brachytherapy
Standard B-mode US is typically used for needle guidance in HDR-BT, including
localization of needle tip positions which is critical for treatment planning. Image artifacts
can limit needle tip visualization in B-mode US which can cause the delivered dose to
deviate from the treatment plan. This chapter describes the development and validation of
a wireless mechanical oscillator for use in a novel PD-based needle localization method
designed specifically for prostate brachytherapy. Our PD method was evaluated in a series
of tissue-mimicking phantom experiments using a simulated HDR-BT needle implant as
well as a needle implant designed to maximize shadowing artifacts. Clinical validation was
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completed in five patients who underwent standard HDR-BT as part of a feasibility clinical
trial.
In tissue-mimicking phantom experiments, our PD method offered identical tip
localization accuracy when needles were clearly visible and demonstrated increased
accuracy for shadowed needles, including providing the ability to visualize needles
previously not visible using B-mode US alone. Across all five patients, our PD method
demonstrated tip localization error of 0.8 ± 0.5 mm compared to 0.9 ± 0.7 mm for B-mode
US, showing reduced variation and a reduction in tip error for difficult to see outlier
needles. This easy-to-implement method requiring no modifications to the clinical
equipment or workflow has the potential to improve needle visualization and thus treatment
accuracy in HDR-BT and may be broadly applied in other minimally invasive needle-based
procedures.
Chapter 5: Validation of a surface-based deformable MRI-3D ultrasound image
registration algorithm towards clinical implementation for interstitial prostate
brachytherapy
MR imaging offers superior soft tissue contrast compared to ultrasound, providing the
ability to visualize the tumour and other points of interest such as the neurovascular
bundles. To utilize this information intraoperatively to target treatment or avoid organs-atrisk, registration between MRI and 3D TRUS is required. This chapter describes the
development and validation of a surface-based MRI-3D TRUS deformable image
registration (DIR) algorithm, which we hypothesize will reduce variability compared to the
manual cognitive fusion technique that is currently employed. Our registration algorithm
was evaluated using a deformable tissue-mimicking prostate phantom comparing
registration accuracy at different levels of deformation versus manual rigid registration.
Clinical validation was completed in three HDR-BT clinical cases where algorithmic
registrations were compared to manual cognitive fusion registrations completed by three
different physicians. Our DIR algorithm was implemented intraoperatively in a prospective
HDR-BT clinical case.
In phantom experiments our DIR algorithm demonstrated a mean Dice similarity
coefficient (DSC) and target registration error (TRE) across all deformation levels of
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0.74±0.08 and 0.94±0.49 mm, respectively, significantly improving the performance
compared to manual rigid registration with 0.64±0.16 and 1.88±1.24 mm, respectively.
Across the three clinical cases, our algorithm demonstrated reduced variability in DSC
score compared to the inter-physician variability of the cognitive fusion approach, offering
the potential to reduce operator dependence, decrease procedure time, and standardize the
registration process between physicians. Clinical implementation of our algorithm allowed
for a successful PSMA-PET-MR targeted biopsy, confirmed by histology, and facilitated
dose scalation to the registered clinical target volume.
Chapter 6: Conclusions, Limitations, and Future Work
This chapter focuses on the overall conclusions of the research described in this thesis and
will discuss the future work that could expand the presented research or address the
limitations and remaining unmet clinical needs.
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Chapter 2

2

A
a ic
a e eg e a i
i g dee lea i g
cli icall di e e 3D a ec al l a
d i age

Manual prostate segmentation in 3D TRUS images is a time-consuming and difficult task
that must be completed in the operating room. An accurate automatic segmentation
algorithm may reduce procedure and increase workflow efficiency in minimally invasive
prostate cancer procedures. The purpose of Chapter 2 is to describe the development and
validation of a deep learning-based automatic prostate segmentation algorithm for 3D
TRUS images.
The contents of this chapter have been previously published in Medical Physics:
Orlando N and Gillies DJ, Gyacskov I, Romagnoli C, D Souza D, and Fenster A. Medical
Physics. 2020;47(6):2413-2426. Permission to reproduce this article was granted by John
Wiley and Sons and is provided in Appendix A

2.1

I

Copyright Releases.

d ci

Diagnosing and treating prostate cancer continues to burden global populations as it
is the second most common noncutaneous cancer among men worldwide.1 Investigation into
methods to diagnose and treat prostate cancer has shifted towards improved needle-based
approaches that utilize three-dimensional (3D) information intraoperatively. Magnetic
resonance imaging (MRI)-3D transrectal ultrasound (TRUS) guided biopsy is one diagnostic
method that fuses the superior soft-tissue contrast of MRI to accurately localize, target, and
sample suspicious tissue regions for prostate cancer with the real-time, low-cost, and portable
capabilities of ultrasound. In the treatment of prostate cancer, high- and low-dose-rate
(H/LDR) brachytherapy (BT) procedures offer therapeutic benefits for patients by exploiting
radiobiological effects and offering shorter treatment times, while minimizing adverse side
effects. By adding 3D ultrasound intraoperatively, improved spatial context and targeting
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can be achieved to further improve the conventional clinical workflow of biopsy and
brachytherapy procedures; however, both procedures rely on accurate segmentation of the
prostate in 3D TRUS images to perform necessary clinical tasks. This includes surface-based
registration approaches with MRI2 and subsequent 3D TRUS images,3 glandular volume
measurements,4,5 and dose-volume calculations,6 especially when using a commercial
guidance system. These segmentations are predominantly performed manually during the
procedure, which is time-consuming, variable, and often difficult, which can lead to
increased patient risk due to increased anesthesia exposure.7
Minimizing procedure time through fully or semi-automatic 3D TRUS prostate
segmentation has been previously investigated.8

11

Many methods have been shown to be

promising, but have lacked clinical translation due to computational complexity,
computation time, and robustness to diverse clinical datasets. Convolutional neural networks
(CNNs) have received widespread attention in many image processing applications with
much work investigating their accuracy and speed in medical imaging tasks. Prostate
segmentation in 3D TRUS is an image processing task that could be an ideal candidate for
the data-driven predictions provided by CNNs, although most existing work has
investigated their application in MRI,12,13 as ultrasound is considered more challenging due
to noise and image artifacts.
Recent work has investigated and provided promising results for the use of CNNs
in 2D TRUS14 and 3D TRUS15,16 prostate segmentation. Ghavami et al.,15 evaluated the
performance of an adapted U-Net on 109 side-fire sagittally-reconstructed (SR) 3D TRUS
images. Predictions were performed on acquired 2D images and varying adjacent
neighboring slices were also investigated to evaluate accuracy due to increasing spatial 3D
context. The best results reported for the 2D Dice similarity coefficient (DSC), 3D DSC,
and boundary distance were 89 ± 12 %, 89 ± 5 %, and 1.68 ± 1.57 mm, respectively. Lei
et al.,16 investigated a multidirectional deeply supervised 3D V-Net with contour
refinement on 44 patient 3D TRUS images. Their method was shown to improve
performance when segmenting the apex and base of the prostate, which is often difficult
due to low image contrast, and reported overall segmentation results for a 3D DSC,
Hausdorff distance (HD), mean surface distance (MSD), and residual mean surface
distance (RMSD) of 92 ± 3 %, 3.94 ± 1.55 mm, 0.60 ± 0.23 mm, and 0.90 ± 0.38 mm,
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respectively. However, these methods were tested using cross-validation approaches on 3D
TRUS images from a single ultrasound machine with matched voxel dimensions and sizes,
so further testing is still required on an unseen and variable dataset to provide a complete
understanding of performance while avoiding potential limitations due to information
bleeding.17,18 Furthermore, investigations into generalizability across procedures and
acquisition geometries have been limited, to our knowledge, which could restrict usability
when applying these techniques across applications.
Our work aims to demonstrate that a diverse image dataset can train a supervised
CNN to provide an accurate, fast, automated, and generalizable 3D prostate segmentation
prediction. We used 206 3D TRUS patient images from two different procedures and
acquisition geometries, two facilities, and four transducers used with three different
ultrasound machine models to modify and train a deep learning-based 2D segmentation
method followed by reconstruction into a 3D surface. Since deep learning approaches often
improve in performance when using large datasets (i.e., >1000 images), we chose to reslice
each 3D image to increase the amount of usable data for prostate segmentation training and
prediction. Testing was performed on 40 unseen 3D TRUS patient images and
segmentation performance was compared to state-of-the-art fully 3D approach s for
assessing the impact of reducing spatial context. Various metrics are reported in the
literature, and typically vary in choice and quantity between studies, but many metrics are
required to obtain a complete understanding of segmentation performance and to allow for
comparison with previous studies. By using a clinically diverse dataset with variable image
representation and image quality of the prostate, we intend to provide a thorough analysis
of performance for a broader scope of comparison. Once this method is evaluated,
completion of required intraoperative image-guidance tasks can be facilitated for different
needle-based prostate cancer procedures and potentially decrease overall clinical procedure
times and anesthesia risks to patients.
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2.2
2.2.1

Ma e ial a d Me h d
Clinical dataset
3D images of the prostate were acquired using end-fire (as used in prostate biopsy)

and side-fire SR (as used in some HDR-BT) mechanical scanning approaches (Fig. 2.1).19
Both methods rotate a TRUS transducer around the long-axis to create geometrically
different reconstructed 3D images that are influenced by the transducer array configuration.
The images used in this study were acquired with the C9-5 transducer with the iU22
(Philips, Amsterdam, the Netherlands), the C9-5 and BPTRT9-5 transducers with the ATL
HDI-5000 (Philips, Amsterdam, the Netherlands), and the 8848 transducer with the
Profocus 2202 (BK Medical, Peabody, MA, United States) ultrasound machine models.
The total dataset of 246 3D TRUS images consisted of 104 end-fire and 142 side-fire 3D
TRUS images and was split into training, validation, and testing datasets as shown in Table
2.1. Manual 3D prostate segmentations (excluding the seminal vesicles) were performed
by an observer (IG) with approximately 15 years of TRUS prostate image analysis
experience. 3D image sizes ranged from [300⨯400⨯784] to [408⨯441⨯870] voxels with
dimensions of [0.094⨯0.154⨯0.154] to [0.183⨯0.186⨯0.186] mm3/voxel for side-fire
images and from [448⨯350⨯448] to [692⨯520⨯692] voxels with dimensions of
[0.115⨯0.115⨯0.115] to [0.190⨯0.195⨯0.190] mm3/voxel for end-fire images.

57

Figure 2.1. Mechanical scanning approaches for acquiring 3D TRUS prostate images using
end-fire (left) and side-fire (right) TRUS transducers. 2D images are acquired by rotating
around the long axis of the transducer at known sample spacings to create 3D TRUS
images. Example 3D TRUS images are shown in the bottom row, with the front face
demonstrating the reconstructed image plane and the white lines showing representative
acquisition planes.

Table 2.1. Clinical 3D TRUS dataset split based on end-fire and side-fire scan geometries
and resulting training, validation, and testing datasets used for deep learning.
Image

Training

Validation

Testing

Total

End-fire
Side-fire
Total

67
98
165

17
24
41

20
20
40

104
142
246
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2.2.2

3D segmentation algorithm
A workflow diagram of our proposed method is shown in Fig. 2.2. This includes

3D TRUS prostate image input, radial sampling, prediction using a trained modified UNet, 3D reconstruction, and 3D prostate surface output.

Figure 2.2. Proposed 3D prostate segmentation workflow. A 3D TRUS prostate image is
used as input, followed by radial sampling to generate 12 2D image planes. Each image
plane was used to predict a prostate boundary with a trained modified U-Net prior to
reconstruction into the 3D prostate surface.

2.2.2.1

Training dataset for modified U-Net

Images from the training and validation split were used to obtain resliced 2D images
of the prostate. These 2D images were obtained at randomized axial, sagittal, coronal,
radial, and oblique image planes with varying rotations and zooms. This resulted in a
dataset of 6,773 2D TRUS images with matched manual contours. All 2D images were
resized to 256⨯256 pixels with no preprocessing (i.e., despeckling or bias correction) and
were separated into an 80/20 training/validation split for deep learning, resulting in 5418
training and 1355 validation 2D TRUS images.

2.2.2.2

Modified U-Net

The previously published U-Net20 was implemented using Keras21 with
TensorFlow22 and modified by adding 50% dropouts at every block on the expansion
section of the network to increase regularization and prevent overfitting. In addition,
transpose convolutions were used at each step in the expansion section instead of the
standard upsampling followed by convolution, as this allowed for improved performance
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in preliminary experiments. Data augmentation from random combinations of horizontal
flips, 2D shifts (up to 20%), rotations (up to 20°), and zooms (up to 20%) were employed
to double the training dataset to 10,836 2D TRUS images. Preliminary experiments led to
the selection of an Adam optimizer, 0.0001 learning rate, Dice-coefficient loss function,
200 epochs, and 200 steps per epoch. This network was trained and used for predicting
unseen data on a personal computer with two Xeon E5645 central processing units at 2.40
GHz (Intel Corporation, Santa Clara, CA, USA), 24.0 GB of memory, and a 6 GB GeForce GTX TITAN (NVIDIA Corporation, Santa Clara, CA, USA) graphics processing
unit (GPU).

2.2.2.3

3D reconstruction

Predicted 3D prostate segmentations were obtained by segmenting multiple 2D
radial frames generated by rotation around a central axis, followed by reconstruction to a
3D surface following a reconstruction method similar to Qiu et al.11 Previous observations
have noted that segmenting the prostate on slices near the apex and base of the prostate can
be challenging due to boundary incompleteness,15 so we chose to radially slice the 3D
prostate image as opposed to transverse slicing in an attempt to improve segmentations at
all boundaries. This choice was motivated by the experience of segmenting the prostate
when the center of the gland is in-plane, which typically presents as an easier image to
accurately define and segment the boundaries on the left and right sides of the 2D image.
In contrast to this, a transverse slicing approach would result in 2D images with the prostate
appearing as a different size and shape, with this difference more pronounced at the prostate
apex and base, and when comparing end-fire and side-fire image geometries. Difficulty
arises, predominantly in side-fire geometries, when segmenting the ends of the prostate
along the axis of acquisition (when using a 2D approach) due to the changes in prostate
appearance and size. Thus, radially slicing and segmenting the prostate in these views
allows for a method that can train and predict on images containing similar structural
shapes, across different acquisition geometries.
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(a)

(b)

( )

Figure 2.3. (a) Method for acquiring radially sliced 2D TRUS image planes (dotted lines)
from previously acquired 3D TRUS images. The axis of rotation (red) is approximately at
the central axis of the prostate and in the anterior-posterior direction. (b) 12 image slices
were obtained to perform prostate segmentation. For an end-fire 3D TRUS image, 2D
images are about the axis of image acquisition. (c) The majority of image slices obtained
from side-fire 3D TRUS images are across many acquisition slices and are subject to
increased interpolation, except for one slice, which matched the original acquired 2D
TRUS image.
Reconstructing a 3D contour was accomplished by radially slicing a 3D image in
equal 15° spacings around the approximate central axis of the prostate (Fig. 2.3) to produce
12 2D images for prediction. These 12 images were predicted using the trained modified
U-Net to produce 2D prostate segmentations, and 204 equally spaced points were sampled
around the boundary of each 2D image. Since the original spatial location of the input 2D
image in the 3D volume was known, each predicted 2D segmentation was placed
appropriately back into the 3D volume and the boundary points on each segmentation were
connected to the adjacent slices. The intermediate surface was smoothed by a windowed
sinc filter, resulting in a final reconstructed 3D contour.

2.2.3

Evaluation and comparison
Our algorithm was evaluated on a test data set of 20 unseen end-fire and 20 unseen

side-fire 3D TRUS images of the prostate. Standard pixel map comparisons (DSC, recall,
precision) were computed for both 2D radial slice segmentations and the reconstructed 3D
segmentation for each prostate to obtain an understanding of the prediction quality and
reconstruction accuracy. We also computed absolute area/volume percent differences
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(A/VPD), absolute mean surface distances (MSD), and absolute Hausdorff distances (HD),
as well as signed A/VPD (sA/VPD), signed MSD (sMSD), and signed HD (sHD) for all
2D predictions and reconstructed 3D segmentations. The signed metrics, while not
commonly reported, are important as they provide information on the segmentation bias
and whether the prostate boundary is over or underpredicted. The inclusion of these metrics
will provide a more complete understanding of the performance of our proposed method.
All pixel map comparisons and 2D MSD/sMSD and HD/sHD distance metrics were
computed using MATLAB R2019a (MathWorks, Natick, MA, United States). The 3D
MSD/sMSD and HD/sHD metrics were computed by measuring the distances between all
points of the automatically predicted segmentation to the closest point on the manual goldstandard segmentation (CloudCompare v2.10.2).23 For comparison purposes, the MSD
reported here is similar to the boundary distance15 and mean surface distance16 presented
previously. Computation times were recorded for 2D slice segmentation, 3D
reconstruction, and overall 3D segmentation time.
The performance of our algorithm was compared against three state-of-the-art fully
3D predicting CNNs (V-Net,24 Dense V-Net,25 and High-resolution 3D-Net26) using an
open-source implementation on the NiftyNet platform.27 It is often assumed that
performing a prediction based on 3D information allows for an improved result due to
increased spatial context, so we completed a direct comparison on the same test dataset to
investigate this hypothesis. Similar to our proposed method, the same 165/41 3D TRUS
images (Table 2.1) were used for training/validation, respectively. The 3D V-Net was
chosen to optimize hyperparameters, including loss function, due to its widespread use and
performance in preliminary experiments. For simplicity, these hyperparameters were also
used for the Dense V-Net and High-resolution 3D-Net. Parameters were chosen to
maximize the spatial window size and usable memory on the GPU with optimized
hyperparameters shown in Table 2.2. Previous work has shown improved performance
with a hybrid loss function,16 so we compared performance between a Dice loss function
and a Dice plus cross-entropy (DiceXEnt) loss function, as provided in NiftyNet, using the
3D V-Net. Although NiftyNet offers a patch-based analysis, preliminary experiments
resulted in 3D segmentations with many flat surfaces throughout the prediction
corresponding to patch edges. Since we had one structure of interest (i.e., the prostate), we
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did not perform a patch-based analysis and predictions were performed on a resized image
to match the spatial window. Data augmentation was employed to double the training
dataset to 330 3D TRUS images. The chosen hyperparameters for the Dense V-Net and
High-resolution 3D-Net were the same as shown in Table 2.2 (with the DiceXEnt loss
function). These networks were trained and used for predicting unseen data on a personal
computer with an Intel Core i7-4770 central processing unit at 3.40 GHz (Intel Corporation,
Santa Clara, CA, USA), 32.0 GB of memory, and a 6 GB Ge-Force GTX TITAN (NVIDIA
Corporation, Santa Clara, CA, USA) graphics processing unit (GPU). Training and 3D
segmentation computation times were recorded.
Table 2.2. Hyperparameter selection when employing the V-Net in NiftyNet.

2.2.4

Hyperparameter

Value

Optimizer
Loss function
Activation function
Learning rate
Spatial window size
Mini-batch size
Weighted L2-decay

Adam
Dice and Dice + cross-entropy
PReLU
0.0001
[64, 64, 64]
2
0.0001

Statistical analysis
Statistical calculations were performed in GraphPad Prism 8.3 (Graphpad

Software, Inc., San Diego, CA, USA). The normality of distributions was evaluated using
the Shapiro-Wilk test and led to the use of nonparametric statistical tests when the
assumption was violated. The corresponding nonparametric alternative tests are presented
in parentheses for the remainder of the section. The significance level for statistical analysis
was chosen such that the probability of making a type I error was less than 5% (p < 0.05),
with statistically significant differences denoted simply as significant for the remainder of
this manuscript.
2D radial slice segmentation and 3D reconstructed segmentation accuracy as well
as Dice and DiceXEnt 3D V-Net loss functions were compared using two-tailed paired ttests (Wilcoxon matched-pairs signed-rank tests). Comparisons between our proposed
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algorithm and three fully 3D CNNs were performed using two-tailed paired t-tests
(Wilcoxon matched-pairs signed-rank tests) with a Bonferroni multiple-comparison
correction, which adjusted the significance level to p < 0.0167. Comparisons between
segmentation accuracy for end-fire and side-fire 3D TRUS images on each network were
completed using two-tailed unpaired t-tests (Mann-Whitney tests).

2.3
2.3.1

Re l
Reconstructed modified U-Net
The results of our modified U-Net for 2D prostate segmentation and the effects of

reconstruction on 3D surface generation are shown in Tables 2.3 and 2.4 for the absolute
and signed evaluation metrics, respectively. Overall, our proposed method generated 3D
surfaces with a median [first quartile (Q1), third quartile (Q3)] 3D DSC, recall, and
precision of 94.1 [92.6, 94.9] %, 96.0 [93.1, 98.5] %, and 93.2 [88.8, 95.4] %, respectively,
for the pixel map comparison metrics. Absolute VPD, MSD, and HD metrics resulted in
5.78 [2.49, 11.5] %, 0.89 [0.73, 1.09] mm, and 2.89 [2.37, 4.35] mm with signed metrics
of 2.38 [-2.98, 11.0] %, 0.11 [-0.24, 0.58] mm, and 2.02 [-3.34, 2.88] mm, respectively.
All metrics, aside from the absolute and signed HD metrics, showed significant differences
between the 2D predictions and 3D reconstructed segmentations. Interestingly, recall and
MSD metrics were observed to significantly improve in performance after 3D
reconstruction, with the HD metric improving as well when evaluating all unseen images.
These findings agreed when splitting the results into end-fire and side-fire 3D TRUS
images, other than end-fire A/VPD and the signed metrics. For end-fire images, absolute
VPD increased after 3D reconstruction, although this was not significant, while the signed
metrics significantly improved after 3D reconstruction. For side-fire images, the opposite
was true, with signed metrics significantly improved for 2D slice segmentations. When
comparing the performance of our proposed method between end-fire and side-fire 3D
TRUS images, we found there was no significant difference in any metric for both 2D
radial segmentations and 3D reconstructed segmentations. Mean computation times were
observed to be 0.029 s for each 2D segmentation (i.e., 12 images) and 0.27 s for
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reconstruction into a 3D surface, resulting in a total throughput time of 0.62 s from 3D
image input to generated 3D surface.

Table 2.3. Absolute median [Q1, Q3] results comparing 2D radial slice segmentation to
3D reconstructed segmentation on an unseen test dataset of 20 end-fire and 20 side-fire 3D
TRUS images of the prostate.
Acquisition

End-fire

Side-fire

Overall

Segmentation

DSC (%)

Recall (%)

95.0
94.5
[93.6, 95.6] [92.7, 97.2]
3D Reconstruction
94.3
96.0
[93.1, 95.2] [93.2, 98.7]
p-value
0.0052*
0.0102*

Precision (%) A/VPD (%) MSD (mm)

HD (mm)

2D Radial

95.9
[92.2, 97.4]
94.6
[88.8, 95.8]
<0.0001

4.71
1.16
3.64
[1.71, 7.32] [0.95, 1.37] [3.11, 4.47]
5.18
0.99
3.41
[1.62, 11.2] [0.78, 1.18] [2.49, 4.41]
0.0532
<0.0001*
0.5217

2D Radial

94.9
[92.6, 96.4]
91.6
[87.8, 94.8]
<0.0001*

4.05
0.95
3.15
[1.07, 6.23] [0.82, 1.26] [2.51, 4.27]
5.89
0.78
2.61
[3.17, 11.9] [0.67, 0.98] [2.32, 4.01]
0.0441
<0.0001
0.3683

2D Radial

95.6
[92.6, 96.7]
93.2
[88.8, 95.4]
<0.0001

4.34
1.06
3.34
[1.60, 6.77] [0.85, 1.32] [2.61, 4.41]
5.78
0.89
2.89
[2.49, 11.5] [0.73, 1.09] [2.37, 4.35]
0.0061
<0.0001*
0.2766

94.6
95.3
[92.7, 95.4] [90.6, 96.9]
3D Reconstruction
93.5
96.2
[91.1, 94.6] [92.5, 98.4]
p-value
0.0037
0.0215
94.9
94.9
[93.2, 95.5] [91.9, 97.0]
3D Reconstruction
94.1
96.0
[92.6, 94.9] [93.1, 98.5]
p-value
<0.0001
0.0005

DSC, Dice similarity coefficient; A/VPD, area/volume percent diff.; MSD, mean surface dist.; HD, Hausdorff dist.
*Normal distribution = paired t-test; Bolded metrics highlight the method with reduced relative error.

Table 2.4. Signed median [Q1, Q3] results comparing 2D radial slice segmentation to 3D
reconstructed segmentation on an unseen test dataset of 20 end-fire and 20 side-fire 3D
TRUS images of the prostate.
Acquisition

Segmentation
sA/VPD (%)
sMSD (mm)
sHD (mm)
2D Radial
-1.39 [-3.82, 5.82]
-0.13 [-0.50, 0.71]
-0.91 [-2.74, 2.81]
End-fire
3D Reconstruction
-0.05 [-2.98, 11.2]
0.06 [-0.38, 0.85]
-0.34 [-3.82, 3.28]
p-value
0.0011*
<0.0001*
0.9563
2D Radial
-0.57 [-5.24, 3.27]
0.09 [-0.46, 0.31]
-0.31 [-1.83, 1.72]
Side-fire
3D Reconstruction
3.20 [-2.96, 10.1]
0.20 [-0.22, 0.46]
2.25 [-2.53, 2.81]
p-value
0.0001*
<0.0001*
0.2305
2D Radial
-0.91 [-4.93, 4.20]
-0.09 [-0.46, 0.37]
-0.91 [-2.15, 2.02]
Overall
3D Reconstruction
2.38 [-2.98, 11.0]
0.11 [-0.24, 0.58]
2.02 [-3.34, 2.88]
p-value
<0.0001*
<0.0001*
0.3611
sA/VPD, signed area/volume percent diff.; sMSD, signed mean surface dist.; sHD, signed Hausdorff dist.
*Normal distribution = paired t-test; Bolded metrics highlight the method with reduced relative error.
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2.3.2

3D CNNs and V-Net optimization
Results of the NiftyNet 3D V-Net with a Dice and DiceXEnt loss function on 20

unseen end-fire and 20 unseen side-fire 3D TRUS images are shown in Tables 2.5 and 2.6
for the absolute and signed evaluation metrics, respectively. When comparing 3D V-Net
performance with Dice and DiceXEnt loss functions on the full testing dataset, all metrics,
aside from DSC, showed significant differences. Precision, VPD/sVPD, MSD/sMSD, and
HD/sHD were significantly improved with the DiceXEnt loss function, while recall was
significantly improved with the Dice loss function. Although there was no significant
difference in the DSC metric, the DiceXEnt loss function showed an improved median
DSC. When considering end-fire and side-fire images individually, identical trends were
observed for precision, recall, sMSD, and sHD. For the DSC, VPD, MSD, and HD metrics,
we observed a significant and nonsignificant increase in performance with the DiceXEnt
loss function for end-fire images and side-fire images, respectively. For end-fire images,
the sVPD metric improved significantly with the DiceXEnt loss function, while the sVPD
metric improved significantly with the Dice loss function for side-fire images. When
comparing the 3D V-Net performance with DiceXEnt between end-fire and side-fire 3D
TRUS images, we found no significant differences in any metric except HD, where sidefire images had a significantly reduced median value compared to end-fire images. Overall,
the 3D V-Net showed improved performance with the DiceXEnt loss function and
produced 3D segmentations with median [Q1, Q3] 3D DSC, recall, and precision results
of 91.3 [88.6, 93.1] %, 90.0 [85.6, 93.3] %, and 94.5 [90.0, 96.5] %, respectively, for the
pixel map comparison metrics. Absolute VPD, MSD, and HD metrics resulted in 7.94
[3.55, 13.4] %, 1.27 [0.92, 1.61] mm, and 6.18 [4.51, 7.82] mm with signed variants of 3.66 [-9.25, 3.34] %, -0.13 [-0.73, 0.26] mm, and -4.16 [-7.04, 4.76] mm, respectively.
Mean computation times were observed to be 3.43 s for a full 3D segmentation.
Results of the Dense V-Net and High-resolution 3D-Net with a DiceXEnt loss
function on 20 unseen end-fire and 20 unseen side-fire 3D TRUS images are shown in
Tables 2.A1 and 2.A2 in Supplement A for the absolute and signed evaluation metrics,
respectively. Compared to the 3D V-Net, the High-resolution 3D-Net showed a reduction
in median performance for all metrics, while the Dense V-Net showed a reduction in
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performance for all metrics except recall. In contrast with our proposed method and the 3D
V-Net, we observed significant differences in segmentation performance for several
metrics when comparing end-fire and side-fire 3D TRUS images using the Dense V-Net
and High-resolution 3D-Net. For the Dense V-Net, improved performance was observed
on side-fire images for every metric except recall, with significant differences observed for
the precision, recall, VPD/sVPD, and sMSD metrics. For the High-resolution 3D-Net,
improved performance was observed on end-fire images for every metric except precision
and HD, with significant differences observed for the DSC, precision, recall, VPD/sVPD,
and sMSD metrics. Mean 3D segmentation times for the Dense V-Net and High-resolution
3D-Net were observed to be 2.98 s and 2.83 s, respectively.

2.3.3

Comparison of reconstructed modified U-Net and 3D CNNs
Sample segmentation results from the 20 unseen end-fire and 20 unseen side-fire

3D TRUS images from our proposed method compared against the 3D V-Net with a
DiceXEnt loss function and manual segmentations are shown in Fig. 2.4 and Fig. 2.5,
respectively. A comparison of segmentation performance between our proposed method
and a standard 3D V-Net is shown in Tables 2.7 and 2.8 for the absolute and signed
evaluation metrics, respectively. Overall, our proposed method had significantly improved
DSC, Recall, sVPD, MSD/sMSD, and HD when compared to the 3D V-Net. Absolute VPD
and sHD, while not significantly different, were reduced for our proposed method. The
only evaluation metric where the 3D V-Net outperformed our proposed method was
precision, where the 3D V-Net showed a nonsignificant increase. Considering
segmentation performance for end-fire and side-fire 3D TRUS images separately, similar
trends hold. For end-fire images, our proposed method had better performance in all
metrics except sHD, with DSC, recall, sVPD, MSD, and HD showing significant
differences, and precision, VPD, and sMSD showing nonsignificant improvements.
However, for side-fire images our proposed method was superior in all metrics except
precision. Significant improvements were shown for DSC, recall, sVPD, MSD/sMSD, and
HD/sHD, while the 3D V-Net had significantly improved precision. As was observed in
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the overall case, our proposed method showed a nonsignificant decrease in VPD compared
to the 3D V-Net for both end-fire and side-fire images.

Table 2.5. Absolute median [Q1, Q3] results comparing a standard 3D V-Net with a Dice
similarity coefficient loss function to a Dice similarity plus cross-entropy (DiceXEnt) loss
function on an unseen test dataset of 20 end-fire and 20 side-fire 3D TRUS images of the
prostate.
Acquisition

End-fire

Loss function

DSC (%)

Recall (%)

Precision (%)

VPD (%)

MSD (mm)

HD (mm)

Dice

89.5
[84.6, 92.0]
91.7
[89.0, 93.2]
0.0037

97.8
[94.6, 98.3]
91.7
[86.8, 94.6]
<0.0001

83.7
[75.1, 88.4]
94.3
[87.1, 95.8]
<0.0001

17.8
[7.57, 30.7]
7.94
[2.95, 12.5]
0.0021

1.79
[1.43, 2.47]
1.32
[0.99, 1.77]
0.0009

8.64
[7.53, 10.8]
6.95
[5.06, 9.10]
0.0172

90.6
[89.1, 93.2]
91.2
[87.4, 92.8]
0.2943

94.5
[91.1, 96.0]
89.5
[80.7, 92.9]
<0.0001

92.8
[89.9, 96.9]
95.0
[90.8, 97.5]
0.0001

9.08
[4.35, 14.0]
7.71
[3.55, 15.9]
0.7012

1.16
[0.89, 1.46]
1.11
[0.84, 1.47]
0.7562

5.81
[3.85, 9.61]
4.92
[4.28, 6.55]
0.2305

90.3
[86.5, 92.1]
91.3
[88.6, 93.1]
0.1538

95.5
[92.5, 97.8]
90.0
[85.6, 93.3]
<0.0001

87.8
[81.0, 91.7]
94.5
[90.0, 96.5]
<0.0001

11.4
[4.66, 19.3]
7.94
[3.55, 13.4]
0.0356

1.46
[1.16, 2.07]
1.27
[0.92, 1.61]
0.0147

7.99
[5.34, 10.4]
6.18
[4.51, 7.82]
0.0067

DiceXEnt
p-value
Dice

Side-fire

DiceXEnt
p-value
Dice

Overall

DiceXEnt
p-value

DSC, Dice similarity coefficient; VPD, volume percent difference; MSD, mean surface dist.; HD, Hausdorff dist.
*Normal distribution = paired t-test; Bolded metrics highlight the loss function with reduced relative error.

Table 2.6. Signed median [Q1, Q3] results comparing a standard 3D V-Net with a Dice
loss function to a Dice plus cross-entropy (DiceXEnt) loss function on an unseen test
dataset of 20 end-fire and 20 side-fire 3D TRUS images of the prostate.
Acquisition

Loss function
sVPD (%)
sMSD (mm)
sHD (mm)
Dice
17.8 [7.57, 30.7]
1.51 [0.85, 2.23]
7.99 [5.37, 10.84]
End-fire
DiceXEnt
-2.16 [-8.47, 6.10]
-0.07 [-0.71, 0.68]
-0.05 [-7.33, 6.50]
p-value
<0.0001*
<0.0001*
0.0009
Dice
5.02 [0.93, 11.5]
0.43 [0.16, 0.80]
5.34 [3.18, 9.61]
Side-fire
DiceXEnt
-5.50 [-15.6, -0.62]
-0.30 [-0.88, 0.02]
-4.52 [-6.27, -3.04]
p-value
<0.0001*
<0.0001*
<0.0001
Dice
9.63 [3.90, 18.9]
0.83 [0.35, 1.78]
6.91 [3.35, 10.31]
Overall
DiceXEnt
-3.66 [-9.25, 3.34]
-0.13 [-0.73, 0.26]
-4.16 [-7.04, 4.76]
p-value
<0.0001*
<0.0001*
<0.0001*
sVPD, signed volume percent difference; sMSD, signed mean surface dist.; sHD, signed Hausdorff dist.
*Normal distribution = paired t-test; Bolded metrics highlight the loss function with reduced relative error.
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Overall, our proposed method significantly improved performance on all metrics
when compared to the Dense V-Net and showed improved performance on all metrics
when compared to the High-resolution 3D-Net, with significant differences observed for
all metrics except precision, sMSD, and sHD, where our method showed a nonsignificant
improvement.
Table 2.7. Absolute median [Q1, Q3] results comparing a standard 3D V-Net to our
proposed reconstructed modified (rm) U-Net on an unseen test dataset of 20 end-fire and
20 side-fire 3D TRUS images of the prostate.
Acquisition
End-fire

Segmentation

DSC (%)

Recall (%)

Precision (%)

VPD (%)

MSD (mm)

HD (mm)

V-Net

91.7
[89.0, 93.2]
94.3
[93.1, 95.2]
0.0003*

91.7
[86.8, 94.6]
96.0
[93.2, 98.7]
<0.0001*

94.3
[87.1, 95.8]
94.6
[88.8, 95.8]
0.5459

7.94
[2.95, 12.5]
5.18
[1.62, 11.2]
0.4980

1.32
[0.99, 1.77]
0.99
[0.78, 1.18]
0.0003*

6.95
[5.06, 9.10]
3.41
[2.49, 4.41]
<0.0001

91.2
[87.4, 92.8]
93.5
[91.1, 94.6]
0.0073

89.5
[80.7, 92.9]
96.2
[92.5, 98.4]
0.0002

95.0
[90.8, 97.5]
91.6
[87.8, 94.8]
0.0153

7.71
[3.55, 15.9]
5.89
[3.17, 11.9]
0.2611

1.11
[0.84, 1.47]
0.78
[0.67, 0.98]
0.0027

4.92
[4.28, 6.55]
2.61
[2.32, 4.01]
0.0001

91.3
[88.6, 93.1]
94.1
[92.6 , 94.9]
<0.0001

90.0
[85.6, 93.3]
96.0
[93.1, 98.5]
<0.0001

94.5
[90.0, 96.5]
93.2
[88.8, 95.4]
0.1499

7.94
[3.55, 13.4]
5.78
[2.49, 11.5]
0.1701

1.27
[0.92, 1.61]
0.89
[0.73, 1.09]
<0.0001*

6.18
[4.51, 7.82]
2.89
[2.37, 4.35]
<0.0001

rmU-Net
p-value
Side-fire

V-Net
rmU-Net
p-value

Overall

V-Net
rmU-Net
p-value

DSC, Dice similarity coefficient; VPD, volume percent difference; MSD, mean surface dist.; HD, Hausdorff dist.
*Normal distribution = paired t-test; Bolded metrics highlight the method with reduced relative error.

Table 2.8. Signed median [Q1, Q3] results comparing a standard 3D V-Net to our proposed
reconstructed modified (rm) U-Net on an unseen test dataset of 20 end-fire and 20 side-fire
3D TRUS images of the prostate.
Acquisition

Segmentation
sVPD (%)
sMSD (mm)
sHD (mm)
V-Net
-2.16 [-8.47, 6.10]
-0.07 [-0.71, 0.68]
-0.05 [-7.33, 6.50]
End-fire
rmU-Net
-0.05 [-2.98, 11.2]
0.06 [-0.38, 0.85]
-0.34 [-3.82, 3.28]
p-value
0.0030*
0.0444*
0.7942*
V-Net
-5.50 [-15.6, -0.62]
-0.30 [-0.88, 0.02]
-4.52 [-6.27, -3.04]
Side-fire
rmU-Net
3.20 [-2.96, 10.1]
0.20 [-0.22, 0.46]
2.25 [-2.53, 2.81]
p-value
0.0001*
0.0025*
0.0107
V-Net
-3.66 [-9.25, 3.34]
-0.13 [-0.73, 0.26]
-4.16 [-7.04, 4.76]
Overall
rmU-Net
2.38 [-2.98, 11.0]
0.11 [-0.24, 0.58]
2.02 [-3.34, 2.88]
p-value
<0.0001*
0.0003*
0.0408
sVPD, signed volume percent difference; sMSD, signed mean surface dist.; sHD, signed Hausdorff dist.
*Normal distribution = paired t-test; Bolded metrics highlight the method with reduced relative error.

69

Figure 2.4. End-fire prostate segmentation results comparing manual (red), our proposed
reconstructed modified (rm) U-Net (blue), and V-Net (yellow) 3D surfaces. The columns
from left to right show the 25th, 50th, and 75th percentile results, respectively, based on DSC
metrics. Segmentations in the axial plane, sagittal plane, 45° oblique radial plane, and
reconstructed 3D surface error are shown in the respective rows from top to bottom.
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Figure 2.5. Side-fire prostate segmentation results comparing manual (red), our proposed
reconstructed modified (rm) U-Net (blue), and V-Net (yellow) 3D surfaces. The columns
from left to right show the 25th, 50th, and 75th percentile results, respectively, based on DSC
metrics. Segmentations in the axial plane, sagittal plane, 45° oblique radial plane, and
reconstructed 3D surface error are shown in the respective rows from top to bottom.
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2.4
2.4.1

Di c

i

Reconstructed modified U-Net
We proposed a new 3D TRUS prostate segmentation method, which utilizes a

modified U-Net to segment 12 2D radial slices, which are then reconstructed into a 3D
surface. We first compared segmentation accuracy in these 2D radial slices to segmentation
accuracy following 3D reconstruction. In general, the performance was better on the 2D
radial slice segmentations compared to the reconstructed 3D surface, but interestingly, our
reconstruction method improved recall, MSD, and HD metrics when compared to 2D slice
segmentation. When considered in combination, the reduced MSD and HD metrics showed
better mean and irregular boundary accuracy, with the improved recall metric implying a
reduction in underprediction (since decreasing underpredicted pixels, i.e., false negatives,
will increase recall). The reduction in underprediction is contrasted with our method
tending to overpredict, supported by the slight positive bias in the signed metrics and
reduced precision. In the metrics where performance was worse for our 3D reconstructed
segmentations, such as DSC and VPD, the difference in median values were less than 1%
and 1.5% respectively. Thus, we saw that our 3D reconstruction method did not drastically
reduce performance of the evaluation metrics when compared to our 2D segmentations,
with the 3D reconstruction improving performance on select metrics. Examining the signed
metrics shown in Table 2.4, we observed that sVPD, sMSD, and sHD are reduced
compared to their absolute metrics, with median sVPD reduced to only 2.38 %, median
sMSD reduced to 0.11 mm, and median sHD reduced to 2.02 mm. This demonstrated that
our algorithm was not significantly biased to over or underpredict the prostate boundary.
As our proposed network was trained and tested on both end-fire and side-fire 3D
TRUS images, we directly compared the performance of our method on each image type
observing no significant difference between performance for end-fire and side-fire images
on any metric. Both independent image geometries also followed the same trends as the
total dataset, aside from a reduced signed bias in the end-fire images following
reconstruction. These results demonstrated the effectiveness of radially sampling 3D
TRUS prostate images to produce similar 2D images for prediction and the ability to
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accurately segment the prostate in different 3D TRUS image geometries without the need
for multiple trained networks, which, to our knowledge, is the first time this has been
shown.

2.4.2

3D CNNs and V-Net Optimization
The initial publication describing the V-Net architecture by Milletari et al.24

proposed the use of a Dice coefficient-based loss function, but recent leave-one-out
validation, described in Lei et al.,16 has advocated for the use of hybrid loss functions that
combine standard logistic loss, such as the cross-entropy loss metric,20 with the Dice loss
metric. We implemented a 3D V-Net with both a Dice loss function and a hybrid DiceXEnt
loss function in order to compare performance between loss functions, as well as to directly
compare performance to previously published V-Net implementations16 on an unseen
dataset. Our results reiterate what has been previously reported, with the hybrid DiceXEnt
loss function significantly improving performance on all metrics except DSC and recall,
where we observed a nonsignificant increase in performance and a significant decrease in
performance, respectively. Similar trends held when examining the results for end-fire and
side-fire 3D TRUS images individually. Comparing 3D V-Net performance when using a
DiceXEnt loss function between end-fire and side-fire 3D TRUS images showed similar
results to our proposed network, as there was no significant difference in any metric except
HD.
Similar segmentation performance on end-fire and side-fire 3D TRUS images for
all three 3D CNNs and our proposed 3D segmentation method demonstrated that we could
potentially train a single network to accurately segment the prostate in geometrically
variable 3D TRUS images. This was demonstrated predominantly with our approach and
the 3D V-Net as the Dense V-Net and High-resolution 3D-Net were observed to have
significant differences between several metrics when comparing end-fire and side-fire
segmentation performance. Interestingly, performance differed between the Dense V-Net
and High-resolution 3D-Net for different image geometries, with better predictions
performed on side-fire and end-fires images, respectively. Although our method performed
the best, the 3D V-Net outperformed the other two 3D CNNs investigated in this study.
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This improved performance on 3D US prostate segmentation could be due to the number
of parameters trained by the network since the 3D V-Net has approximately two orders of
magnitude more parameters relative to the Dense V-Net and High-resolution 3D-Net.
Although the latter networks are more efficient and required less computation time, we
found this did not benefit performance.
Although Lei et al.16 reported on a deep supervision method with contour
refinement, they also reported on the use of a standard 3D V-Net with a hybrid DiceXEnt
loss function to segment the prostate in side-fire 3D TRUS images, showing a 3D DSC,
precision, recall, HD, MSD, and RMSD of 90.5 ± 3.0 %, 88.1 ± 6.0 %, 93.5 ± 3.5 %, 4.643
± 1.926 mm, 0.657 ± 0.270 mm, and 0.977 ± 0.410 mm, respectively. Comparatively, a
standard 3D V-Net with a DiceXEnt loss function trained on our dataset and predicted on
side-fire images resulted in a 3D DSC, precision, recall, HD, and MSD of 91.2 [87.4, 92.8]
%, 95.0 [90.8, 97.5] %, 89.5 [80.7, 92.9] %, 4.92 [4.28, 6.55] mm, and 1.11 [0.84, 1.47]
mm, showing very similar performance. Investigating the differences between mean and
median values showed our V-Net implementation demonstrated improved 3D DSC and
precision, while Lei et al.16 demonstrated improved recall, HD, and MSD. Although VDP
or any signed metrics were not reported, this demonstrated similarity in performance. Thus,
we suggest future comparisons should use a standardized V-Net, like the NiftyNet opensource implementation, to provide a baseline for comparing network performance on
different data sets.

2.4.3

Comparison with 3D V-Net and previously published methods
For an identical training and testing dataset, our proposed method performed

significantly better than the standard 3D V-Net with a hybrid loss function, with DSC,
recall, sVPD, MSD/sMSD, and HD/sHD showing significant improvement. Our proposed
method also demonstrated a reduced median VPD, although this difference was not
significant. Similar differences in performance were observed when considering end-fire
and side-fire 3D TRUS images separately. Fig. 2.4 and 2.5 show this difference in
performance qualitatively for both image geometries, with the 3D V-Net often over or
underpredicting the correct prostate boundary. This difference is readily apparent in the
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side-fire middle 50th percentile column of Fig. 2.5. The V-Net is shown to have incorrectly
contoured part of the bladder as the prostate, drastically affecting the overall segmentation
accuracy. In contrast, our proposed method was able to correctly avoid the bladder,
resulting in a more accurate segmentation. A similar result is shown in the left column of
Fig. 2.4 as well as in Fig. 2.6, where we show that the 3D V-Net mistakenly underpredicted
the prostate boundary due to the presence of a hyperechoic calcification artifact in the
TRUS image, whereas our proposed method was typically able to avoid artifacts of this
nature. We demonstrated a mean 3D segmentation time of 0.62 s with our proposed
method, over five times faster than the 3D V-Net, which required an average of 3.43 s per
segmentation. All segmentations were completed with the same NVIDIA GeForce GTX
TITAN GPU with 6 GB of memory.

Figure 2.6. A sample end-fire prostate segmentation result comparing manual (red), our
proposed algorithm (blue), and V-Net (yellow) 3D surfaces in the presence of a
hyperechoic calcification image artifact.

Recent work by Ghavami et al.15 and Lei et al.16 report on automatic prostate
segmentation in 3D TRUS images, with Ghavami et al.15 reporting best results for 2D DSC,
3D DSC, and boundary distance of 89 ± 12 %, 89 ± 5 %, and 1.68 ± 1.57 mm, respectively,
and Lei et al.16 reporting overall segmentation results for 3D DSC, precision, recall, HD,
MSD, and RMSD of 91.9 ± 2.8 %, 90.6 ± 5.5 %, 93.8 ± 4.3 %, 3.938 ± 1.550 mm, 0.599
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± 0.225 mm, and 0.900 ± 0.377 mm, respectively. Our proposed method demonstrated
overall segmentation results for 2D DSC, 3D DSC, precision, recall, HD, and MSD of 94.9
[93.2, 95.5] %, 94.1 [92.6, 94.9] %, 93.2 [88.08, 95.4] %, 96.0 [93.1, 98.5] %, 2.89 [2.37,
4.35] mm, and 0.89 [0.73, 1.09] mm, respectively, outperforming the network reported by
Ghavami et al.15 on all reported metrics, and outperforming the network reported by Lei et
al.16 on all metrics except MSD. In addition, our paper reports on metrics not used in the
studies described here, including VPD, and signed variants of VPD, MSD, and HD,
providing additional insight into the performance of our network that is otherwise not
present when these metrics are excluded. Lei et al.16 reported segmentation times of
approximately 1-2 s for a U-Net, V-Net, and their proposed network, with segmentations
completed using an NVIDIA TITAN XP GPU with 12 GB of memory. Comparatively, our
V-Net implementation in NiftyNet had a mean segmentation time of 3.43 s, while our
proposed method had a mean segmentation time of 0.62 s, with segmentations completed
using an NVIDIA GeForce GTX TITAN GPU with 6 GB of memory. Although our V-Net
had slower segmentation times, our proposed method was one and a half to three times
faster, using a GPU with half the memory, demonstrating the advantage of our proposed
method regarding segmentation time.
Studies reported by Ghavami et al.15 and Lei et al.16 are also limited by their use of
cross-validation approaches, in addition to their dataset consisting of only one image
geometry and a single ultrasound machine with matched voxel dimensions and sizes. In
contrast, we used a clinically diverse dataset of 3D TRUS images of different image
geometries, generated by several different ultrasound transducers used with different
machine models, and used in distinct procedures. This dataset contains images with varying
voxel dimensions, size, and image quality, and we have employed no pre-processing before
training to reduce process complexity. To our knowledge, the use of a dataset with different
image geometries, ultrasound transducers, ultrasound machine models, voxel dimensions,
and image sizes for 3D TRUS prostate segmentation is unique and may allow for a more
robust and generalizable segmentation method. In addition, we have not used a crossvalidation approach, instead testing our algorithm on 3D TRUS images that were
completely unseen by the network, which we believe strengthens the significance of our
results and may result in improved generalizability.
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2.4.4

Limitations and future work
Although we have demonstrated excellent performance with our proposed

algorithm, a parameter that may be interesting to explore in future work is the step angle
for radial slice generation. Specifically, it would be interesting to investigate whether a
decreased step angle and thus an increased number of radial slices would significantly
increase performance, or whether a decreased number of slices could be used while
maintaining similar performance. An increased number of radial slices would increase
computation time, which motivated our choice of a 15° step angle for the proposed method.
When training the 3D CNNs for performance comparison, hyperparameters were
optimized on the V-Net and were used for the other two networks. Even though we
investigated other combinations and found these hyperparameters to perform the best on
the Dense V-Net and High-resolution 3D-Net, a rigorous optimization was not performed
and has the potential to increase performance. Another limitation of our study is the use of
only one observer for providing ground truth segmentations. This meant we could not
directly assess inter-observer variability for our dataset. In addition, we did not directly
assess intra-observer variability over several time points. Inter- and intra-observer
variability in end-fire 3D TRUS images were previously assessed by our group,11 and are
summarized here. To assess intra-observer variability, one observer segmented 15 3D
images five times each, resulting in a 3D DSC of 93.0 ± 2.1 %. To assess inter-observer
variability, three untrained observers segmented 15 3D images three times each, resulting
in a DSC of 93.5 ± 2.1 %, 92.6 ± 3.1 %, and 92.3 ± 3.2 %, with an ANOVA demonstrating
no significant difference. Inter- and intra-observer variability in side-fire 3D TRUS images
were also assessed by our group,28 reporting 5.1 % variability and 99 % reliability in intraobserver prostate volume estimates, and 11.4 % variability and 96 % reliability in interobserver estimates, for a study of eight observers measuring 15 prostate images twice. This
variability is comparable to the reported DSC of our proposed method in this work,
showing that our algorithm is performing at the level of intra-observer variability in the
ground truth segmentations. Due to the demonstrated variability between different
observers when segmenting 3D TRUS images, segmentations from other observers should
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be incorporated into our testing dataset to further improve the robustness of our proposed
method.

2.5

C

cl i

This study investigated the development of a 2D deep learning with 3D
reconstruction approach for automatic prostate segmentation in 3D TRUS images. Multiple
facilities, ultrasound machine models, and acquisition geometries were investigated to
evaluate robustness and generalizability, with comparisons performed against multiple 3D
CNNs. A fast, accurate, and generalizable automatic prostate segmentation algorithm could
reduce physician burden and procedure time, offering potential workflow benefits for
fusion-guided prostate biopsy, tumor-targeted HDR-BT, and TRUS-guided whole-gland
BT. Reducing the time a patient is under anesthesia, as in HDR-BT, also promotes a
potentially safer procedure with fewer adverse side effects.
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Table 2.A1. Absolute median [Q1, Q3] results comparing a Dense V-Net (DenseNet) and
High-resolution 3D Network (HighRes3dNet) on an unseen test dataset of 20 end-fire and
20 side-fire 3D TRUS images of the prostate.
Acquisition

Segmentation
DenseNet

End-fire
HighRes3dNet

DenseNet
Side-fire
HighRes3dNet

DenseNet
Overall
HighRes3dNet

DSC (%)

Recall (%)

Precision (%)

VPD (%)

MSD (mm)

HD (mm)

87.9
[84.9, 90.4]
90.0
[87.3, 91.4]

95.4
[92.9, 97.0]
91.7
[84.6, 94.9]

82.2
[77.4, 86.5]
89.3
[87.0, 93.7]

15.6
[9.42, 20.8]
6.88
[4.30, 15.7]

2.11
[1.55, 2.85]
1.62
[1.41, 2.08]

10.0
[7.82, 12.5]
8.95
[7.56, 11.2]

88.7
[81.6, 90.7]
86.2
[84.3, 88.7]

89.1
[86.0, 95.1]
80.5
[76.8, 86.0]

89.6
[82.8, 91.9]
94.9
[90.9, 96.1]

6.38
[4.22, 12.6]
15.3
[9.77, 20.0]

1.47
[1.26, 2.56]
1.64
[1.36, 1.93]

8.96
[5.93, 13.8]
7.82
[6.67, 9.31]

88.2
[84.3, 90.6]
87.5
[85.5, 90.3]

93.0
[88.9, 96.1]
85.4
[79.8, 92.1]

84.8
[79.2, 90.2]
92.3
[88.4, 95.8]

11.0
[5.96, 19.3]
11.8
[4.68, 18.0]

2.00
[1.36, 2.63]
1.63
[1.40, 1.97]

9.23
[7.00, 13.2]
8.37
[6.89, 10.9]

DSC, Dice similarity coefficient; VPD, volume percent difference; MSD, mean surface dist.; HD, Hausdorff dist.

Table 2.A2. Signed median [Q1, Q3] results comparing a Dense V-Net (DenseNet) and
High-resolution 3D Network (HighRes3dNet) on an unseen test dataset of 20 end-fire and
20 side-fire 3D TRUS images of the prostate.
Acquisition

Segmentation

sVPD (%)

sMSD (mm)

sHD (mm)

End-fire

DenseNet
HighRes3dNet

15.6 [9.42, 20.8]
2.86 [-6.42, 8.86]

1.44 [0.92, 2.18]
0.37 [-0.46, 0.93]]

9.13 [7.19, 12.3]
6.47 [-8.97, 9.71]

Side-fire

DenseNet
HighRes3dNet

0.36 [-4.91, 7.07]
-13.8 [-20.0, -7.55]

0.38 [-0.15, 1.03]
-0.76 [-1.23, -0.08]

8.67 [-2.86, 13.8]
-6.69 [-8.40, 4.38]

Overall

DenseNet
HighRes3dNet

8.77 [-2.84, 18.3]
-6.89 [-16.4, 4.09]

0.95 [0.29, 1.61]
-0.24 [-1.15, 0.58]

8.87 [5.72, 13.2]
-5.84 [-8.46, 8.32]

sVPD, signed volume percent difference; sMSD, signed mean surface dist.; sHD, signed Hausdorff dist.
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While deep learning-based segmentation approaches are promising, access to large
clinically diverse datasets is rare, especially in US imaging. An efficient automatic
segmentation algorithm that could maintain high segmentation accuracy when trained with
smaller datasets may increase access to deep learning segmentation, even if data is scarce.
The purpose of Chapter 3 is to examine the effect of dataset size and image quality on deep
learning segmentation of the prostate in 3D TRUS images.
The contents of this chapter have been previously published in Physics in Medicine
& Biology: Orlando N, Gyacskov I, Gillies DJ, Guo F, Romagnoli C, D Souza D, Cool
DW, Hoover D, and Fenster A. Physics in Medicine & Biology. 2022;67:074002.
Permission to reproduce this article was granted by IOP Publishing Ltd. and is provided in
Appendix A

Copyright Releases.

3.1

d ci

I

Prostate biopsy is the current clinical standard for prostate cancer (PCa) diagnosis,
but the conventional two-dimensional (2D) transrectal ultrasound (TRUS)-guided biopsy
has been reported to have a false negative rate up to 30%.1 Improved tumour sampling can
be achieved with the addition of three-dimensional (3D) TRUS imaging using a magnetic
resonance imaging (MRI)-3D TRUS fusion guided biopsy approach, which utilizes the
superior soft-tissue contrast of MRI to identify suspicious tissue regions for targeting with
real-time TRUS guidance.2 For PCa treatment, high-dose-rate (HDR) brachytherapy is a
common treatment modality for intermediate and high-risk localized PCa.3,4 3D TRUS
imaging provides spatial context through visualization of the anatomy in 3D, in addition to
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improving intraoperative needle tip identification and patient-specific dose optimization.5
While 3D TRUS imaging offers many benefits, it also necessitates accurate segmentation
of the prostate to perform the biopsy and brachytherapy clinical tasks. Segmentations are
often completed manually by the physician during the procedure, which can be timeconsuming and highly variable, extending procedure times and increasing risk due to
anesthesia exposure.6
Multiparametric MRI is quickly becoming a standard of care imaging modality for
both biopsy and brachytherapy procedures based on the results of recent randomized
controlled clinical trials.7

9

While MRI offers high soft-tissue contrast, limitations

including high-cost limit widespread adoption. For MRI-guided brachytherapy, patient
movement to the MRI scanner after needle implant may cause needle shifts,10 while inbore procedures require highly specialized magnet-safe tools. In hospitals where MRI is
utilized for MRI-3D TRUS fusion-guided biopsy or brachytherapy, registration between
the modalities is required, often utilizing a surface-based approach, which requires accurate
segmentation of the prostate in both image modalities. Thus, even with an MRI-based
approach, accurate and fast prostate segmentation in 3D TRUS images is critical.
With the increasing prevalence of deep learning in medicine,11 and specifically of
convolutional neural networks (CNNs) for medical imaging tasks, many deep learningbased automatic prostate segmentation approaches have been proposed for TRUS imaging,
promising reduced procedure time and similar performance compared to manual
approaches.12

16

Recently, Lei et al. proposed an anchor-free mask CNN for multi-organ

segmentation in 3D TRUS volumes, trained using data from 83 PCa patients with five-fold
cross-validation.17 They reported prostate segmentation accuracy with a Dice similarity
coefficient (DSC) of 0.93 ± 0.03 and 95% Hausdorff distance (HD95) of 2.27 ± 0.79 mm.
van Sloun et al. propose a U-Net based approach for zonal prostate segmentation trained
on a large multi-institutional dataset of 436 3D TRUS volumes from 181 men, reporting a
median (95% confidence interval) accuracy of 98 (95-99)%, Jaccard index of 0.93 (0.800.96), and Hausdorff distance (HD) of 3.0 (1.3-8.7) mm.18
We previously proposed an automatic segmentation algorithm involving deep
learning prediction with a modified U-Net on 2D TRUS images radially sliced from 3D
TRUS volumes followed by reconstruction into a 3D surface.19 The algorithm was trained
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on a large dataset with nearly 7000 2D images resliced from 206 clinically variable 3D
TRUS images from various acquisition methods, procedure types (biopsy and HDR
brachytherapy), ultrasound machines, and ultrasound transducers. On a testing set of 40
unseen 3D TRUS volumes from different acquisition methods, we demonstrated high
performance with a median [quartile 1, quartile 3] DSC, mean surface distance (MSD), and
HD of 94.1 [92.6, 94.9] %, 0.89 [0.73, 1.09] mm, and 2.89 [2.37, 4.35] mm, respectively.
This algorithm outperformed a fully 3D V-Net and state-of-the-art methods in the
literature.19
However, large and diverse medical image datasets are rare, especially for
ultrasound, with recent papers reporting utilization of datasets with 2238 2D TRUS
images,12 and 40,16 44,14 86,17 and 10913 3D TRUS volumes. Generation of large clinical
datasets is time-consuming and costly, so generalizable and accurate automatic
segmentation approaches suitable for small datasets are critical for the widespread
integration of deep learning in minimally invasive PCa procedures. The U-Net++
architecture, an evolution of the standard U-Net, has recently been proposed and may help
accomplish this goal, introducing multiple CNN backbones as well as nested, dense skip
connections.20,21 These redesigned skip connections attempt to reduce the semantic gap
between feature maps in the encoder and decoder sections of the network, resulting in an
easier optimization problem and thus higher performance with small training datasets.
Image quality is highly variable between 3D TRUS volumes, including differences
in acquisition methods, image acquisition artifacts, patient anatomy artifacts such as gas,
calcifications, catheters, and prostate boundary visibility. These factors may influence
prostate segmentation results, so a 3D TRUS image quality grading scale is required to aid
in comparing results from different datasets and identify key image quality factors that will
influence segmentation performance.
Our work aims to demonstrate that our 2D radial deep learning plus 3D
reconstruction approach offers efficient utilization of training data and thus high
segmentation performance when trained with smaller datasets and datasets split based on
3D TRUS acquisition type (end-fire and side-fire). To assess the impact of image quality
on segmentation performance, we propose an image quality grading scale containing three
distinct image quality factors. By rigorously evaluating our deep learning segmentation

84

approach in the context of image quality, training dataset size, and 3D TRUS acquisition
type (end-fire and side-fire), we intend to provide a widely accessible, robust,
generalizable, and efficient prostate segmentation algorithm. This approach may allow for
reduced clinical procedure time and increased efficiency for minimally invasive PCa
procedures, allowing for optimization to a clinic s local preferences, without requiring
access to large ultrasound image datasets.

3.2
3.2.1

Ma e ial a d

eh d

Complete ultrasound dataset
The complete ultrasound dataset consisted of 246 3D TRUS volumes of the

prostate.22 This dataset contained 104 end-fire 3D TRUS volumes, obtained from clinical
prostate biopsy procedures, and 142 side-fire 3D TRUS volumes, obtained from clinical
prostate brachytherapy procedures. Patient clinical information such as age, stage of
prostate cancer, and Gleason score were not recorded. The methods to acquire 3D TRUS
volumes have been described previously, but are briefly summarized here.23

25

To generate

these images, a TRUS transducer was mechanically rotated using a motorized fixture about
its long axis. 2D TRUS images were acquired at set angular intervals, which were then
reconstructed to generate 3D TRUS volumes. The choice of TRUS transducer leads to
geometrically variable images: the end-fire transducer used for prostate biopsy was rotated
180° while 2D TRUS images were acquired at 1.0° intervals and reconstructed into a 3D
volume; the side-fire transducer used for prostate brachytherapy was rotated 140° while
2D TRUS images were acquired at 0.5° intervals and reconstructed into a fan-shaped 3D
TRUS volume.
These 3D TRUS volumes were acquired with 3 transducers used with 3 different
ultrasound systems of different ages and from two manufacturers. Specifically, an 8848
transducer was used with the Profocus 2202 ultrasound system (BK Medical, Peabody,
MA, USA), C9-5 and BPTRT9-5 transducers were used with the ATL HDI-5000
ultrasound system (Philips, Amsterdam, the Netherlands), and a C9-5 transducer was used
with the iU22 ultrasound system (Philips, Amsterdam, the Netherlands). 3D TRUS image
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sizes ranged from [448⨯350⨯448] to [692⨯520⨯692] voxels with dimensions of
[0.115⨯0.115⨯0.115] to [0.190⨯0.195⨯0.190] mm3/voxel for end-fire images and from
[300⨯400⨯784] to [408⨯441⨯870] voxels with dimensions of [0.094⨯0.154⨯0.154] to
[0.183⨯0.186⨯0.186] mm3/voxel for side-fire images. Manual prostate segmentations in
the 3D TRUS volumes, excluding the seminal vesicles, were completed by an observer
experienced with 3D TRUS imaging (IG). 20 end-fire 3D TRUS volumes and 20 side-fire
3D TRUS volumes were randomly selected from the complete dataset and reserved as a
testing dataset, thus were not included during training.
As outlined in Orlando and Gillies et al., the complete training dataset of 206 3D
TRUS volumes was resliced at randomized axial, sagittal, coronal, radial, and oblique
image planes, resulting in a final training dataset of 6761 2D TRUS images with matched
manual segmentations.19 This reslicing allowed for more efficient use of the TRUS data,
demonstrating improved performance compared to a fully 3D V-Net approach.19,26 2D
images were resampled to 256⨯256 pixels with no other applied preprocessing. The
complete training dataset of 2D TRUS images was split for deep learning, with 80% (5409
images) used for training and 20% (1352 images) used for validation.

3.2.2

Reduced-size datasets
To evaluate our method s efficiency in utilizing the training data, we generated

smaller datasets by splitting and reducing the complete dataset of 6761 2D TRUS images.
In all smaller datasets, we maintained the 80/20 training/validation split for deep learning.

3.2.2.1

Split end-fire and side-fire datasets

We first split the complete dataset into an end-fire training dataset of 2738 2D
TRUS images and a side-fire training dataset of 4023 2D TRUS images (Table 3.1). This
allowed for an assessment of generalizability by training two sets of parameters and testing
on the opposite 3D TRUS acquisition type, which was unseen during training.

86

3.2.2.2

Smaller end-fire, side-fire, and mixed datasets

Smaller datasets were generated by reducing the split end-fire and side-fire datasets
to assess how segmentation performance depends on the size of the dataset used for
training, with an aim to find the smallest dataset which still maintains high segmentation
performance. Using the split end-fire and side-fire datasets, images were removed at
random to create training datasets with 1000, 500, 250, and 100 2D TRUS images of each
acquisition type (Table 3.1). These smaller datasets were generated by reslicing from 36,
18, 9, and 4 3D TRUS volumes, respectively. Thus, variation in image quality and
anatomical features, as determined by the 3D TRUS volume, were similarly reduced. This
resulted in eight reduced-size datasets (four end-fire and four side-fire).

Table 3.1. Breakdown of the clinical 3D TRUS training dataset of 206 volumes resliced
into 2D images for training 2D neural networks. Rows from top to bottom show the
complete and reduced-size side-fire, end-fire datasets, and mixed datasets.
Complete Dataset
Split Dataset

6761 2D TRUS Images
4023 Side-fire

[Images]

Smaller Datasets
[Images]

4023 Mixed
2738 End-fire

2738 Mixed

1000 Side-fire

1000 End-fire

1000 Mixed

500 Side-fire

500 End-fire

500 Mixed

250 Side-fire

250 End-fire

250 Mixed

100 Side-fire

100 End-fire

100 Mixed

Similarly, smaller mixed datasets were generated by reducing the complete 2D
TRUS dataset. Images were removed at random to create training datasets with 4023, 2738,
1000, 500, 250, and 100 mixed 2D TRUS images (Table 3.1), resliced from 119, 86, 36,
18, 9, and 4 3D TRUS volumes, respectively. The segmentation performance of a network
trained using 4023 mixed acquisition images was compared to a network trained using
4023 side-fire images; similarly, the segmentation performance using a training dataset of
2738 mixed images and 2738 end-fire images were compared. In all reduced-size mixed
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datasets, the ratio between end-fire and side-fire images matched the complete dataset, with
40.5% end-fire images and 59.5% side-fire images. This resulted in six reduced-size mixed
datasets.

3.2.3

Image quality assessment

3D TRUS image quality varies across patients and 3D acquisition methods, and so
it is expected to impact segmentation performance. To explore this effect, an experienced
interventional and genitourinary radiologist (DC) developed a 3D TRUS image quality
grading scale, provided in Table 3.2. To ensure the scale was not biased and was
generalizable, it was developed before the physician viewed our 3D TRUS dataset. Image
quality was graded using three factors: acquisition quality, artifact severity, and prostate
boundary visibility. Acquisition quality rated the quality of the 3D TRUS acquisition itself,
ignoring the anatomy artifacts and visibility, ranging from 1 (poor) to 5 (ideal). Examples
of poor acquisition quality included image shadowing due to inadequate transducer contact,
transducer translation during 3D TRUS acquisition causing anatomy distortion, and issues
with ultrasound gain or depth. Artifact severity estimated the degree of image degradation
caused by artifact-generating items within the prostate gland, such as calcifications, gas,
urinary catheters, and brachytherapy seeds, ranging from 1 (major artifacts) to 5 (no
artifacts at all). Prostate boundary graded the visibility or clarity of the prostate boundary
with the adjacent periprostatic soft tissue, a key factor in the prostate segmentation task,
ranging from 1 (more than 75% of the boundary is indistinguishable) to 3 (40% of the
boundary is indistinguishable) to 5 (the entire boundary is clearly visible). The test dataset
of 20 end-fire and 20 side-fire 3D TRUS volumes was graded by the same radiologist who
was blinded to the qualitative and quantitative segmentation performance. Only the test
dataset was graded; as the test dataset was randomly selected from the complete dataset,
its images quality distribution was representative of the complete dataset. Five-point
numerical grading allowed for a quantitative comparison between end-fire and side-fire 3D
TRUS volumes, including the calculation of means and statistical testing.
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Table 3.2. Image quality grading scale for 3D TRUS images of the prostate.
Image Quality Factor

Description

Scale

Acquisition Quality

Quality of the 3D TRUS image
acquisition regardless of anatomy

1 (poor) - 5 (ideal)

Anatomy Artifacts

Severity of anatomy artifacts
(calcification, gas, catheter, etc.)

1 (major artifacts)

Prostate Boundary

Visibility/clarity of the prostate
boundary

1 (> 75% of boundary indistinguishable) - 3
(40% of boundary indistinguishable) - 5 (entire
boundary visible)

3.2.4

5 (no artifacts)

3D segmentation algorithm
Our radial prostate segmentation algorithm was first described in Orlando and

Gillies et al. and will be briefly summarized here (Fig. 3.1). This method utilized a radial
segmentation approach, first proposed by Qiu et al. for a prostate segmentation algorithm
based on convex optimization with shape priors.27 In this approach, a 3D TRUS volume is
resliced radially about the approximate center of the prostate gland at 15° intervals,
generating 12 2D TRUS images. The extracted 2D TRUS images appear very similar, as
each plane passes through the mid-gland of the prostate, resulting in similar prostate size
and shape regardless of the 3D TRUS acquisition method. This radial approach has been
shown to improve segmentation performance in the apex and base of the prostate compared
to alternative approaches such as transverse reslicing.27 The 12 radial 2D TRUS images
were automatically segmented using neural networks trained with the 2D datasets
described in sections 3.2.1 and 3.2.2 to generate 12 segmented prostate boundaries, which
were used to reconstruct the 3D surface of the prostate (Fig. 3.1).

3.2.5

2D neural networks
Two neural network architectures were used in this work, which were trained with

identical 2D TRUS datasets (See sections 3.2.1 and 3.2.2). Detailed network diagrams are
provided in Fig. 3.A1 and 3.A2 in Supplement A for the modified U-Net and U-Net++,
respectively. Data augmentation using random combinations of horizontal flips, shifts up
to 20%, rotations up to 20°, and zooms up to 20% were applied to double the training
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datasets. A personal computer with an i7-9700K central processing unit (CPU) at 3.60 GHz
(Intel Corporation, Santa Clara, CA, USA), 64 GB of RAM, and a 24 GB NVIDIA TITAN
RTX (NVIDIA Corporation, Santa Clara, CA, USA) graphics processing units (GPU) was
used for training all 2D neural networks and for subsequent prediction on unseen testing
data.

Figure 3.1. 3D prostate segmentation workflow using an example end-fire 3D TRUS
volume. The input 3D TRUS volume was resliced radially at 15° spacing to generate 12
2D TRUS images with similar size and shape. A trained 2D neural network was used to
predict the prostate boundary locations in 2D binary masks, which were used to reconstruct
the 3D prostate surface.

3.2.5.1

Modified U-Net

A five-layer deep modified version of the widely prevalent U-Net28 was
implemented using Keras29 with TensorFlow.30 First, 50% dropouts were applied at the last
block on the contracting section of the network and at every block on the expansion section
of the network to increase regularization and prevent overfitting.19 In addition, transpose
convolutions were applied in the expansion section of the network instead of the standard
upsampling followed by convolution (upconvolution), as this allowed for improved
performance

19

. Padding and ReLU activation were applied in each (3⨯3) convolution

operation, with sigmoid activation used in the final (1⨯1) convolution operation.
Additional hyperparameter selection based on preliminary experiments included the use of
an Adam optimizer, a learning rate of 0.0001, a Dice-coefficient loss function, 100 epochs,
and 200 steps per epoch.
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3.2.5.2

U-Net++

A state-of-the-art U-Net++ architecture20,21 was also implemented using Keras29
with TensorFlow.30 We used a standard ResNet-50 architecture31 with batch normalization
and a batch size of 10 as our CNN backbone, as it balanced the number of parameters and
overfitting risk for the scale of our training datasets. As described in Section 3.2.5.1, the
convolution operations and hyperparameters matched the modified U-Net implementation,
including the use of transpose convolutions, Adam optimizer, 0.0001 learning rate, Dicecoefficient loss function, and number of epochs.

3.2.6

Evaluation and comparison
All trained models were evaluated using a testing dataset which consisted of 20

end-fire plus 20 side-fire 3D TRUS volumes unseen by the networks during training. The
evaluation metrics included Dice Similarity Coefficient (DSC), recall, precision, absolute
volume percent differences (VPD), mean surface distances (MSD), and Hausdorff
distances (HD), computed for both 2D radial slice and reconstructed 3D segmentations for
each prostate. Computation times were recorded for 2D slice segmentation, 3D
reconstruction, and overall 3D segmentation time. We have previously demonstrated
significantly improved performance with a 2D radial deep learning plus 3D reconstruction
approach compared to fully 3D CNNs; consequently, no 3D CNNs were used for
comparison in this work. A detailed list of comparisons and corresponding statistical tests
is provided in Table 3.3.
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Table 3.3. List of comparisons and corresponding statistical tests. Parametric tests are
shown with corresponding nonparametric alternative tests presented in parentheses.
Comparison

Statistical Test

Complete Dataset (6,761 2D images)
Modified U-Net vs U-Net++ with complete training
dataset
Segmentation performance vs prostate volume

Paired t-test (Wilcoxon matched-pairs signedrank test)
Pearson (Spearman) correlation coefficient

Split end-fire and side-fire datasets (Table 3.1)
End-fire training dataset: U-Net vs U-Net++ tested on
both end-fire and side-fire images
Side-fire training dataset: U-Net vs U-Net++ tested on
both side-fire and end-fire images
Split end-fire or side-fire network vs complete training
dataset

Paired t-test (Wilcoxon matched-pairs signedrank test)
||
||

Smaller end-fire, side-fire, and mixed datasets (Section
3.2.2.2) *
Performance with reduced-size datasets vs complete
dataset
Mixed training dataset vs end-fire or side-fire dataset of
equal size

Repeated measured one-way ANOVA with
Tukey s correction (Friedman Test with
Dunn s correction)
Paired t-test (Wilcoxon matched-pairs signedrank test)

Image quality (Section 3.2.3)
End-fire vs side-fire image quality grades for each factor
Segmentation performance for U-Net and U-Net++ vs
image quality grade in each factor and overall
Correlation between segmentation performance and
image quality

Unpaired t-test (Mann-Whitney U test)
One-way ANOVA with Tukey s correction
(Kruskal-Wallis test with Dunn s correction)
Pearson (Spearman) correlation coefficient

* Due to superior performance of the U-Net++ when trained using split datasets, only the U-Net++ was
used for reduced-size dataset experiments

Statistical calculations were performed in GraphPad Prism 9.2 (Graphpad
Software, Inc., San Diego, CA, USA). The Shapiro-Wilk test was used to evaluate the
normality of distributions. Failure of the Shapiro-Wilk test led to the use of nonparametric
statistical tests and the reporting of median [quartile 1, quartile 3] results. The significance
level for statistical analysis was chosen such that the probability of making a type I error
was less than 5% (p < 0.05), with statistically significant differences denoted simply as
significant for the remainder of this manuscript.
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3.3
3.3.1

Re l
Complete dataset
Example U-Net, U-Net++, and manual segmentations for median end-fire and side-

fire cases are shown in Fig. 3.2. The evaluation metric results comparing the modified UNet to the U-Net++ when trained using the full dataset of 6761 images are shown in Table
3.4. No significant differences were observed between the U-Net and U-Net++ for any
metric for the full testing dataset. When considering the side-fire and end-fire test datasets
separately, no significant differences were observed for the end-fire testing images, while
only the precision and recall metrics were significantly different for side-fire testing
images, with the U-Net demonstrating higher precision and the U-Net++ demonstrating
higher recall. The mean computation time per 2D segmentation was 0.028 s for the
modified U-Net and 0.088 s for the U-Net++. The mean 3D reconstruction time was 0.27s,
resulting in a total 3D segmentation time of 0.61 s for the modified U-Net and 1.33 s for
the U-Net++.
Of note, a comparison of segmentation performance relative to prostate volume for
the U-Net and U-Net++ demonstrated significant correlations between prostate size and
the DSC and VPD metrics. The DSC metric showed a Spearman r coefficient of 0.58 and
0.61 for the U-Net and U-Net++, respectively, while the VPD metric showed a Spearman
r coefficient of -0.44 and -0.51 for the U-Net and U-Net++, respectively.
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Figure 3.2. Example end-fire (top row) and side-fire (bottom row) prostate segmentation
results comparing manual (red), modified U-Net (blue), and U-Net++ (yellow) 3D surfaces
for median cases based on DSC. The columns from left to right show the prostate surface
in the axial plane, sagittal plane, and an oblique radial plane, respectively.

Table 3.4. Median [Q1, Q3] 3D results showing the modified U-Net and U-Net++ trained
using the complete dataset and tested on an unseen test dataset of 20 end-fire and 20 sidefire 3D TRUS volumes.
Test
Dataset

Seg. Alg.

DSC (%)

Recall (%)

Precision (%)

VPD (%)

MSD (mm)

HD (mm)

End-fire

U-Net

94.3
[93.1, 95.2]
94.5
[92.8, 95.5]
0.2904*

96.0
[93.2, 98.7]
96.0
[93.3, 98.1]
0.9932*

94.6
[88.8, 95.8]
94.1
[90.4, 96.5]
0.4749

5.18
[1.62, 11.2]
3.54
[1.80, 9.28]
0.0696

1.01
[0.80, 1.21]
0.93
[0.77, 1.20]
0.4284*

3.44
[2.50, 4.65]
3.39
[2.81, 4.97]
0.8695

93.5
[91.1, 94.6]
93.3
[91.7, 95.0]
0.9563

96.2
[92.5, 98.4]
97.7
[95.5, 98.4]
0.0153

91.6
[87.8, 94.8]
89.8
[86.0, 94.1]
0.0495*

5.89
[3.17, 11.9]
6.27
[3.89, 12.8]
0.3884

0.86
[0.71, 0.97]
0.84
[0.69, 1.03]
0.7562

2.73
[2.42, 4.28]
3.19
[2.69, 4.33]
0.1536

94.1
[92.6, 94.9]
94.0
[92.2, 95.1]
0.6179

96.0
[93.1, 98.5]
96.7
[94.1, 98.3]
0.0641

93.2
[88.8, 95.4]
92.9
[87.1, 95.1]
0.2265

5.78
[2.49, 11.5]
4.79
[2.93, 10.9]
0.6656

0.89
[0.77, 1.10]
0.90
[0.73, 1.14]
0.5657*

3.14
[2.49, 4.47]
3.27
[2.71, 4.33]
0.2317

U-Net++
p-value
Side-fire

U-Net
U-Net++
p-value

Overall

U-Net
U-Net++
p-value

DSC, Dice similarity coefficient; VPD, volume percent difference; MSD, mean surface dist.; HD, Hausdorff dist.
*Normal distribution = paired t-test; Bolded metrics highlight the method with significantly reduced relative error.
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3.3.2

Split end-fire and side-fire datasets
Qualitative segmentation results comparing the modified U-Net and U-Net++ to

manual segmentations for networks trained with only end-fire and only side-fire images
are shown in Figs. 3.3 and 3.4, respectively, and the corresponding quantitative
comparisons are shown in Tables 3.5 and 3.6. Plots showing DSC for the modified U-Net
and U-Net++ trained using only end-fire and only side-fire datasets are shown in Fig. 3.5.
For both the end-fire and side-fire networks evaluated on the complete testing dataset,
which included images from both acquisition methods, the U-Net++ significantly
outperformed the modified U-Net for all metrics except VPD for the side-fire networks.
When evaluated on the end-fire and side-fire testing datasets separately, the U-Net++ also
significantly outperformed the U-Net for all metrics aside from VPD when tested on the
same image type it was trained on.

Figure 3.3. Example end-fire (top row) and side-fire (bottom row) median DSC prostate
segmentation results comparing manual (red), modified U-Net (blue), and U-Net++
(yellow) 3D surfaces for networks trained only using end-fire images. The columns from
left to right show the prostate surface in the axial plane, sagittal plane, and an oblique radial
plane, respectively.
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Figure 3.4. Example side-fire (top row) and end-fire (bottom row) median DSC prostate
segmentation results comparing manual (red), modified U-Net (blue), and U-Net++
(yellow) 3D surfaces for networks trained only using side-fire images. The columns from
left to right show the prostate surface in the axial plane, sagittal plane, and an oblique radial
plane, respectively.

Figure 3.5. Plot of median DSC for the modified U-Net and U-Net++ trained using only
end-fire (left) and only side-fire (right) images and tested on both end-fire and side-fire
images shown on the left and right half of each graph, respectively.
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Table 3.5. Median [Q1, Q3] 3D results showing the modified U-Net and U-Net++ trained
using only end-fire images and tested on an unseen test dataset of 20 end-fire and 20 sidefire 3D TRUS volumes.
Test
Dataset

Seg. Alg.

DSC (%)

Recall (%)

Precision (%)

VPD (%)

MSD (mm)

HD (mm)

End-fire

U-Net

86.8
[82.6, 89.9]
94.2
[92.4, 95.0]
<0.0001

89.3
[82.7, 90.8]
95.8
[92.1, 98.3]
<0.0001*

84.5
[80.5, 89.4]
93.0
[89.5, 96.2]
<0.0001*

7.80
[2.30, 12.2]
5.31
[3.56, 8.48]
0.3118

1.96
[1.63, 2.39]
1.00
[0.85, 1.21]
<0.0001*

6.43
[5.25, 9.11]
3.78
[2.95, 5.20]
<0.0001*

75.7
[63.4, 82.6]
87.9
[78.2, 92.0]
<0.0001

91.7
[83.7, 96.0]
93.1
[89.8, 96.6]
0.2611

64.8
[50.0, 78.1]
84.0
[71.6, 90.5]
<0.0001*

35.9
[12.1, 91.9]
18.2
[5.40, 34.9]
0.0005

3.36
[1.97, 4.49]
1.75
[1.17, 2.89]
0.0003

12.4
[8.35, 16.1]
10.0
[5.89, 11.4]
0.0363*

82.6
[75.5, 87.4]
92.3
[87.7, 94.3]
<0.0001

89.5
[83.7, 94.6]
93.6
[91.2, 97.4]
0.0002

78.9
[64.2, 86.4]
89.8
[82.9, 95.0]
<0.0001

12.0
[4.24, 37.3]
6.84
[4.35, 18.2]
0.0006

2.19
[1.69, 3.43]
1.18
[0.90, 1.78]
<0.0001

8.92
[6.15, 12.7]
5.53
[3.61, 10.1]
<0.0001

U-Net++
p-value
Side-fire

U-Net
U-Net++
p-value

Overall

U-Net
U-Net++
p-value

DSC, Dice similarity coefficient; VPD, volume percent difference; MSD, mean surface dist.; HD, Hausdorff dist.
*Normal distribution = paired t-test; Bolded metrics highlight the method with significantly reduced relative error.

Comparing the results shown in Tables 3.4 and 3.5 of the U-Net++ trained with the
full 6761 image dataset to the U-Net++ trained using only end-fire images, use of the full
dataset only demonstrated a significant improvement for the HD metric (0.4 mm) when
tested on end-fire images. Similarly, comparing the U-Net++ trained with the full dataset
to one trained using only side-fire images, only the precision metric was significantly
different (1.8%) when tested on side-fire images. When tested on the unseen acquisition
type, the use of the full dataset demonstrated improved performance for every metric in
both cases.

3.3.3

Smaller end-fire, side-fire, and mixed datasets
Example segmentation results for the U-Net++ trained with varying-sized end-fire,

side-fire, and mixed datasets are shown in Fig. 3.6. Plots of DSC as a function of training
dataset size are shown in Fig. 3.7, highlighting the high performance of the U-Net++ when
trained with small datasets. Corresponding quantitative comparisons are provided in
Supplement B Tables 3.B1, 3.B2, and 3.B3.
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Table 3.6. Median [Q1, Q3] 3D results showing the modified U-Net and U-Net++ trained
using only side-fire images and tested on an unseen test dataset of 20 end-fire and 20 sidefire 3D TRUS volumes.
Test Dataset

Seg. Alg.

DSC (%)

Recall (%)

Precision (%)

VPD (%)

MSD (mm)

HD (mm)

End-fire

U-Net

81.4
[77.8, 86.3]
84.5
[66.9, 90.3]
0.9854

74.4
[68.3, 85.3]
75.3
[51.0, 86.9]
0.2679*

90.2
[86.3, 93.9]
96.5
[95.7, 99.2]
<0.0001

17.4
[9.87, 26.3]
23.3
[13.0, 48.3]
0.0121

2.48
[1.79, 3.38]
2.44
[1.50, 4.72]
0.5459

8.57
[6.80, 11.8]
8.90
[7.18, 13.8]
0.2436*

84.9
[79.2, 87.8]
92.4
[91.8, 95.1]
<0.0001

85.9
[78.7, 92.3]
95.2
[91.8, 97.9]
<0.0001*

82.2
[77.5, 85.9]
91.6
[87.2, 95.5]
<0.0001*

5.16
[4.13, 13.0]
7.11
[3.34, 12.4]
0.4091

1.81
[1.43, 2.37]
0.95
[0.66, 1.05]
<0.0001

7.77
[6.29, 8.68]
3.21
[2.58, 4.75]
<0.0001

82.8
[78.4, 87.4]
91.5
[84.3, 92.7]
0.0035

80.4
[71.4, 87.6]
89.3
[75.3, 96.0]
0.0394

86.3
[80.7, 90.6]
95.6
[88.0, 96.9]
<0.0001

11.9
[5.03, 20.4]
13.0
[6.78, 23.4]
0.0972

2.26
[1.54, 2.83]
1.25
[0.95, 2.51]
0.0192

7.98
[6.62, 9.60]
5.46
[3.18, 9.48]
0.0436

U-Net++
p-value
Side-fire

U-Net
U-Net++
p-value

Overall

U-Net
U-Net++
p-value

DSC, Dice similarity coefficient; VPD, volume percent difference; MSD, mean surface dist.; HD, Hausdorff dist.
*Normal distribution = paired t-test; Bolded metrics highlight the method with significantly reduced relative error.

Figure 3.6. Example results for the U-Net++ trained with varying-size end-fire (top row),
side-fire (middle row), and mixed (bottom row) datasets. The full dataset corresponds to
2738 images for the end-fire network, 4023 images for the side-fire network, and 6761 for
the mixed network.
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As shown in Table 3.B1, for the U-Net++ trained with reduced-size end-fire
datasets and tested on end-fire images, significant differences were observed between the
full (2738 images) end-fire training dataset and the 250 and 100 image sets for the DSC
and MSD metric, and all reduced-size image sets for the HD metric.
When the U-Net++ was trained with reduced-size side-fire datasets and tested on
side-fire images (Table 3.B2), multiple comparisons tests showed significant differences
for the DSC, MSD, and HD metrics between the full (4023 images) side-fire training
dataset and the 500 and 100 image sets.
As shown in Table 3.B3, for the U-Net++ trained with reduced-size mixed datasets
and tested on end-fire images, multiple comparisons tests showed significant differences
between the full (6761 images) mixed training dataset and the 500, 250, and 100 image
sets for the DSC, MSD, and HD metrics. When tested on side-fire images significant
differences were observed between the full mixed training dataset and the 1000 through
100 image sets for the DSC, MSD, and HD metrics.

End-fire

Side-fire

Mixed

Figure 3.7. Median DSC for the U-Net++ trained using varying-sized end-fire (left), sidefire (middle), and mixed (right) datasets, and tested on both end-fire (solid red) and sidefire (dashed line) images. The number of training images are provided along the x-axis.
The dotted line denotes the maximum performance achieved by the U-Net++ trained with
the full 6761 image dataset.

Comparing the U-Net++ trained with 2738 mixed images to the U-Net++ trained
with 2738 end-fire images, no significant differences were observed when tested on endfire images, but when tested on side-fire images, use of the mixed training dataset
demonstrated significantly improved performance for all metrics. Similarly, for the U-
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Net++ trained with 4023 mixed images compared to the network trained with 4023 sidefire images, only the precision and recall metrics were significantly different when tested
on side-fire images, with all metrics except precision significantly improved with use of
the mixed training dataset when tested on end-fire images.

3.3.4

Image quality
A comparison of average image quality grading results for side-fire and end-fire

3D TRUS images of the prostate is shown in Table 3.7. There were no significant
differences between end-fire and side-fire image quality for any image quality factor or for
the total averaged image quality.

Table 3.7. Mean plus/minus standard deviation image quality grading results for side-fire
and end-fire 3D TRUS images of the prostate. Mean grades are provided out of five for
each individual image quality factor and for the total image quality.
Image Quality Factor

Description

End-fire 3D TRUS

Side-fire 3D TRUS

Acquisition Quality

Quality of the 3D TRUS image
acquisition regardless of anatomy

4.4 ± 0.7

4.2 ± 1.2

Anatomy Artifacts

Severity of anatomy artifacts
(calcification, gas, catheter, etc.)

4.0 ± 0.7

4.1 ± 1.0

Prostate Boundary

Visibility/clarity of the prostate
boundary

4.2 ± 0.7

4.2 ± 1.0

Total

Mean of three individual image
quality factors

4.2 ± 0.5

4.1 ± 0.9

A graph of DSC as a factor of grade for each individual image quality factor is
shown in Fig. 3.8. For end-fire testing images, image quality grade did not have a
significant effect on segmentation performance in any metric. For side-fire testing images,
only the boundary visibility grade had a significant effect for the modified U-Net, while all
image quality factors except anatomy artifact grade had a significant effect on the DSC
metric for the U-Net++.
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Analysis of plots of DSC as a function of total image quality grade for the U-Net
and U-Net++ (Fig. 3.9) showed no significant correlation for the end-fire testing dataset
for any metric, with Spearman r coefficients less than 0.4. For the side-fire testing images,
the modified U-Net showed a significant correlation between total image quality grade and
DSC, recall, and HD metrics, with Spearman r coefficients of 0.60, 0.61, and -0.56,
respectively, while the U-Net++ showed a significant correlation for the DSC and recall
metrics with Spearman r coefficients of 0.46 and 0.55, respectively.

U-Net

U-Net++

Figure 3.8. Mean DSC as a factor of acquisition quality (left), anatomy artifacts severity
(middle), and boundary visibility (right) for the modified U-Net (top row) and U-Net++
(bottom row) trained on the full dataset and tested on end-fire and side-fire images shown
on the left and right side of each graph, respectively.
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U-Net

U-Net++

Figure 3.9. DSC as a function of total averaged image quality for the modified U-Net (left)
and U-Net++ (right) trained on the full dataset and tested on end-fire (red) and side-fire
(black) images. A linear regression is provided for each dataset.

3.4
3.4.1

Di c

i

Complete dataset
To provide a baseline maximum performance level, we first compared the

segmentation accuracy of the modified U-Net to the U-Net++ for both networks trained on
the complete dataset. The results shown in Table 3.4 demonstrate the nearly equivalent
performance of the networks. This highlights that with a large training dataset of nearly
7000 2D images, the more advanced U-Net++ network with significantly more parameters
did not offer any improvement in performance, motivating the experiments described in
sections 3.3.2 and 3.3.3 focused on reduced-size datasets. Using the same 24 GB NVIDIA
TITAN RTX GPU, the modified U-Net demonstrated a segmentation time that was three
times faster, with speeds of 0.028 s per 2D slice compared to 0.088 s per slice for the UNet++. After reconstruction of the 2D predictions into a 3D prostate surface, the total
segmentation time was 0.61 s for the modified U-Net, which was half of the 1.33 s for the
U-Net++. While this is a large relative difference, in a clinical setting the difference is
inconsequential, as both present a significant reduction in segmentation time relative to
manual segmentations, which can take 10-20 minutes.
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Correlations between segmentation performance and prostate size were only
significant for the DSC and VPD metrics. This is an expected result due to the nature of
these metrics, as absolute differences that would be readily apparent for smaller prostate
volumes would be reduced for large volumes when considering these overlap and volumebased metrics. As expected, boundary-based metrics showed no correlation with prostate
size. The correlations we did observe were still weak, however, with Spearman coefficients
of roughly r = 0.6 for DSC and r = -0.4 to -0.5 for VPD, highlighting the general robustness
of our approach to prostate size differences.
Recent work by Lei et al. and van Sloun et al. report state-of-the-art methods for
automatic prostate segmentation in 3D TRUS volumes. Lei et al. report best results for
DSC, MSD, and HD95 of 93.0 ± 3.0, 0.57 ± 0.20 mm, and 2.27 ± 0.79 mm, respectively.17
Our proposed 3D segmentation method using the modified U-Net and the U-Net++
demonstrated median [Q1, Q3] DSC of 94.1 [92.6, 94.9] % and 94.0 [92.2, 95.1] %,
showing improved performance. Our proposed networks demonstrated median MSD [Q1,
Q3] of 0.89 [0.77, 1.10] mm and 0.90 [0.73, 1.14] mm, with Lei et al. showing improved
performance for this metric. We do not report an HD95 metric, but our networks
demonstrated a median HD [Q1, Q3] of 3.14 [2.49, 4.47] mm and 3.27 [2.71, 4.33], which
while higher, is a more stringent metric showing the full HD, not excluding the worst five
percent. van Sloun et al. report a median (95% confidence interval) accuracy of 98 (9599)%, Jaccard index of 93.0 (80.0-96.0), and HD of 3.0 (1.3-8.7) mm.18 While not reported,
our modified U-Net and U-Net++ demonstrated a median [Q1, Q3] accuracy of 98.8 [98.4,
99.2] % and 98.9 [98.4, 99.2] %, and a median HD [Q1, Q3] of 3.14 [2.49, 4.47] mm and
3.27 [2.71, 4.33], both of which are similar, with our approach reporting higher accuracy
and van Sloun et al. reporting lower HD. Our results were obtained with considerably less
data, however, as van Sloun et al. utilized a training dataset of 436 3D TRUS volumes
compared to our complete training dataset of 206 3D TRUS volumes.
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3.4.2

Split end-fire and side-fire datasets
Segmentation performance of the modified U-Net and U-Net++ trained with only

end-fire or only side-fire images (Fig. 3.5 and Tables 3.5 and 3.6) showed that the U-Net++
significantly outperformed the modified U-Net in nearly all cases. When trained using sidefire images and tested on end-fire images, no difference was observed, but the U-Net++
did have higher median performance, countered by a larger variation. These differences
highlight the generalizability and efficiency of the U-Net++ in utilizing small training
datasets. The modified U-Net had boundary errors due to shadowing artifacts, even when
tested on the same image type as seen in the top row of Fig. 3.3. When tested on the image
type not seen during training of the network, the U-Net++ still performed better, although
it also had difficulties with shadowing artifacts (e.g. the bottom row of Fig. 3.3, with the
heavily shadowed region seen near the top of the prostate). The modified U-Net had a depth
of five layers compared to 50 for the U-Net++. This reduction in depth and number of
parameters for the U-Net compared to the U-Net++ may alleviate the overfitting problem,
which is important as training dataset size is reduced.
When assessing how the U-Net++ trained with only end-fire or only side-fire
images compared to one trained with the full dataset, we found that there was little
difference when tested on the same TRUS acquisition type the networks were trained with.
This highlights a potentially practical finding that the presence of other image types in the
training dataset do not add a significant benefit to the segmentation performance when only
one image type is required to be segmented. However, when the U-Net++ trained with only
end-fire or only side-fire images were tested on the TRUS acquisition type they had never
seen before, use of the full dataset significantly improved performance. This demonstrates
the necessity of including all image types in the training dataset, especially when
generalizability and widespread application is important. DSC performance in these cases
was still in the range of 85-89% for the U-Net++, however, demonstrating the
generalizability of our approach.
Differences between end-fire and side-fire images, including image quality and
artifact prevalence, may explain the observed segmentation performance differences
between TRUS image types. The differences in acquisition method between end-fire and
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side-fire 3D TRUS may result in artifacts in side-fire images such as air gaps due to lack
of transducer contact or distal shadowing due to transducer distance from the prostate. Due
to the nature of end-fire image acquisition, the radial plane used for deep learning
segmentation matches closely the acquisition plane, resulting in improved segmentation
accuracy. For side-fire images, only one of the twelve radial planes is the acquisition plane
and the other eleven are interpolated slices resulting in reduced resolution, potentially
explaining some of the observed differences in segmentation performance. In HDR
brachytherapy procedures where side-fire 3D TRUS is utilized, urinary catheters are
commonly used, which create artifacts that are not seen in end-fire images used for prostate
biopsy. The appearance of other organs such as the rectum and bladder also differ between
end-fire and side-fire leading to increased prostate segmentation error where the algorithm
included parts of the rectum or bladder when tested on the 3D TRUS type unseen by the
network. Furthermore, due to differences in patient selection and the prevalence of
hormone therapy prior to HDR brachytherapy treatment, the prostate sizes in patients
presenting for end-fire TRUS-guided biopsy are typically larger than the prostate sizes of
patients undergoing side-fire TRUS-guided HDR brachytherapy. This led to
underpredictions for side-fire networks tested on end-fire images and overpredictions for
end-fire networks tested on side-fire images, limiting generalizability and necessitating the
presence of both 3D TRUS types in the training dataset so the network can learn differences
in size and shape.

3.4.3

Smaller end-fire, side-fire, and mixed datasets
For as small as 500 end-fire images used in the training dataset, which is just over

7% of the full dataset, DSC performance was within 1% of the U-Net++ trained with the
full dataset of 6761 images. Results were similar for the U-Net++ trained with reducedsize side-fire datasets and tested on side-fire images. Networks trained with end-fire images
performed better when tested on side-fire images compared to networks trained with sidefire images and tested on end-fire images, suggesting features the network learns from endfire images are more generalizable to side-fire images. As expected, mixed training datasets
had high segmentation performance when tested on both image types even as the dataset
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size was reduced. This improved performance and generalizability is apparent in Fig. 3.7,
highlighting the benefit of including all image types in the training dataset.
For a segmentation task involving only one image type, performance plateaus at a
training dataset size of 1000 2D training images of that type, which were obtained from
approximately 36 3D volumes. A dataset of this size is achievable at even small hospitals
or research centers, showing that deep learning segmentation in 3D may be possible even
with limited data by utilizing organ symmetry and a radial approach. The reduced training
data requirement reduces the amount of manual segmentation required, a key benefit as
accurate manual segmentation is a difficult and time-consuming process that is often a
bottleneck in supervised machine learning. These results also show that for a segmentation
task involving multiple image types, the presence of all image types in the training dataset
is critical. Segmentation performance for mixed training datasets also plateaus at
approximately 1000 training images, suggesting that deep learning segmentation in two
image types is possible even if data is scarce.

3.4.4

Image quality
We developed a 5-point image quality grading scale based on three factors

specifically for 3D TRUS prostate images. This grading scale helps provide transparency
regarding the image quality of our clinical dataset, helping to contextualize our results. A
numerical scale with clearly defined image quality factors rated from one to five may
enable an easier comparison of segmentation performance between networks trained using
different datasets. Designing the image quality grading scale independently of our dataset
should allow it to be successfully applied to 3D TRUS datasets of varying quality.
Mean image quality grades for each individual factor provided in Table 3.7
highlight the overall high quality of our dataset and the general similarity in image quality
between end-fire and side-fire images, with no statistically significant differences observed
and a maximum difference in mean of only 0.2. Side-fire images did have an increased
standard deviation for each individual factor, highlighting the larger range of image
qualities, including the presence of grades of 2 in each factor, which was not seen in the
end-fire images. Our dataset contained no images with a grade of 1.
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For end-fire images in our testing dataset, image quality had no significant effect
on segmentation performance. In contrast, for side-fire images in our testing dataset, the
boundary visibility grade and the acquisition quality, boundary visibility, and total
averaged image quality grades significantly impacted segmentation performance for the UNet and U-Net++, respectively. Boundary visibility showed to be a key factor in the
algorithm s ability to accurately segment the prostate boundary for both networks, as
expected. These results were further confirmed with the correlation analysis shown in Fig.
3.9, highlighting the significant effect of image quality on segmentation performance for
side-fire images, but not for end-fire images. Correlations were not strong with Spearman
r coefficients in the range of 0.46-0.6 for the DSC metric for both the U-Net and U-Net++.
The lack of significant differences observed when comparing how segmentation
performance varies with image quality, especially considering the end-fire images, may be
attributed to the high mean image quality and subtle variation between the poorest quality
image and the highest quality image. A dataset with more variation in image quality may
better demonstrate the dependence of segmentation performance on image quality. In
addition, due to the testing set size of 20 end-fire and 20 side-fire 3D TRUS volumes, some
individual image quality grades had a very small sample size, which likely factored into
the lack of significant differences observed for some of the image quality factors.
The differences in image quality and its effect on segmentation performance for
end-fire compared to side-fire images may be explained in part due to the nature of image
acquisition. Ultrasound transducer orientation is one critical component; during end-fire
image acquisition the transducer contacts the rectal wall at the end of the transducer
pointing towards the prostate. During side-fire acquisition, however, the transducer is
positioned horizontally inside the rectum, requiring a much larger contact area, which can
result in increased prevalence of air gaps due to lost contact, reducing image quality.
Furthermore, due to differences in transducer position based on the intended application
the side-fire transducer is further away from the prostate, leading to hypoechoic regions
away from the transducer due to issues with time-gain compensation.
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3.4.5

Limitations and future work
Only one observer provided manual gold standard segmentations, thus inter- and

intra-observer variability were not directly assessed; however, these considerations were
addressed in Orlando et al.19 In addition, only one observer defined the image quality
grading scale and graded the testing dataset, which did not assess the impact of inter- or
intra-observer variability. Future work will include validation of our image quality grading
scale and its reliability, including an assessment of inter- and intra-observer variability.
Image quality of the training dataset may play a critical role in segmentation performance,
and although image quality of the testing dataset should have been representative of the
training dataset, direct grading of the training images would allow for confirmation of this
assumption. As shown in Table 3.7, our 3D TRUS dataset was of high quality on average.
A wide range in image quality is important for algorithm generalizability. Future work
should investigate our segmentation approach when trained and tested with a lower quality
dataset, ideally from a different center.
Patient clinical information, such as age, stage of prostate cancer, and Gleason score
was not recorded for our dataset, and thus an assessment of how segmentation performance
is impacted by these measures could not be completed. While this has not been assessed in
previous work to our knowledge, differences in such measures could manifest as
differences in image quality, potentially captured by our image quality grading scale as
anatomy artifact severity for example. Future work could explicitly investigate the
influence of patient clinical information on segmentation quality.
For our U-Net++ implementation, only one type of CNN backbone (ResNet) was
used. Future work will utilize a U-Net++ ensemble network with results from multiple
CNN backbones combined into one segmentation result using a method such as averaging,
majority vote, or the STAPLE algorithm.32 Finally, a leave-one-out vendor study
examining the impact of ultrasound machine vendor on segmentation performance would
offer a strong assessment of generalizability, which is critical for widespread clinical
translation.
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3.5

C

cl i

This study investigated the effect of training dataset size, image quality, and image
type on prostate segmentation in 3D TRUS volumes using a 2D radial plus 3D
reconstruction approach, comparing a modified U-Net to a U-Net++ architecture.
Beginning with a large, clinically diverse dataset of TRUS images, smaller training datasets
were generated by splitting and reducing the dataset. Segmentation performance for the UNet++ plateaued at end-fire, side-fire, or mixed training dataset sizes of 1000 2D images,
resliced from approximately 36 3D volumes. This high performance with small datasets
highlights the potential for widespread use of our approach or similar methods, even if data
is scarce, demonstrating the possibility for increased access to automated segmentation
methods. The development of an image quality grading scale specifically for 3D TRUS
imaging provides a quantitative tool for assessing segmentation performance, with an aim
to increase transparency regarding dataset quality and aid in comparison between
segmentation methods trained using different datasets.
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Figure 3.A1. Network diagram for the modified U-Net.

Figure 3.A2. Network diagram for the U-Net++ based on Zhou et al. 2018.
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Table 3.B1. Median [Q1, Q3] 2D results for the U-Net++ trained using end-fire datasets
of varying size, from 2738 (full end-fire set) to 100 images. The networks were evaluated
on an unseen test dataset of 20 end-fire and 20 side-fire 3D TRUS images of the prostate.
Test
Dataset
End-fire

End-fire
Training

DSC (%)

Recall (%)

Precision (%)

MSD (mm)

HD (mm)

Images
2738

94.5
93.7
95.8
1.18
[93.5, 95.1]
[91.0, 95.9]
[93.6, 97.4]
[0.98, 1.42]
1000
93.7
93.8
95.9
1.35
[91.7, 94.8]
[89.8, 95.3]
[94.0, 97.2]
[1.20, 1.97]
500
93.9
95.1
94.5
1.38
[92.0, 94.8]
[90.3, 96.2]
[91.8, 97.1]
[1.06, 1.96]
250
93.2
93.1
95.4
1.52
[91.9, 94.9]
[90.1, 95.8]
[93.1, 97.2]
[1.13, 1.70]
100
90.1
87.5
95.1
2.04
[88.5, 92.6]
[84.0, 92.2]
[92.0, 96.8]
[1.46, 2.91]
Side-fire
2738
88.8
89.7
90.8
2.00
[80.3, 92.7]
[84.7, 93.4]
[82.4, 94.5]
[1.46, 3.64]
1000
86.4
92.6
83.2
3.81
[74.1, 90.7]
[89.2, 95.2]
[63.2, 91.2]
[1.96, 6.17]
500
83.8
82.1
88.9
2.89
[73.9, 90.4]
[67.1, 90.9]
[81.8, 94.8]
[1.89, 4.89]
250
82.1 [
85.1
85.9
3.62
75.0, 88.2]
[70.8, 91.1]
[73.7, 92.9]
[2.64, 4.99]
100
75.3
86.3
71.3
5.29
[64.4, 84.4]
[78.6, 92.5]
[59.3, 82.9]
[3.57, 6.84]
Overall
2738
93.3
92.0
94.0
1.44
[88.5, 94.7]
[88.5, 95.1]
[90.6, 96.2]
[1.07, 2.03]
1000
91.3
93.2
93.3
1.95
[86.2, 94.2]
[89.5, 95.3]
[82.9, 96.0]
[1.34, 4.55]
500
91.5
90.5
92.7
1.94
[83.3, 93.9]
[81.8, 95.3]
[86.9, 95.7]
[1.24, 2.93]
250
89.2
90.6
93.1
1.98
[81.7, 93.2]
[82.2, 93.8]
[83.8, 96.5]
[1.48, 3.75]
100
87.7
87.0
87.3
3.01
[74.8, 90.3]
[82.5, 92.3]
[70.8, 95.2]
[2.03, 5.32]
DSC, Dice similarity coefficient; MSD, mean surface dist.; HD, Hausdorff dist.
Bolded metrics denotes significant differences compared to the full (2738 images) dataset.

3.79
[2.97, 4.58]
4.76
[3.89, 6.19]
4.39
[3.54, 5.60]
4.66
[3.86, 5.67]
6.24
[4.55, 7.60]
6.38
[5.01, 11.1]
12.4
[6.72, 17.5]
9.83
[6.14, 13.0]
12.0
[8.83, 14.5]
16.1
[11.7, 18.6]
4.78
[3.47, 6.94]
6.40
[4.26, 14.1]
5.83
[4.08, 9.83]
6.60
[4.63, 12.0]
9.13
[5.88, 16.7]
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Table 3.B2. Median [Q1, Q3] 2D results for the U-Net++ trained using side-fire datasets
of varying size, from 4023 (full end-fire set) to 100 images. The networks were evaluated
on an unseen test dataset of 20 end-fire and 20 side-fire 3D TRUS images of the prostate.
Test
Dataset
End-fire

Side-fire
Training

DSC (%)

Recall (%)

Precision (%)

MSD (mm)

HD (mm)

Images
4023

83.5
74.8
97.6
3.07
[71.8, 90.7]
[58.3, 85.6]
[96.5, 98.8]
[2.15, 4.89]
1000
77.7
64.5
98.8
3.83
[71.1, 84.2]
[57.2, 74.2]
[97.8, 99.7]
[3.13, 5.44]
500
74.4
62.5
98.0
4.05 [
[66.0, 81.7]
[50.0, 71.3]
[95.8, 99.4]
3.33, 6.15]
250
73.8
60.2
98.6
4.59
[69.7, 81.1]
[57.1, 69.8]
[95.2, 99.6]
[3.76, 5.57]
100
65.3 [
49.2
97.0
6.28
58.0, 71.7]
[52.6, 59.1]
[94.8, 99.6]
[4.19, 7.28]
Side-fire
4023
93.3
92.1
95.1
1.13
[91.5, 95.0]
[88.5, 94.6]
[93.7, 97.7]
[0.90, 1.48]
1000
90.3
93.8
93.7
1.59
[89.0, 94.9]
[87.4, 95.5]
[87.9, 95.1]
[0.95, 2.13]
500
90.3
86.6
95.7
1.68
[84.0, 92.7]
[78.9, 90.5]
[91.1, 98.0]
[1.20, 2.79]
250
89.2
87.2
91.8
2.21
[85.4, 92.6]
[84.7, 91.8]
[89.0, 95.9]
[1.20, 2.98]
100
81.0
75.9
85.4
3.46
[73.1, 83.7]
[67.0, 85.2]
[81.9, 95.9]
[2.88, 4.27]
Overall
4023
91.0
86.7
97.0
1.65
[83.3, 93.6]
[74.5, 92.8]
[94.1, 98.1]
[1.09, 3.08]
1000
85.9
84.6
95.9
2.35
[76.2, 92.9]
[63.7, 94.4]
[92.6, 99.0]
[1.26, 4.59]
500
82.4
74.4
97.1
2.85
[70.9, 90.5]
[58.3, 87.2]
[94.3, 98.3]
[1.59, 4.79]
250
83.6
80.4
95.5
3.13
[73.4, 89.5]
[60.1, 87.5]
[91.0, 98.6]
[1.85, 4.70]
100
72.1
63.9
93.5
4.25
[62.3, 81.3]
[48.8, 77.2]
[84.7, 97.1]
[3.26, 6.76]
DSC, Dice similarity coefficient; MSD, mean surface dist.; HD, Hausdorff dist.
Bolded metrics denotes significant differences compared to the full (4023 images) dataset.

8.56
[7.32, 12.4]
10.9
[8.47, 14.2]
12.4
[9.31, 16.5]
12.3
[10.2, 14.6]
14.8
[10.8, 16.3]
3.50
[2.96, 4.67]
4.95
[3.59, 6.89]
5.84
[3.88, 8.99]
8.44
[4.17, 10.1]
9.76
[8.80, 11.6]
5.30
[3.48, 8.60]
7.43
[4.12, 11.8]
9.32
[5.54, 14.3]
10.2
[6.89, 12.7]
11.5
[9.45, 15.5]
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Table 3.B3. Median [Q1, Q3] 2D results for the U-Net++ trained using mixed (end-fire
and side-fire) datasets of varying size, from 6761 (full dataset) to 100 images. The networks
were evaluated on an unseen test dataset of 20 end-fire and 20 side-fire 3D TRUS images.
Test
Dataset
End-fire

Mixed
Training

DSC (%)

Recall (%)

Precision (%)

MSD (mm)

HD (mm)

Images
6761

94.9
94.6
96.3
1.10
[93.8, 95.5]
[92.7, 95.6]
[94.0, 97.2]
[0.95, 1.38]
4023
94.4
96.2
94.0
1.31
[93.4, 95.6]
[93.3, 97.6]
[90.7, 96.3]
[1.04, 1.50]
2738
94.8
94.1
96.4
1.17
[93.2, 95.5]
[90.4, 95.6]
[95.5, 98.1]
[0.99, 1.41]
1000
94.3
95.2
94.4
1.29
[92.0, 95.0]
[91.4, 96.6]
[91.8, 97.3]
[1.05, 1.95]
500
92.0
90.0
96.4
1.58
[89.6, 93.8]
[84.5, 94.6]
[93.4, 98.0]
[1.38, 2.07]
250
89.5
84.3
96.5
2.11
[84.3, 91.1]
[74.2, 88.9]
[93.3, 98.2]
[1.82, 3.42]
100
75.2
60.5
99.6
4.90
[63.6, 80.2]
[48.9, 69.0]
[97.1, 99.9]
[3.88, 6.99]
Side-fire
6761
94.6
95.7
94.2
1.00
[92.3, 95.1]
[91.3, 96.5]
[92.2, 96.4]
[0.83, 1.32]
4023
93.6
94.4
93.7
1.09
[91.0, 95.2]
[90.8, 96.6]
[90.1, 95.9]
[0.91, 1.80]
2738
93.1
92.5
95.5
1.23
[89.6, 94.9]
[89.3, 93.6]
[91.3, 96.7]
[0.88, 1.69]
1000
91.8
92.5
94.2
1.44
[88.2, 94.6]
[88.8, 95.6]
[88.0, 96.4]
[1.00, 2.33]
500
90.5
93.8
90.9
1.73
[86.4, 93.6]
[88.3, 95.5]
[83.8, 95.2]
[1.21, 2.74]
250
85.2
92.2
80.9
3.05
[81.4, 90.8]
[88.6, 94.9]
[74.1, 89.1]
[1.73, 4.56]
100
84.3
80.9
85.6
2.74
[77.4, 86.0]
[76.4, 87.1]
[80.2, 92.5]
[2.52, 3.88]
Overall
6761
94.7
95.1
95.7
1.07
[92.6, 95.4]
[92.7, 96.4]
[92.9, 96.8]
[0.90, 1.33]
4023
94.2
95.2
93.9
1.21
[92.6, 95.4]
[92.8, 97.1]
[90.6, 96.1]
[1.00, 1.52]
2738
94.1
92.9
96.1
1.19
[92.1, 95.2]
[90.2, 94.8]
[92.4, 97.4]
[0.98, 1.56]
1000
93.2
94.6
94.3
1.32
[89.7, 94.9]
[89.4, 95.9]
[88.3, 96.5]
[1.01, 2.03]
500
91.8
92.0
95.1
1.63
[88.4, 93.8]
[87.4, 94.9]
[87.5, 96.7]
[1.35, 2.40]
250
87.0
88.9
91.4
2.41
[82.9, 91.0]
[82.9, 92.5]
[80.8, 96.5]
[1.82, 3.56]
100
79.6
73.1
93.2
3.88
[67.7, 85.8]
[58.0, 81.8]
[83.4, 99.7]
[2.61, 5.81]
DSC, Dice similarity coefficient; MSD, mean surface dist.; HD, Hausdorff dist.
Bolded metrics denotes significant differences compared to the full (6761 images) dataset.

3.68
[2.87, 4.54]
4.34
[3.60, 5.33]
3.71
[3.30, 4.68]
4.05
[3.45, 5.87]
5.03
[4.14, 6.65]
6.16
[5.10, 9.08]
11.8
[8.51, 14.9]
3.27
[2.85, 4.19]
3.84
[3.10, 5.72]
4.29
[3.12, 5.69]
4.96
[3.63, 7.14]
5.61
[3.78, 8.69]
8.85
[5.85, 15.6]
8.48
[6.66, 11.6]
3.60
[2.87, 4.45]
4.00
[3.50, 5.33]
3.98
[3.30, 4.76]
4.45
[3.52, 6.15]
5.14
[4.10, 7.99]
7.84
[5.46, 10.6]
9.86
[7.28, 13.4]
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Intraoperative needle tip localization is critical for treatment planning in prostate
brachytherapy. However, tip visibility can be limited with conventional B-mode US due to
image artifacts. A method to improve needle tip visibility intraoperatively may improve tip
identification accuracy for difficult-to-see needles, thus improving treatment accuracy. The
purpose of Chapter 4 is to describe the development and validation of a PD US-based
needle tip localization method designed specifically for interstitial prostate brachytherapy.
The contents of this chapter have been submitted for publication in Medical Physics
and are currently under peer review: Orlando N, Snir J, Barker K, D Souza D, Velker V,
Mendez LC, Fenster A, and Hoover DA.

4.1

I

d ci

High-dose-rate (HDR) brachytherapy (BT) is a common treatment technique for
localized intermediate to high-risk prostate cancer.1

3

In this treatment a single high-

activity radioactive source is passed through needles inserted into the prostate through the
perineum, guided by a rigid grid of evenly spaced holes known as a template. Needles are
typically inserted under transrectal ultrasound (TRUS) guidance, as it is a widely available
and low-cost modality, offering real-time imaging and comparable needle tip localization
accuracy to computed tomography (CT),4 making it the preferred method for prostate
HDR-BT guidance at many centers.5 In addition, TRUS-guided procedures allow for all
aspects of the treatment workflow to occur in the operating room, including intraoperative
imaging and treatment planning, allowing the patient to remain stationary.
Identification of needle tip position directly influences the radiation treatment plan,
making accurate tip localization critical for a safe and effective HDR-BT treatment.6 8 Error
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in needle tip localization is the primary component of uncertainty in HDR-BT setup, with
errors greater than 3 mm potentially leading to adverse outcomes including overexposed
organs-at-risk or cancer recurrence due to an under-dosed tumor.7 For TRUS-guided HDRBT procedures, needle tip positions are typically identified using live two-dimensional (2D)
brightness (B)-mode sagittal ultrasound (US).6 Siebert et al.6 investigated needle tip
localization accuracy in water phantoms, demonstrating errors between 0.8 and 2.8 mm for
2D sagittal US. Due to the homogeneity of water, images obtained using this phantom are of
higher quality than typical clinical images, making this a best-case scenario. Image artifacts
such as shadowing or reverberation from nearby anatomy and needles can make it difficult
to clearly visualize the needle tip in clinical ultrasound images, limiting the accuracy of
needle tip localization.9
The use of Doppler US has been suggested to improve the visualization of surgical
instruments in minimally invasive procedures.10
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Doppler US images display the velocity

component in the plane of the B-mode US image of tissues or instruments as a colored
overlay. Doppler-based visualization techniques apply some form of perturbation to the
surgical instrument, generating motion that can be detected and displayed by Doppler US,
typically in one of two modes, Colour Doppler (CD) or Power Doppler (PD), to improve
visibility. While CD can display the direction of motion, PD is typically preferred in these
applications as it has a higher sensitivity, and the direction of motion is unimportant.
Doppler-based techniques for improving surgical instrument detection have been applied
in a variety of procedure types and disease sites.10
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This includes various tissue

biopsies,10,11,13 pericardiocentesis,14 and radiofrequency ablation,12,13,15,20 with none
focusing on brachytherapy to our knowledge. The motion was generated in numerous ways
including vibrating devices clipped onto the needle,10,11,14,20 piezoelectric crystals,13,15,17
and electromagnetic actuation of small permanent magnets inside the needle.12 These
methods often required modifications to the clinical equipment or physical attachment to
the needle or surgical tool. This is impractical in the BT workflow where 12 or more
needles are typically used. There is also a clear lack of clinical validation in the literature
of the use of PD methods to identify BT needles in human tissues. Thus, a PD-based
method designed specifically for the BT workflow is required, in addition to an exploration
of clinical feasibility.
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We have previously proposed a PD needle visualization method utilizing a simple
mechanical device capable of oscillating at a fixed and controllable frequency, requiring
no modifications to the clinical workflow.22 The device was both powered and controlled
by a laptop computer, requiring two operators to use the device. The additional computer
and required cables were cumbersome in the busy operating room environment. In
addition, consistent Doppler signal generation was difficult with this end-piece design, as
it required precise positioning of the device. These limitations made the device not feasible
for long-term and efficient clinical use. To overcome these limitations and improve clinical
translation potential, we presented the initial feasibility design of a wireless mechanical
oscillator designed specifically for BT, tested in a small-scale proof-of-concept phantom
study with six needles.23
In this paper, we report on the development and validation of our clinically-ready
novel wireless mechanical oscillator and PD US needle tip localization method through
comprehensive tissue-equivalent phantom experiments simulating prostate HDR-BT
procedures and scenarios with extensive shadowing artifacts limiting needle visibility. In
addition, we validated our PD US method in five prostate cancer patients undergoing
standard HDR-BT as part of a prospective feasibility clinical trial, the first of its kind to
our knowledge. Our cost-effective and easy to implement method, requiring no
modifications to the clinical equipment or workflow, may allow for improved
intraoperative needle tip localization accuracy, especially in cases with reduced needle
visibility in standard US images. This has the potential to improve both patient safety and
treatment accuracy in HDR-BT and more broadly in any minimally invasive needle-based
procedure.

4.2
4.2.1

Ma e ial a d Me h d
Wireless mechanical oscillator design
Photographs of the wireless mechanical oscillator are shown in Fig. 4.1. The

oscillator contains a Faulhaber 1331T006SR brushed DC motor and MCDC 3002 series
motion controller (Faulhaber MicroMo LLC, Clearwater, FL, USA) powered by a 1200
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milliamp hour Lithium-ion polymer battery, rechargeable via a micro-USB cable. The
ergonomic cylindrical case, 3D printed using a nylon-aluminum material, had a diameter
of 4.2 cm and length of 17.8 cm (including the end-piece). The oscillation frequency is
controlled on the device using a 16-position rotary switch with resistances tuned to specific
oscillation frequencies ranging from 22.0 Hz to 44.5 Hz. Frequency values are printed
directly on the device, as shown in Fig. 4.1C, allowing the user to easily change to the
desired frequency while still in the operating room. As the oscillator is battery-powered
with frequency-control directly on the device, it is completely wireless and easily operated
by one user, requiring no additional equipment, computer, or personnel in the operating
room.
The end-piece, machined from 400 series stainless steel, features a cylindrical cup
shape, custom-designed for BT applications to fit over top of the commonly used
cylindrical mandrins. The end-piece and example mandrins are shown in Fig 4.1B. This
design provides two points of contact for needle vibration, while also removing ambiguity
surrounding oscillator placement, as the cylindrical cup can be placed directly over the
mandrin. Thus, our method requires no modifications or attachment to the standard clinical
equipment. Finally, the end-piece design ensures needle oscillation is perpendicular to the
insertion direction, minimizing the possibility of vibration pushing the needle deeper into
the patient. When powered, the end-piece oscillates with an amplitude of 1 mm. As clinical
needle mandrins vary in shape, the end-pieces can be machined to any size. In our
application, two end-piece sizes were required as shown in Fig. 4.1B. For easy removal,
the end-piece is attached to the oscillator magnetically. This allows for easy bagging of the
device in the sterile operating room environment, as a plastic covering can be placed over
the 3D-printed case, with the magnetic end-piece attached through the plastic. The endpiece and plastic covering can then be disposed of after the procedure, maintaining a sterile
device.
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Figure 4.1. (A) Photograph of our wireless mechanical oscillator. (B) Front view showing
the magnetically attached cylindrical end-pieces and example plastic needle with the
corresponding mandrin. Two end-piece sizes were used corresponding to plastic and metal
Varian needles. (C) The oscillation frequency is controlled using a 16-position rotary dial
at the bottom of the device. Frequency values are printed on the device for ease of use.

4.2.2

Phantom validation
Prior to clinical testing, phantom validation of our PD needle tip localization

method involved three experiments, with details outlined in sections 4.2.2.1 and 4.2.2.2.
For each experiment, a tissue-mimicking agar phantom was made containing 35 g agar
powder (Sigma Aldrich Co., St. Louis, MO, USA) and 80 mL glycerol (Sigma Aldrich Co.,
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St. Louis, MO, USA) per 1 L of distilled water, simulating the speed of sound in soft tissue,
approximately 1540 m/s.24 10 g of SigmaCell cellulose powder (Sigma Aldrich Co., St.
Louis, MO, USA) per 1 L distilled water was also added to simulate soft tissue scatter. A
prostate mold with a volume of 50.0 cm3 was 3D printed based on a prostate segmented
from a patient MR image. An identical agar mixture was used to fill the mold; however,
only 1 g of cellulose powder per 1 L distilled water was used to provide contrast between
the prostate and the background in the US image and 10 g of Tungsten powder (Sigma
Aldrich Co., St. Louis, MO, USA) per 1 L distilled water was added to ensure visibility of
the prostate in CT images. In addition to the embedded agar prostate, multiple landmarks
were embedded in three layers 1 cm away from the prostate to facilitate US-to-CT rigid
image registration. Each layer contained two 1.5 mm steel ball bearings (McMaster-Carr,
Elmhurst, IL, USA) and three 9.5 mm agar spheres. To provide contrast with the phantom
background and allow visibility in CT, the agar spheres contained 10 g Tungsten powder
per 1 L distilled water but no cellulose powder.
All US imaging was completed using a BK3000 system with an E14CL4b biplane
endocavity transducer (BK Medical, Peabody, MA, USA), supported by a CIVCO EX3
Stepper (CIVCO Medical Solutions, Coralville, IA, USA). B-mode gain and frequency
were 60% and 9 MHz, respectively, with a depth of 6.5 cm. For all experiments, the pulse
repetition frequency (PRF) was 0.8 kHz and Res/Hz was 4/22 Hz. Doppler gain and
oscillation frequency were the two key parameters used to optimize the power Doppler
signal. To best optimize the Doppler signal, Doppler gain and oscillation frequency were
increased until flash artifacts were observed, then the gain was reduced. The optimal
Doppler gain and oscillation frequency varied depending on needle type, distance from the
transducer, and artifact presence. Specific values are provided in sections 4.2.2.1 and
4.2.2.2. All PD US imaging and needle perturbations were done with the mandrins inserted
and the needle position locked by the template. This ensured that needle vibration did not
change the position of the needle.
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Plastic
Needle
s
Metal
Needles

Figure 4.2. Photograph of our experimental set-up showing needle implant patterns for a
simulated HDR-BT procedure with metal needles (A), and a simulated case with extensive
needle shadowing with plastic needles (B). The US transducer, needle template, and
varying size needle mandrins can be seen in both experiments.

4.2.2.1

Mock HDR-BT procedure

In a phantom experiment simulating standard prostate HDR-BT procedures at our
center, 12 stainless steel needles (17G) with corresponding mandrins (Varian Medical
Systems, Palo Alto, CA, USA) were inserted into our tissue-equivalent phantom through
the Crook prostate template (Varian Medical Systems, Palo Alto, CA, USA) shown in Fig.
4.2A. Following the standard clinical procedure, needles were inserted to provide the best
possible radiation coverage for the embedded agar prostate, as shown in Fig. 4.2A. All 12
needles were first inserted into the prostate mid-gland, where they were identified in the
axial US plane in Vitesse (Varian Medical Systems, Palo Alto, CA, USA). Needles were
then advanced, one at a time, to the base of the prostate and verified in the sagittal US
plane.
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Needle tip locations were first identified using standard B-mode US in the sagittal
plane by a board-certified medical physicist experienced with prostate brachytherapy
(D.H.). To maintain the highest image resolution, needle tip positions were identified
directly on the US screen and subsequently transferred to Vitesse. Next, needle tip locations
were identified using PD US with perturbation from our wireless mechanical oscillator. To
test needle tip localization accuracy without B-mode US information, the observer was
blinded by reducing the B-mode gain to 0, as shown in Fig. 4.3C. The needle tip position
was then identified using only the PD signal after mechanical perturbation. This also
simulated the clinical case of a needle that is not visible in the standard B-mode US image
due to shadowing. Finally, needle tip positions were identified using B-mode US and PD
US together with mechanical perturbation. The needle tip location was selected directly on
the US screen as the furthest point in the Doppler signal. The distance from the template to
the end of the needle, the so-called end length, was recorded for each needle, verified by a
second observer.
For PD US imaging, the optimal Doppler gain and oscillation frequency varied
depending on the needle position and the presence or absence of needle shadowing
obstructions. For unobstructed needles close to the US transducer, Doppler gain was 1015% and oscillation frequency was 32.5-40 Hz. For the needles far from the US transducer
or obstructed by needle shadowing artifacts the Doppler gain was 32-40% and oscillation
frequency was 43 Hz.

4.2.2.2

Explicit needle shadowing

The second set of phantom experiments examined needle tip localization accuracy
in the presence of needle shadowing artifacts. 15 stainless steel needles with corresponding
mandrins were inserted into our tissue-equivalent agar phantom. Needles were inserted in
three columns extending from the transducer. The left and right columns formed a V-shape,
while the middle column extended upwards away from the transducer, as shown in Fig.
4.2B. This needle insertion pattern ensured every needle, apart from the three closest to the
US transducer, was shadowed by one or multiple needles below it, simulating the clinical
scenario where the needle tip location in the B-mode US image is obscured by shadowing

124

artifacts. This implant pattern was repeated in a second experiment utilizing 13 plastic
needles (2 mm diameter) with corresponding metal mandrins (Varian Medical Systems,
Palo Alto, CA, USA). In this implant, the left and right columns had four needles each,
while the central column had five needles.
As described in section 4.2.2.1, needle tip locations were identified in an identical
manner, starting with standard B-mode US alone, then PD US with mechanical
perturbation alone by reducing B-mode gain to 0, and finally B-mode and PD US together.
Once again, the distance from the template to the end of the needle, the end length, was
recorded for each needle.
For PD US imaging with the stainless-steel needles, the Doppler gain and
oscillation frequency ranged from 35% and 32.5 Hz for needles close to the transducer to
45-55% and 40-44.5 Hz for shadowed needles far from the transducer. Similarly, for the
plastic needles, the Doppler gain and oscillation frequency ranged from 35-40% and 32.5
Hz for close needles to 40-50% and 43 Hz for obstructed needles far from the transducer.

4.2.2.3

Evaluation of tip localization accuracy

Needle tip localization error was computed using a clinical method based on ideal
reference needles. For each phantom experiment, 1-2 clearly visible, unobstructed needles
were selected as reference needles, which were typically along the row closest to the US
transducer. Using the measured exposed needle end lengths and the known total needle
length, the difference between the identified needle tip location and the expected tip
location based on the reference needles was computed in Vitesse, providing a metric for
tip localization error. In addition, the absolute distance in the insertion (z) direction
between needle tip positions identified using PD US only and PD plus B-mode US were
computed for each needle using MATLAB (MathWorks, Natick, MA, USA) to examine
the impact of B-mode context on PD US tip localizations.
Needle tip localizations using B-mode and PD US were also compared to tip
localizations using CT as a gold standard. To enable registration between US and CT,
axially reconstructed step-back 3D US images were acquired with 1 mm step spacing using
Vitesse after needle insertion was completed. 3D US images had a size of [1100⨯700⨯70]
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voxels with a voxel size of [0.083⨯0.110⨯1.00] mm3. CT imaging was completed using a
Philips Brilliance Big Bore CT Scanner (Philips Healthcare, Andover, MA, USA) with 120
KV potential, 325 mA x-ray tube current, and 2 mm slice thickness, generating images
with a size ranging from [512⨯512⨯299] to [512⨯512⨯339] voxels and voxel size ranging
from [0.355⨯0.355⨯1.00] to [0.684⨯0.684⨯1.00] mm3. All CT scans were performed
with the mandrins removed to limit metal artifacts. The needle tip positions were manually
identified in the CT images by an experienced medical physicist (D.H.). Manual rigid
landmark registration between 3D US and CT was performed using the embedded
landmarks described in section 4.2.2. With a total of six 1.5 mm steel ball bearings and
eight 9.5 mm agar spheres per phantom, three ball bearings, and four agar spheres were
used as fiducials for registration, while the remaining landmarks were used to compute
target registration error (TRE).25 After registration to the same coordinate system, the
distance in the insertion (z) direction between needle tip positions identified in B-mode or
PD US and in CT could be calculated.

4.2.3

Clinical validation
Our PD US needle localization method was validated in a prospective feasibility

clinical trial (NCT03861507) approved by the Research Ethics Board at Western
University (London, ON, Canada). This feasibility trial had a planned accrual of five
patients with a maximum of 20 patients, all of whom were scheduled to undergo standard
interstitial HDR prostate brachytherapy at the London Regional Cancer Program. To be
considered for the study, patients had to be male, aged 18 years or older, willing to provide
informed consent, have pathologically confirmed prostate cancer on a previous biopsy, and
are suitable for and consenting to HDR-BT for treatment as standard of care. Any patient
who previously received radiotherapy to the prostate was excluded from the study.
Treatments were completed by three radiation oncologists specializing in brachytherapy.
Our study protocol was completed during the time required to create and validate the
radiation treatment plan and did not influence treatment decision-making or the total
procedure time. 12-15 stainless steel needles were used per patient, inserted following the
standard clinical protocol (63 needles total).
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Needle tip locations were first identified using standard B-mode US alone. The
treating radiation oncologist rotated the US transducer to the optimal plane. The needle tip
location was identified by consensus between the radiation oncologist and board-certified
medical physicist (D.H.) on the live sagittal US view directly on the US machine as
described in section 4.2.2.1. The tip location was then transferred to Vitesse. This B-mode
localization is distinct from the clinical version as the needles are already inserted to the
base of the prostate and are locked in position by the needle template, meaning they cannot
be rotated. The visibility of each needle in the live B-mode US image was labeled on a
three-tiered scale as clearly visible, partially visible, or mostly/completely obscured.
Needle tip locations were then identified using PD US with mechanical perturbation using
our wireless oscillator, which was controlled by the radiation oncologist. The optimal
Doppler gain and oscillation frequency varied between patients and was dependent on
needle position and the presence or absence of obstructions, leading to a wide range of
values. Doppler gain ranged from 8% to 50%, with an average for unobstructed needles of
15-25%. The oscillation frequency was consistently high, ranging from 38.5 Hz to 44.5
Hz. All needle perturbations were performed with the mandrins inserted and the needles
locked in place individually using the Crook prostate template. Exposed needle end length
measurements were repeated after the study protocol was complete to ensure that needle
position remained the same.
As described in section 4.2.2.3, needle tip localization accuracy was computed
using the clinical method based on the ideal reference needles selected during the clinical
procedure. Tip localization error was computed in Vitesse using the measured exposed
needle end lengths and the known total needle length to compare the identified needle tip
location and the expected tip location based on the reference needles. Our center does not
use a post-implant CT scan for HDR prostate brachytherapy, so the comparison to CT as
ground truth was not possible for the clinical study.

4.2.4

Statistical analysis
All statistical analyses were performed in GraphPad Prism 9.3.1 (Graphpad

Software, Inc., San Diego, CA, USA). The normality of distributions was assessed using
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the Shapiro-Wilk test. Failure of this test led to the use of alternative nonparametric
statistical tests, presented in parentheses in the following paragraph. The significance level
for statistical analysis was chosen such that the probability of making a type I error was
less than 5% (p < 0.05). Statistically significant differences are denoted simply as
significant for the remainder of this manuscript.
Comparisons between needle tip localization accuracy using B-mode US, PD US
only, and PD plus B-mode US in phantom experiments, including comparisons to CT as a
gold standard, were completed using repeated measures one-way ANOVA with Tukey s
multiple comparisons tests (Friedman test with Dunn s multiple comparisons tests).
Differences in tip localization accuracy in the mock HDR-BT procedure and the explicit
shadowing experiment for each US visualization method were compared using two-tailed
unpaired t-tests (Mann-Whitney U Tests). Similarly, the accuracy for identifying plastic
and metal needle tips in the explicit shadowing experiments were directly compared using
the same tests. For clinical validation, comparisons of needle tip localization accuracy
using B-mode US and PD US for all needles and specifically for unobstructed, partially
obstructed, and unobstructed needles were compared using two-tailed paired t-tests
(Wilcoxon matched-pairs signed-rank tests) for each individual patient and overall. A
comparison of needle tip localization accuracy between the three visibility grades for Bmode and PD US was completed using a two-way ANOVA with Tukey s multiple
comparisons test. Needle localization accuracy between physicians for both B-mode and
PD US were compared using one-way ANOVA with Tukey s correction for multiple
comparisons (Kruskal-Wallis tests with Dunn s correction for multiple comparisons).

4.3
4.3.1

Re l
Phantom validation
Examples of needle visualization using standard B-mode US, PD plus B-mode US,

and PD US only are shown in Fig. 4.3.
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Figure 4.3. Example needle visualization results in phantom, showing (A) a standard Bmode US image, (B) PD US image with perturbation from our mechanical oscillator, and
(C) PD US only with B-mode context blinded to the observer.

Quantitative comparisons of absolute needle tip localization error, computed based
on clearly visible reference needles, are shown in Fig. 4.4 for three phantom experiments,
with complete absolute and signed results provided in Table 4.1. For the metal needles
inserted to mimic a standard HDR-BT procedure, only PD US alone had significantly
higher signed tip error compared to PD plus B-mode US, with no significant difference
observed for absolute tip error (Fig. 4.4A). With metal needles implanted to maximize
shadowing artifacts, no significant differences in tip error were observed for either absolute
or signed metrics (Fig. 4.4B). Similarly, no significant differences were observed for the
identical shadowing experiment with plastic needles, although the mean tip error and
variance we variance were much higher for standard B-mode US compared to both PD US
approaches, as shown in Fig. 4.4C.
The impact of B-mode information on needle tip identification was investigated by
computing the difference in the insertion (z) direction between needle tip locations
identified using PD US alone and PD plus B-mode US. The absolute difference was 0.7 ±
0.8 mm, 0.5 ± 0.5 mm, and 0.7 ± 0.9 mm while the signed difference was 0.6 ± 0.9 mm,
0.5 ± 0.5 mm, and -0.6 ± 0.9 mm for the mock HDR-BT procedure, shadowing experiment
with metal needles, and shadowing experiment with plastic needles, respectively.
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A

B

C

Figure 4.4. Box and whisker plots of absolute needle tip localization errors, in mm,
comparing needle visualization with standard B-mode US, PD US alone, and PD plus Bmode US. Plots from left to right show results for the mock HDR-BT procedure with (A)
metal needles (N=12) and the explicit needle shadowing implant patterns with (B) metal
(N=15) and (C) plastic needles (N=13). Boxes denote interquartile range from the 25th to
75th percentile while whiskers show the minimum and maximum values. Each individual
tip error is shown with a bar representing the median.

Table 4.1. Mean ± standard deviation absolute and signed tip localization errors based on
ideal reference needles for visualization with standard B-mode US, PD US alone, and PD
plus B-mode US in three phantom experiments with two needle types. Negative values
represent an underprediction relative to the expected tip location.
Tip Error (mm)
Absolute

Signed

Experiment

N

B-mode
US

PD US
Alone

PD+Bmode

B-mode
US

PD US
Alone

PD+Bmode

Mock HDR-BT
Procedure

12

0.3 ± 0.3

0.6 ± 0.5

0.4 ± 0.2

0.1 ± 0.4

0.6 ± 0.5

-0.2 ± 0.4

Shadowing
Metal Needles

15

0.5 ± 0.2

0.5 ± 0.3

0.6 ± 0.2

0.3 ± 0.5

0.3 ± 0.5

0.3 ± 0.5

Shadowing
Plastic Needles

13

0.8 ± 1.7

0.4 ± 0.6

0.3 ± 0.5

0.3 ± 1.9

-0.1 ± 0.8

-0.3 ± 0.5
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Needle tip localization error for B-mode US, PD US alone, and PD plus B-mode
US compared to CT imaging as a gold standard is shown in Table 4.2. The mean ± standard
deviation TRE using a total of 18 landmarks for the rigid registrations between 3D US and
CT was 0.8 ± 0.3 mm. For metal needles inserted in a standard HDR-BT configuration, tip
locations identified using B-mode US had significantly higher agreement to the CT gold
standard compared to PD plus B-mode US. When metal needles were inserted to maximize
shadowing artifacts, PD plus B-mode US demonstrated significantly higher error compared
to PD US alone and B-mode US. For plastic needles inserted to maximize needle
shadowing artifacts, the difference compared to needle tip locations identified using CT
imaging was significantly lower for PD plus B-mode US compared to PD US alone.
Although B-mode US and PD plus B-mode US compared to the CT gold standard were not
significantly different in this case, we did observe reduced mean tip error and variance
compared to CT for PD plus B-mode US.

Table 4.2. Mean ± standard deviation absolute and signed tip localization errors compared
to the CT gold standard for needle visualization with standard B-mode US, PD US alone,
and PD plus B-mode US in three phantom experiments with two needle types.
Tip Error vs CT (mm)
Absolute

Signed

Experiment

N

B-mode
US

PD US
Alone

PD+Bmode

B-mode
US

PD US
Alone

PD+Bmode

Mock HDR-BT
Procedure

12

0.9 ± 0.5

1.6 ± 0.7

1.9 ± 0.6

0.9 ± 0.6

1.3 ± 1.2

1.9 ± 0.6

Shadowing
Metal Needles

15

0.7 ± 0.4

0.9 ± 0.5

1.4 ± 0.5

0.7 ± 0.4

0.9 ± 0.5

1.4 ± 0.5

Shadowing
Plastic Needles

13

3.7 ± 0.5

4.1 ± 0.5

3.7 ± 0.4

3.3 ± 1.9

4.1 ± 0.5

3.7 ± 0.4
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4.3.2

Clinical validation
Six patients consented to our prospective feasibility clinical trial. Due to treatment

complications unrelated to our study, we had insufficient time to complete the study
protocol for one patient (PD-04), meaning five patients completed the study. 12 needles
were inserted for all patients apart from PD-05, where 15 needles were used. Example Bmode US and PD US needle visualizations in clinical prostate HDR-BT patients are shown
in Fig. 4.5 for varying needle visibilities.
Figure 4.6 shows clinical results comparing absolute tip localization error
computed using the reference needles chosen during the clinical procedure for standard Bmode US and PD US with mechanical perturbation. Complete numerical results are
provided in Table 4.3, with the mean absolute tip error computed for each individual patient
and averaged for each of the three physicians who participated in the trial. As shown in
Table 4.3, there were no significant differences in tip localization error between B-mode
US and PD US with mechanical perturbation for any individual patient or overall, although
PD US did show reduced mean tip error and variance. A scatter plot of PD US tip error as
a function of B-mode US tip error for all needles in clinical cases is shown in Fig. 4.7.
When tip errors were averaged for each physician, there was once again no
significant difference between the US visualization methods, as seen in the right side of
Table 4.3. Physician 1, who completed three cases, was observed to have the largest
improvement when utilizing PD US, although B-mode tip error was also the highest with
a mean of 1.0 mm. Comparing standard B-mode US tip localization between physicians,
significant differences were observed, specifically between physician 1 and 3. When PD
US tip localizations were compared between physicians, no significant differences were
observed.
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Figure 4.5. Example images from the clinical trial showing needle visualization in patients
using standard B-mode US (left) and PD US with perturbation (right). The rows show an
example (A) unobstructed needle, (B) partially obstructed needle, and (C) obstructed
needle. Arrows point to the needle in question.
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Figure 4.6. Box and whisker plot of absolute needle tip localization errors comparing
needle visualization with standard B-mode US to PD US with perturbation in clinical cases.
Tip error for each individual patient and the total tip error are shown from left to right.
Boxes denote interquartile range from the 25th to 75th percentile while whiskers show the
minimum and maximum values. Each individual tip error is shown with a bar representing
the median.

Table 4.3. Mean ± standard deviation absolute tip localization errors comparing needle
visualization with standard B-mode US to PD US with perturbation for clinical cases. Tip
errors for each individual patient and averaged for each physician are shown in the left and
right halves of the table, respectively. Overall tip error is shown in the bottom row.
Tip Error (mm)
Physician

Patient

B-mode US

PD US

1

1
2
6

1.0 ± 0.9
0.9 ± 0.7
1.2 ± 0.5

2

3

3

5
Total

Tip Error per Physician (mm)
p-value

B-mode US

PD US

p-value

0.9 ± 0.5
0.7 ± 0.7
1.0 ± 0.2

1.0 ± 0.7

0.9 ± 0.5

0.6036b

0.9 ± 0.6

1.0 ± 0.7

0.9 ± 0.6

1.0 ± 0.7

0.7681a

0.5 ± 0.4

0.7 ± 0.5

0.5 ± 0.4

0.7 ± 0.5

0.1843a

0.9 ± 0.7

0.8 ± 0.5

0.9563b

p-values correspond to apaired t-test or bWilcoxon matched-pairs signed-rank test between B-mode and
PD US
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Figure 4.7. Scatter plot of PD US absolute tip error as a function of B-mode US absolute
tip error for all 63 needles in the feasibility clinical trial.

For a total of 63 needles inserted across our five clinical cases, 27 were identified
as unobstructed needles, 25 were identified as partially obstructed needles, and 11 were
identified as obstructed needles. Absolute mean tip errors using B-mode US and PD US
needle tip localization methods for each needle visibility tier are shown in Fig. 4.8. A twoway ANOVA showed a significant main effect for needle visibility grade, with the multiple
comparison tests showing significant differences between unobstructed and obstructed
needles. The US visualization method showed no significant main effect, although PD US
corresponded to lower variance as visibility worsened, also reducing mean tip error for
partially obstructed needles, as shown in Fig. 4.8.
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Figure 4.8. Plot of the mean ± standard deviation absolute tip localization errors comparing
B-mode US to PD US with perturbation in clinical cases with varying needle visibility.
Mean tip error for unobstructed, partially obstructed, and obstructed needles are shown
from left to right.

4.4
4.4.1

Di c

i

Phantom validation
For the first experiment, an implant with metal needles meant to simulate a clinical

prostate HDR-BT procedure showed nearly identical performance between B-mode US
alone and PD plus B-mode US, with our PD approach reducing the maximum tip error
(Fig. 4.4A). Tip error for our PD US method alone had a higher mean and variation, likely
due to the inherent limitations of our blinding approach. By reducing the B-mode gain to
zero for the entire PD procedure, it became impossible to tell whether transducer contact
with the phantom was maintained, or whether the transducer was in proper alignment with
the needle plane. Doppler signal is dependent on transducer alignment and contact,
potentially resulting in increased mean tip error. For phantom experiments where needle
implant was determined to maximize needle shadowing artifacts, a second observer
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ensured the transducer alignment to the needle plane and contact with the phantom was
maintained before reducing B-mode gain to zero, effectively eliminating this source of
uncertainty. For the explicit shadowing experiment with metal needles, tip error was nearly
identical regardless of visualization method, as shown in Fig. 4.4B, but for the same
experiment with plastic needles, large differences can be seen in Fig. 4.4C. Maximum tip
error and variation for B-mode US alone is more than double that of PD US alone and PD
plus B-mode US. The high mean and standard deviation are due to difficulty visualizing
the needle tip as a result of excessive needle shadowing, including two needles where the
tip was not at all visible using only B-mode US, resulting in the observer needing to guess
the tip location. These same needles were clearly visible in PD US both with and without
B-mode context to less than 1 mm tip error, demonstrating a clear use case for the PD
method. The ability to clearly visualize needles using PD US with mechanical perturbation
that were otherwise not visible in standard B-mode US was also shown in Orlando et al.23
The similarity in tip error between PD US alone and PD plus B-mode US for both explicit
shadowing experiments demonstrates the reliability of our PD US method, as it does not
depend on B-mode information.
The impact of needle implant pattern and shadowing artifacts on tip error was
investigated by comparing the mock HDR-BT implant with metal needles and the implant
designed to maximize needle shadowing with metal needles. For B-mode US, the tip error
was significantly higher when needles were implanted to maximize shadowing, showing
that artifacts significantly influenced needle visibility in B-mode images. Contrary to this,
no significant differences were observed for PD US visualization, demonstrating increased
robustness to shadowing artifacts, with the PD signal helping to improve visibility.
Calculation of the difference in the insertion (z) direction between needle tip
positions identified using PD US alone and PD plus B-mode US allowed for examination
of the impact of B-mode information on needle tip localization. With mean absolute
difference ranging from 0.5-0.7 mm, needle tip localization with PD US was very similar
regardless of the presence or absence of B-mode information. This demonstrates the
robustness of our method, as we can accurately identify the needle tip without seeing the
B-mode image at all.
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As shown in Table 4.2, B-mode US demonstrated higher agreement with gold
standard tip locations identified using CT imaging compared to PD+B-mode US for metal
needles. Although tip error vs CT was higher, the standard deviation for PD+B-mode US
was approximately equal to B-mode US. This demonstrated that the PD method was
consistently identifying the same point on the needle, thus this systematic offset could be
corrected with commissioning experiments to adjust the needle digitization technique. For
plastic needles, both B-mode and PD had identical absolute tip error compared to CT;
however, B-mode US had considerably higher variation when considering signed tip error.
Deviation from the CT tip location for all US methods was higher for plastic needles with
mean values between 3.7 and 4 mm. Standard deviation was less than or equal to 0.5 mm,
so this large difference may be explained by a systematic shift. Tip locations identified in
the US images rely on the step-back 3D US image coordinate system, which is defined
before needle insertion begins. The needle tip location identified in the live sagittal US
image is then mapped to the 3D US coordinate system based on this initial registration.
Any phantom movement during needle insertion could result in a global shift in needle
position relative to the 3D US coordinate system, and thus potential large differences even
if tip localization in the live US image was accurate. In addition, the needle tip does not
appear as clearly in the B-mode US image for plastic needles compared to metal needles.
The London Regional Cancer Program also transitioned from plastic needles to metal
needles as their standard of care during this work, so recent practice was heavily weighted
towards metal needles. Registration error was low with an average TRE of only 0.8 mm.
As fiducial landmarks included large agar spheres, we believe fiducial localization error
(FLE) may account for some of the observed TRE due to difficulty identifying the centroid.
Future work could include a formal evaluation of FLE to assess the impact on registration
accuracy.
Limitations of our phantom experiments included the use of only one observer to
identify the needle tips and landmarks in both US and CT, preventing the evaluation of
inter-observer variability. The use of live US meant needle tip positions were identified
only once, thus intra-observer variability could not be computed either. Although the
reference needle-based error metrics are utilized clinically, there are limitations to address.
Importantly, the accuracy of reference-based approaches relied on accurately identifying

138

the needle tip of the reference needle(s). This error is mitigated by selecting clear, easy to
see, needle tips. In addition, the calculation assumed no needle bending or deflection,
which for a homogenous phantom is a good assumption. Any bending that does occur could
influence the calculated tip error. The reference needle calculations also rely on end-length
measurements, which are only accurate to 0.5 mm as they were measured using a ruler.
The experiments were also limited by their small sample size, with only 12-15 needles
inserted per experiment. This may have been a factor in the lack of observed statistically
significant differences.

4.4.2

Clinical validation
Our PD US-based needle tip localization method was validated in five patients who

underwent HDR-BT to treat prostate cancer. To our knowledge, this was the first Doppler
US-based needle localization technique applied in a clinical BT procedure. The wireless
design of the oscillator, with no cables or computer required to provide power to or control
of the device, allowed for easy operation by one user, which will help increase the ease of
further clinical translation. The easy-to-use design also allowed for the application of the
oscillator in quick bursts as envisioned for difficult-to-see needles. The magnetically
attached end-piece allowed for easy bagging of the device for use in the sterile operating
room environment, while not negatively impacting Doppler signal generation. During the
clinical HDR-BT procedures, the oscillator was controlled by the treating radiation
oncologist. Three physicians participated in the trial, and in all cases, the physicians were
able to competently use the oscillator after only a brief two-minute demonstration,
highlighting the ease-of-use.
For clearly visible needles as shown in Fig. 4.5A, the addition of our PD approach
did not offer much benefit for these cases. As needle visibility decreased (Fig. 4.5B and
4.5C), the PD US signal helped to clearly define the needle tip, increasing physician
confidence in its location. This example also shows the PD flash artifacts that occur more
commonly in clinical cases due to the tissue softness compared to the firm agar phantom.
As seen in the PD image, these artifacts typically have no negative impact on needle tip
localization.
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Although there were no statistically significant differences in tip error observed
between B-mode and PD US for both individual patients and overall (Fig. 4.6 and Table
4.3), some interesting trends were observed. In three of five patients, the mean and standard
deviation tip error were reduced with the use of PD US. This improvement in performance
was especially clear in patient 1 and patient 6, with a clear decrease in mean tip error and
a reduction in standard deviation by a factor of two to three. Patient 5 represented an
interesting case, as both B-mode US and PD US tip errors were smaller than for any other
patient due to very clear needle visibility for almost all needles, and thus B-mode US alone
allowed for good visualization of the needle tips. Although the PD US tip error was also
small, it did not offer an improvement compared to B-mode US, further highlighting the
use case of difficult-to-see needles. Considering the total tip error across all patients, PD
US showed a reduction in mean tip error and variance. Fig. 4.6 also highlights the reduction
in outliers seen with PD US compared to B-mode US, demonstrating our method s ability
to improve needle visibility for challenging needles. This is clear when examining the tip
error of all patients together, with an approximately equal median but greatly reduced
variation and reduction in maximum tip error. This is critical clinically, as 1-2 needles with
tip error greater than 2 mm could result in deviation from the planned radiation dose. This
point is further reinforced in Fig. 4.7 where the tip error distribution is skewed towards the
B-mode US axis, including several needles where tip error was greater than 2mm with Bmode US and less than 1.5 mm with PD US. This demonstrated ability to reduce the tip
error of outlier needles with PD US, offering the potential for improved patient safety and
treatment effectiveness.
Needle tip localization error separated by physician was shown in Table 4.3.
Interestingly, the three patients where PD US offered the largest improvement compared
to B-mode US corresponded to physician 1 who had substantially more time and
experience using the device compared to physician 2 and 3 who only treated one patient
each. Difference in the level of needle tip localization improvement based on physician
could be explained in several ways. Although all physicians were able to successfully use
the device after a brief tutorial, there was a learning curve for generating a strong,
consistent Doppler signal. As physician 1 had substantially more time using the oscillator,
the Doppler signal was more consistent suggesting that with further practice Doppler signal
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generation would improve. For clinical cases, there was more difficulty generating a useful
PD image compared to phantom experiments, necessitating trial and error with oscillator
position to achieve the best signal which contributed to the learning curve for physicians.
In addition, alignment of the transducer with the needle plane is critical for Doppler signal
generation, and can be very difficult, so any deviation in this angular alignment could result
in increased tip localization error. Differences between physicians may also be explained
in part by the inherent differences in needle visibility between patients as opposed to
differences in skill identifying the needle tip. In addition, the metal needles have a trocar
tip, so alignment of the face of the needle tip with the US plane results in better needle
visibility. As our experiments were completed with the needle position locked, they could
not be rotated to take advantage of this in all cases.
Needle visibility was approximately equally split between unobstructed and
partially obstructed needles, with only 11 fully obstructed needles, indicating in general
good needle visibility. There was a clear increase in the mean and variance as needle
visibility worsened for B-mode US, but PD US showed approximately no change in
variation, demonstrating some level of robustness to needle visibility. This was most
evident in the obstructed case where PD US showed approximately half the standard
deviation of B-mode US. These results clearly demonstrate the utility of PD US in
improving needle tip localization accuracy when needle visibility is poor.
There are several limitations to consider in our prospective clinical trial. Although
no inter-observer calculations were possible, this is mitigated by the fact that needle tip
locations in the clinical trial were the result of a consensus between the physician and
expert medical physicist. Many of the clinical results utilize a reference needle-based
metric, so concerns outlined in section 4.4.1 also apply here. Since we did not have access
to alternative imaging such as CT or MRI, we did not have a proper ground truth to compare
to. As we could not lengthen the standard procedure time, there was a clear time constraint
imposed by the planning period in which we completed our study protocol resulting in
different lengths of time case-to-case, often leading to rushed PD needle localizations that
could have a negative impact on the obtained results. The relatively small sample size of
63 total needles may have played a role in the lack of statistically significant differences
observed. As needle tip localization was completed after all needles were inserted to the
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base of the prostate, there may be increased needle shadowing artifacts compared to the
clinical scenario where needle tips are typically localized individually starting anteriorly
and moving posteriorly to limit shadowing.
Future work includes redesigning the end-piece to improve signal generation and
decrease operator dependence. As well, identification of multiple needles at once using PD
US may be beneficial. Using an axial US image as shown in Fig. 4.9A, the needles can be
seen as bright spots in the prostate. By vibrating the needle template directly, motion is
induced in all needles, allowing for visualization of all needles in the PD US image (Fig.
4.9B). By obtaining a 3D US scan during PD US with mechanical perturbation, all needles
could be simultaneously identified in 3D, with potential use as an initialization for an
automatic needle segmentation approach26 or as a confirmation for the needle position
before the radiation treatment plan is generated. Furthermore, although our PD US-based
method was first tested in prostate HDR-BT, it could be extended to any template-based
brachytherapy procedure, such as gynecological brachytherapy, and more broadly to other
minimally invasive procedures such as radiofrequency ablation. Future work will
investigate these applications.

Figure 4.9. (A) Example axial B-mode US image of a tissue-mimicking agar phantom with
an embedded agar prostate showing 12 implanted needles. (B) Example PD US image after
vibration of the needle template, showing visualization of all needles.
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4.5

C

cl i

This study investigated the development and validation of a PD US-based needle
tip localization method utilizing a novel wireless mechanical oscillator in both phantom
experiments and clinical HDR-BT treatments. The oscillator design is inexpensive and
easy to manufacture, and the PD US method is easy to implement requiring no
modifications to the clinical equipment or workflow. Phantom validation demonstrated
improved tip localization accuracy relative to B-mode US for heavily shadowed needles,
including the ability to accurately visualize needles previously not visible using B-mode
US alone. Results of our prospective feasibility clinical trial demonstrated, for the first time
to our knowledge, the promising utility of a PD US tip localization method in clinical HDRBT procedures. PD US offered clear visualization of needle tips with a demonstrated ability
to reduce tip error for outlier needles that were difficult to see in B-mode US, increasing
confidence in tip localization, especially as needle visibility worsens. The proposed PD US
method may offer improved needle tip localization accuracy and reduced variability,
potentially improving HDR-BT treatment accuracy.
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Chapter 5
5

Valida i
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a e b ach he a

In tumour-targeted brachytherapy procedures, the integration of MRI information into the
intraoperative 3D US image is commonly done using cognitive fusion, resulting in
variation between physicians. An automated registration algorithm could standardize the
registration procedure, potentially reducing operator dependence and facilitating dose
escalation to the MR-defined tumour. The purpose of Chapter 5 is to describe the
development and clinical implementation of a surface-based deformable MRI-3D US
image registration algorithm designed for prostate brachytherapy.
The contents of this chapter have been submitted for publication in Brachytherapy
and are currently under peer review: Orlando N, Edirisinghe C, Gyacskov I, Vickress J,
Sachdeva R, Gomez JA, D Souza D, Velker V, Mendez LC, Bauman G, Fenster A, and
Hoover DA.

5.1

I

d ci

Conventional prostate brachytherapy (BT) aims to deliver a uniform dose to the
whole prostate, with maximum dose limited by the surrounding organs-at-risk.1 Studies
have demonstrated that the site of local recurrence following radiation therapy is often the
dominant intraprostatic lesion (DIL).2

4

Tumour-targeted brachytherapy has been

suggested as an alternative treatment technique, proposing the escalation of dose to the DIL
while maintaining the conventional whole-gland dose, potentially offering improved
tumour control while limiting toxicity.5,6 Unfortunately, US imaging lacks the sensitivity
to effectively detect and localize the DIL and other sensitive organs-at-risk such as the
neurovascular bundles (NVB).7 Magnetic resonance imaging (MRI) provides higher soft
tissue contrast compared to US, allowing for effective DIL identification and localization.8
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Intraoperative MRI needle guidance is costly and challenging, requiring incorporation

of MRI information into the operating room environment where US is the primary imaging
modality. In many centres, the current standard of care involves rigid or cognitive fusion
of MR contours into the US image, done intraoperatively by the physician. This results in
inter-physician variability and high operator dependence. In addition, this manual approach
is cumbersome if performed in the operating room, adding up to 15 minutes to complete
both the registration and contour transfer. An automated MR-US registration approach is
required to standardize the registration and reduce procedure time.
Conventional automated and semi-automated MR-US registration approaches have
been proposed for use in minimally invasive prostate procedures.11

15

The majority of these

image registration methods have focused on MR-US fusion-guided prostate biopsy, with
both rigid16

18

and non-rigid approaches.11,12,19

22

The presence of the US transducer or

endorectal coil in the rectum during US or MR imaging, respectively can deform the
prostate, suggesting deformable registration approaches may offer improved registration
accuracy.15 Shaaer et al. proposed a deformable registration approach for prostate BT based
on a modified rigid registration algorithm using 6 degrees-of-freedom, demonstrating
increased registration accuracy compared to rigid registration in 10 patients.14 More
recently, deep learning-based registration approaches have been proposed,23
methods including segmentation-based algorithms24

26

28

utilizing

and adversarial networks.27 These

approaches require large, curated image datasets, which can be rare in BT settings,
presenting a barrier for widespread clinical translation.
Prostate biopsy-based registration approaches typically use different 3D US image
acquisition methods than those used in BT. However, no study focused on BT applications
for the purpose of dose sparing has described the registration and translation of MR-defined
organ-at-risk contours outside of the prostate, such as the NVBs. Furthermore, prospective
validation and clinical implementation for these approaches is lacking. An automated
algorithm capable of accurate MR-US deformable registration of both target and organ-atrisk contours, designed for BT, including demonstrated clinical feasibility, may improve
the clinical translation potential for MR-US fusion-guided BT procedures.
In this paper, we report on the development and validation of a surface-based MRUS deformable image registration (DIR) algorithm for prostate BT, including registration
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and translation of MR-defined targets and organs-at-risk into the intraoperative US image.
Our DIR method was validated in tissue-mimicking phantom experiments with varying
deformation levels as well as in retrospective high-dose-rate brachytherapy (HDR-BT)
clinical cases. Clinical implementation of our method demonstrated the feasibility of
intraoperative registration, facilitating tumour-targeted dose escalation. This has the
potential to reduce procedure time, standardize the registration procedure between
physicians, thus reducing operator dependence, and could be extended to any minimally
invasive prostate procedure employing MR and US imaging.

5.2
5.2.1

Me h d a d

a e ial

Deformable surface-based image registration
The workflow of our DIR algorithm is summarized in Fig. 5.1. The algorithm takes

as input an MR image, 3D US image, and corresponding 3D prostate contours. The
algorithm is fully automated, requiring no manual initialization, but does require a preoperative preprocessing step if the 3D US and MR images are not in the same orientation.
Surface contours can be equidistant parallel 2D contours or radial 2D contours with equal
angular separation about an arbitrary axis. Using these 2D contours, 3D surfaces are formed
using Delaunay Triangulation, available in the Visualization Toolkit (VTK).29
The registration workflow has two fully automated steps: rigid translation, scaling,
and alignment, and non-rigid warping. First, 3D cuboids are determined that enclose all the
points in each of the US-and MR-defined prostate surfaces. The center points of each
cuboid are then matched, overlapping the surfaces. The MR-defined cuboid is then scaled
in the x, y, and z-directions to align its edges with the US-defined cuboid and the
triangulated surfaces are scaled accordingly. Then, iterative closest point (ICP)
transformation is used to align the MR and US prostate surfaces through a series of affine
transformations.29 Finally, thin plate spline (TPS) deformation is used for non-rigid
warping of the MR prostate surface to match the US prostate surface. This is accomplished
by creating a sphere with a 5 mm margin around the aligned surfaces. From the center point
of the sphere, 2304 equidistant lines are drawn outwards to the sphere surface. The MR
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and US prostate surface points that intersect with each line are labelled as corresponding
point pairs. Using the VTK TPS module, a transformation is then computed to warp the
MR prostate image such that corresponding points on the MR prostate surface match the
points on the US prostate surface.29 Using the computed transformation, other organs
contoured in the MR image are warped and translated to the US image space.

Figure 5.1. Summary of proposed deformable image registration algorithm workflow.
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The DIR algorithm was implemented on a personal computer using a Windows 10
operating system (Microsoft, Redmond, WA, USA) with an Intel Core i7-4770 central
processing unit (Intel Corporation, Santa Clara, CA, USA), 32.0 GB of memory, and a 6
GB Ge-Force GTX TITAN (NVIDIA Corporation, Santa Clara, CA, USA) graphics
processing unit.

5.2.2

Phantom validation
The proposed DIR algorithm was first validated in phantom using the 053L tissue-

equivalent US deformable prostate phantom (CIRS Inc., Norfolk, VA, USA) for use with
an endocavity US transducer. A simulated 53 cm3 prostate, urethra, and three stiff 1 cm
diameter spherical simulated lesions distributed uniformly throughout the prostate are
contained within the 11.5⨯7.0⨯9.5 cm3 acrylic container.
3D US images of the phantom were acquired at three different deformation levels
to simulate potential clinical scenarios. Deformation levels were no deformation, moderate
deformation, and large deformation, controlled by the amount of upward force applied to
the phantom by the transducer. The US images were acquired using a BK3000 system with
an E14CL4b biplane endocavity transducer (BK Medical, Peabody, MA, USA). The
transducer was supported by an encoded CIVCO EX3 Stepper (CIVCO Medical Solutions,
Coralville, IA, USA), allowing for axially reconstructed 3D US step-back acquisition with
a 1-mm step spacing using Vitesse v4.03 (Varian Medical Systems, Palo Alto, CA, USA).
3D US images had a size of [1100⨯700⨯73] voxels with a voxel size of
[0.083⨯0.110⨯1.00] mm3. B-mode US frequency was 9 MHz with a depth of 6.5 cm for
all image acquisitions.
The phantom was imaged using 1.5T and 3T MR scanners to simulate different
clinical scenarios and examine the impact of MR image quality on registration accuracy.
The 1.5T MR image was acquired using a GE SIGNA HDxt scanner (GE Healthcare
Systems, Chicago, IL, USA) with an 8-channel body coil. An axial T2-weighted fast spin
echo (FSE) sequence was used, acquiring a 3D image with a size of [512⨯512⨯30] voxels,
voxel size of [0.430⨯0.430⨯5.00] mm3, and slice thickness of 2 mm. The 3T MR image
was acquired using a GE Discovery MR750 scanner (GE Healthcare Systems, Chicago,
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IL, USA) with a 32-channel cardiac coil. For consistency, an axial T2-weighted FSE
sequence was once again used for the 3T MR image acquisition, resulting in a 3D image
with a size of [512⨯512⨯65] voxels, voxel size of [0.352⨯0.352⨯2.00] mm3, and slice
thickness of 2 mm.
The prostate, urethra, and spherical landmarks were manually contoured by a
trained observer (NJO) using custom-made image visualization software.30 To overcome
the limitation of large slice spacing for the MR images, manual prostate and landmark
contours were generated using a radial approach. Contours were drawn on 18 radial slices
extracted every 10 degrees about an arbitrary axis of rotation defined by the observer at the
object s centroid. The boundary points of neighbouring slices were then connected with a
smoothing filter, generating a 3D surface. For the 3D US images, the parallel manual
contouring method was used on the axial/acquisition planes, which were separated by
1mm.
The 1.5T and 3T MR images were each registered to the 3D US images with three
levels of deformation, resulting in a total of 6 registrations. Each registration used our
surface-based DIR algorithm and the manually defined prostate surfaces in the MR and 3D
US images. For comparison, manual rigid registrations of the 1.5T and 3T MR images to
the 3D US images based on the prostate surfaces were completed using MIM 7.0.5 (MIM
Software Inc., Cleveland, OH, USA).

5.2.3

Retrospective clinical validation
Our DIR algorithm was retrospectively validated using three patients who were

imaged with 3D US and MRI and underwent standard whole-gland HDR-BT treatment.
All 3D US images were acquired as described in section 5.2.2. 3D US image sizes were
[1100⨯700⨯52], [1100⨯700⨯57], and [1100⨯700⨯46] voxels for patients 1, 2, and 3,
respectively. All MR images were acquired with 1.5T scanners. Images of patients 1 and 2
were acquired using a Philips Achieva 1.5T MRI system (Philips Healthcare, Andover,
MA, USA) with an axial T2-weighted pulse sequence generating images with a voxel size
of [0.3125⨯0.3125⨯3.00] mm3 and image sizes of [576⨯576⨯32] and [576⨯576⨯30],
respectively. The image of patient 3 was acquired using a GE Optima MR450w 1.5T MRI
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System (GE Healthcare Systems, Chicago, IL, USA) with an axial T2-weighted FSE pulse
sequence

to

produce

a

[512⨯512⨯76]

voxel

image

with

voxel

size

of

[0.3906⨯0.3906⨯3.00] mm3.
The prostate in each 3D US image and the prostate, urethra, clinical target volume
(CTV), and left/right NVBs in each MR image were manually contoured by a radiation
oncologist specializing in brachytherapy (physician 1) in parallel axial slices using
contouring tools within ARIA 15.6 (Varian Medical Systems, Palo Alto, CA, USA). Using
these prostate contours, the surface-based DIR algorithm was used to register the MR
image to the 3D US image. For comparison, a manual rigid registration from MRI to 3D
US was completed for each clinical case using MIM. The proposed DIR algorithm was
then compared to the standard approach at our cancer centre, which involves rigid MR-toUS registration and transfer of MR contours to the US space followed by manual physician
editing using a cognitive fusion approach. Three physicians with 5, 7, and 21 years of
experience performing prostate brachytherapy procedures completed these cognitive
fusions using the contours from physician 1.

5.2.4

Evaluation of registration accuracy

Phantom validation
As the spherical simulated lesions and urethra were clearly visible in both US and
MR images, direct comparisons between the contour locations in the 3D US image and the
locations of the MR contours registered into the 3D US image could be completed for all
registrations. The target registration error (TRE)31 was computed for each registration by
comparing the centroid locations of each of the three spherical landmarks in the 3D US
image to the registered 1.5T and 3T MR-defined contour centroid locations. The centroid
locations were selected by a trained observer (NJO) using custom-made image
visualization software.30 In addition, the fiducial localization error (FLE)31 was computed
for both the 3D US contours and the registered MRI contours to assess the variability in
the centroid localization. Centroid localization was repeated three times by the same
observer with a one-week washout period between each localization.
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Using tools within MIM, the Dice similarity coefficient (DSC) metric was
computed to assess the overlap between the US-identified contours and the registered MR
contours of the three spherical landmarks and the urethra.
Retrospective clinical validation
Due to the lack of reproducible identification of anatomical landmarks visible in
both US and MRI, evaluation of registration accuracy utilized the DSC metric. The DSC
between the registered contours generated using our proposed DIR algorithm and the
manual rigid registration were compared to the manual MR-to-US cognitive registrations
performed by the three physicians. Inter-physician variability was computed as the average
DSC when comparing between physician cognitive fusion outputs. This allowed for
comparison of the algorithm accuracy and variability to the variability between different
physicians. The DSC metric was computed for the CTV and the left and right NVBs in
MIM.

5.2.5

Clinical implementation
Our proposed DIR algorithm was implemented for the first patient of a prospective

randomized clinical trial at the London Regional Cancer Program approved by the
Research Ethics Board at Western University. The trial involved a two-part clinical
procedure including an initial targeted biopsy based on MRI and prostate specific
membrane antigen-positron emission tomography (PSMA-PET) imaging followed by
standard HDR-BT treatment with boosted dose to the lesion identified in MRI and PSMAPET. Pre-procedural MRI and PSMA-PET images were acquired simultaneously using a
Siemens Biograph mMR PET-MR system (Siemens Healthineers, Erlangen, Germany).
The prostate, urethra, rectum, MR-defined gross tumour volume (GTV), PSMA-PETdefined GTV, and CTV were manually contoured by a radiation oncologist.
In the operating room, a pre-biopsy 3D US image was first acquired using the
BK3000 system with the same image parameters described in section 5.2.2. The prostate
was contoured in the pre-biopsy 3D US image by the treating radiation oncologist using
Vitesse v4.03. MR-to-US registration was completed in the operating room using our DIR
algorithm and the physician-defined prostate contours, thus registering the PET-MR
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contours to the 3D US image space. The registered CTV and combined GTV contours were
imported into Vitesse using existing rigid registration tools and were subsequently used to
guide 3 targeted biopsy needles. The standard HDR-BT procedure was initiated following
the targeted biopsy. With all needles implanted, a second 3D US image was acquired, and
the prostate was contoured by the treating radiation oncologist. MR-to-US registration was
once again completed using our DIR algorithm in the operating room. The registered
combined GTVs and CTV were edited by the radiation oncologist and were subsequently
used during the treatment planning process to ensure dose coverage and facilitate accurate
dose escalation to the CTV. To quantify the registration accuracy of our DIR algorithm,
one of the targeted biopsy cores was analyzed pathologically to determine the presence of
cancer. Due to the lack of ground truth or reproducible anatomical landmarks visible in
both US and MRI, further evaluation of registration accuracy was limited to qualitative
comparison.

5.2.6

Statistical analysis
All statistical analyses were performed in GraphPad Prism 9.3.1 (Graphpad

Software, Inc., San Diego, CA, USA). Shapiro-Wilk tests were used to assess the normality
of distributions. Failed normality tests led to the use of nonparametric statistical tests,
presented in parentheses in the following paragraph. The significance level for statistical
analysis was set such that the probability of making a type I error is less than 5% (p < 0.05).
Statistically significant differences are denoted simply as significant for the remainder of
this manuscript.
A comparison of registration accuracy in phantom in terms of DSC and TRE
between the three deformation levels for our DIR algorithm and manual rigid registration
was completed using a two-way ANOVA with Tukey s correction for multiple
comparisons. This test was repeated for comparisons of DSC and TRE between 1.5T and
3T MR images registered to 3D US images with varying deformation levels. 1.5T and 3T
MRI FLE, and US and total MRI FLE for the varying deformation levels were compared
using the same two-way ANOVA. For the retrospective clinical validation, registration
accuracy in terms of DSC for our DIR algorithm, rigid registration, and physician cognitive
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fusion were compared using one-way ANOVA with Tukey s multiple comparisons tests
(Kruskal-Wallis tests with Dunn s multiple comparisons tests).

5.3
5.3.1

Re l
Phantom validation
Examples of the registration results obtained using our DIR algorithm and manual

rigid registration for three deformation levels of the phantom are shown in Fig. 5.2.

Figure 5.2. Example phantom registration results for three deformation levels ranging from
no deformation to large deformation shown in columns from left to right, respectively. The
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top row shows an example 3T MR image, 3D surface view of the phantom highlighting
landmark distribution, and contour legend. The middle and bottom rows show MR-to-US
registration results generated using our DIR algorithm and manual rigid registration,
respectively. Each deformation level examines a different landmark location.

Quantitative comparisons of the registration accuracy using our DIR algorithm and
rigid registration in terms of landmark DSC and TRE are shown in Figs. 5.3A and 5.3B,
respectively, with complete results provided in Table 5.1. Mean DSC across all
deformation levels and MR images were 0.80±0.12 and 0.72±0.17 for the DIR algorithm
and rigid registration, respectively. Mean TRE for the embedded spherical landmarks using
the DIR algorithm and rigid registration was 0.94±0.49 mm and 1.88±1.24 mm,
respectively. Although registration type and deformation level had no significant effect on
DSC for the prostate and urethra, the mean prostate DSC was lower for the rigid
registrations. For the spherical landmarks, registration type, deformation level, and the
interaction between them had significant effect on DSC score, with the DSC increasing
when using the DIR algorithm and decreasing as deformation increases. These results were
mirrored for the TRE measurements based on landmark centroid location, with registration
type, deformation level, and the interaction between them significantly impacting TRE
values. MR field strength showed no significant main effect on DSC and TRE for
algorithmic or rigid registrations. Landmark location within the prostate had no significant
effect on DSC and TRE for either registration method. Total registration computation time
ranged from 85s to 150s depending on the number of registered contours.
Landmark centroid localization for the three deformation levels had a mean ±
standard deviation FLE of 0.16±0.07 mm (N=54), 0.19±0.09 mm (N=27), and 0.18±0.10
mm (N=27) for US, registered 1.5T MR, and registered 3T MR contours, respectively, for
a total mean of 0.17±0.08 mm (N=108). There was no significant difference in FLE
between 1.5T and 3T MR, between US and MR, or based on landmark position.
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Table 5.1. Mean ± standard deviation registration error metrics for our deformable image
registration (DIR) algorithm and manual rigid registration evaluated using 1.5T and 3T
MRI phantom images with three deformation levels. Dice similarity coefficient (DSC)
scores are provided for the prostate, urethra, and three spherical landmarks. Target
registration error (TRE), in mm, is provided for the three spherical landmark centroids.
1.5T MRI
DIR Algorithm

3T MRI

No Def.

Med Def.

Large Def.

No Def.

Med Def.

Large Def.

Prostate

0.98

0.98

0.97

0.98

0.98

0.98

Landmarks

0.79±0.02

0.74±0.03

0.64±0.03

0.82±0.06

0.78±0.04

0.64±0.06

Urethra

0.84

0.80

0.76

0.81

0.79

0.73

0.52±0.36

1.13±0.81

1.34±0.23

0.58±0.01

0.75±0.04

1.32±0.43

No Def.

Med Def.

Large Def.

No Def.

Med Def.

Large Def.

Prostate

0.94

0.91

0.83

0.95

0.93

0.85

Landmarks

0.76±0.05

0.65±0.03

0.45±0.06

0.81±0.03

0.69±0.05

0.46±0.17

Urethra

0.83

0.84

0.78

0.84

0.80

0.68

0.77±0.07

1.79±0.46

3.22±0.66

0.50±0.09

1.73±0.42

3.24±1.42

DSC

TRE (mm)
Landmarks
Rigid Registration
DSC

TRE (mm)
Landmarks

Figure 5.3. Box and whisker plots showing (A) landmark Dice similarity coefficient (DSC)
and (B) target registration error (TRE) for 1.5T and 3T MRI images registered to 3D US
using our DIR algorithm and manual rigid registration in phantom, averaged across three
deformation levels. Boxes denote the interquartile range while whiskers show the
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minimum and maximum values. A bar and plus sign represent the median and mean,
respectively. Statistically significant differences (p<0.05) are denoted by an asterisk.

5.3.2

Retrospective clinical validation
Example clinical registration results for one of our three retrospective cases are

shown in Fig. 5.4, including results obtained using our DIR algorithm, manual rigid
registration, and physician cognitive fusion.

Figure 5.4. Example clinical registration results for one retrospective HDR-BT case. The
top row shows the physician-contoured MRI and US as well as the contour legend. The
bottom row shows the MR-to-US registration using our DIR algorithm, manual rigid
registration, and cognitive fusion completed by three physicians, respectively.

Figure 5.6 shows the DSC score for the MR-defined CTV and NVBs registered to
US using our DIR algorithm, rigid registration, and physician cognitive fusion. Complete
results are provided in Table 5.2, including comparisons to each physician individually and
all together, as well as the inter-physician variability. Mean DSC between the US and
registered MR-defined prostate was 0.98±0.01 and 0.89±0.02 for the DIR algorithm and
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manual rigid registration, respectively. When comparing the DIR and rigid registration
output to the individual physician cognitive fusion results, only comparisons to physician
1 showed significant differences, with the DIR algorithm demonstrating significantly
higher DSC score for the right NVB relative to the rigid registration approach.
Furthermore, when comparing DSC scores averaged for comparisons to all physicians,
there was no significant difference observed between the DIR algorithm and rigid
registration results and the inter-physician variability.

Table 5.2. Mean ± standard deviation Dice similarity coefficient (DSC) values averaged
from three clinical cases registered using our deformable image registration (DIR)
algorithm and manual rigid registration. Columns show DSC values for the clinical target
volume (CTV) and the left and right neurovascular bundles (NVB) compared to cognitive
fusion results for each physician individually, averaged DSC results compared to all
physicians, and inter-physician variability, from left to right respectively.
Total Mean DSC
DIR
Alg.

Contour

Compared to
Physician 1
0.66±0.11

Compared to
Physician 2
0.49±0.21

Compared to
Physician 3
0.50±0.37

Compared to
all Physicians
0.55±0.23

Interphysician var.
0.56±0.29

NVB-L

0.51±0.18

0.50±0.08

0.59±0.09

0.53±0.12

0.52±0.18

NVB-R

0.48±0.09

0.50±0.05

0.50±0.08

0.50±0.06

0.41±0.14

Mean

0.55±0.14

0.49±0.11

0.53±0.20

0.53±0.15

0.50±0.21

Contour

Compared to
Physician 1
0.67±0.03

Compared to
Physician 2
0.53±0.19

Compared to
Physician 3
0.49±0.34

Compared to
all Physicians
0.56±0.21

Interphysician var.
0.56±0.29

NVB-L

0.49±0.13

0.41±0.29

0.51±0.24

0.47±0.20

0.52±0.18

NVB-R

0.30±0.04

0.50±0.04

0.65±0.17

0.48±0.18

0.41±0.14

Mean

0.48±0.17

0.48±0.18

0.55±0.24

0.50±0.19

0.50±0.21

CTV

Rigid
Reg.

CTV
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Figure 5.5. Box and whisker plots showing the Dice similarity coefficient (DSC) score for
clinical target volume (CTV) and neurovascular bundle (NVB) contours registered using
our DIR algorithm, manual rigid registration, and manual cognitive fusion by the physician,
presented as inter-physician variability. Boxes denote the interquartile range while
whiskers show the minimum and maximum values. A bar and plus sign represent the
median and mean, respectively.

5.3.3

Clinical implementation
Our DIR algorithm was implemented intraoperatively for one patient who

consented to a prospective clinical trial approved by the Research Ethics Board at Western
University. Example MR as well as pre- and post-implant US images and the
corresponding registration results are shown in Fig. 5.6. After pathological evaluation, the
biopsy core targeted to the combined PET-MRI GTV based on the registration results
obtained using our DIR algorithm, was positive for prostate cancer. The corresponding
histology slide is shown in Fig. 5.7.
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Figure 5.6. Example intraoperative clinical registration results in a prospective clinical
case. The physician-contoured MR image is shown in the top left pane. The pre- and postimplant US image and registration results generated using our DIR algorithm are shown in
the top and bottom row, respectively. The contour legend is provided in the bottom left
pane.

Figure 5.7. Histology slide demonstrating the presence of cancer for the GTV-targeted
biopsy result obtained using our DIR algorithm.
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5.4

Di c

i

Results from the phantom experiments showed that the deformation level and
registration type had a significant impact on the segmentation performance, highlighting
the need for deformable registration. This is mirrored in the qualitative results shown in
Fig. 5.2, which showed similar results between the rigid and deformable methods when no
deformation was applied. In the second and third column where deformation was applied,
there was significant misalignment between the MR-defined landmarks and US-defined
landmarks when using the rigid approach. In addition, the MR prostate contour no longer
matches the US prostate contour, which would make accurate contour translation from the
MR to the US images and treatment planning difficult. Both DSC and TRE results showed
that our DIR algorithm was robust to MR field strength and landmark location within the
prostate, which is a critical finding as both these parameters vary between clinical cases.
When examining the TRE results, it is important to consider the FLE for centroid
identification. A TRE less than 1 mm for all deformation levels with our DIR algorithm
and a mean FLE of 0.17 mm suggest that the TRE value is only minimally affected by the
observer s ability to reliably identify the landmark centroid. With an average computation
time under two minutes, our DIR algorithm may also reduce procedure time, as manual
rigid registration and physician cognitive fusion may require up to 15 minutes in the
operating room.
The retrospective clinical validation results show similar mean DSC scores between
our DIR algorithm, rigid registration, and physician cognitive fusion. This may be due in
part to the low levels of deformation in our clinical cases, compounded by the lack of
endorectal coil for MR image acquisition. We did observe a greater than 5% reduction in
variability for our DIR algorithm compared to the inter-physician variability. This was
most prominent for the NVB contours where mean DSC was 5% higher and variation was
approximately 7% lower when using the DIR algorithm compared to cognitive fusion,
highlighting the ability of our algorithm to accurately translate small contours outside of
the prostate volume, which is critical for dose-avoidance during treatment planning. Interphysician variability is demonstrated in the bottom right pane of Fig. 5.4, where there is
inconsistent placement of both the CTV and NVBs between physicians. Deformation may
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impact posterior structures such as the NVBs and peripheral zone lesions more than
anterior targets, contributing to the DIR algorithm s observed improvement in registration
accuracy relative to the rigid approach for the NVB. This reduced variation afforded by the
DIR algorithm demonstrates that standardized use of our method would result in more
consistent registration results compared to the current inter-physician variability, thus
improving treatment planning consistency and highlighting the potentially clinical utility
of our method.
Our DIR algorithm was successfully implemented in a prospective clinical case,
demonstrating the feasibility of integrating our method into the clinical workflow. The ease
of integration highlights the clinical translation potential of our method, as it required only
minimal pauses in the workflow and the registration result integrated seamlessly into the
clinical software. This allowed for a successful targeted biopsy of the combined PSMAPET/MR-GTV, confirmed histologically as shown in Fig. 5.7. Qualitative results shown in
Fig. 5.6 highlight the large urethra defect resulting from a previous transurethral resection.
Our DIR algorithm was shown to be robust to this artifact, successfully registering the
prostate contours and translating the CTV and GTVs. Application of the algorithm preimplant to target biopsy needles and post-implant to facilitate dose escalation demonstrated
the versatility of our method, further highlighting translational potential. The method could
be easily extended to other minimally invasive prostate procedures employing MRimaging such as fusion-guided prostate biopsy and tumour-targeted low-dose-rate BT.
The main limitation of our surface-based DIR algorithm is its reliance on accurate
and consistent manual contouring, particularly for the prostate in US and MRI.
Implementation of defined contouring guidelines for the prostate in both MR and US would
reduce contouring variability between physicians, further improving registration
consistency and accuracy. The addition of AI-based automatic prostate contouring
tools32,33 could also help to standardize the contouring process and further reduce procedure
times. The retrospective clinical dataset used to validate our algorithm is small with only
three cases, so further validation with a larger dataset is an important next step in our future
work. Furthermore, validation using MR images acquired with endorectal coils would be
important, as we expect the increased deformation necessitates a DIR approach. Future
work will also include expanding the prospective implementation of our algorithm to
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additional patients and additional procedure types, including an approved study assessing
the benefits of NVB avoidance in BT.

5.5

C

cl i

This study investigated the development and validation of a surface-based MR-US
DIR algorithm for prostate BT. This approach demonstrated improved registration
accuracy compared to rigid registration, as well as decreased variation compared to the
clinical standard of physician cognitive fusion. Prospective clinical implementation
demonstrated the feasibility of applying our DIR algorithm intraoperatively, facilitating
targeted biopsies and dose escalation to a PET-MR-defined lesion. This algorithm offers
the potential to reduce operator dependence and standardize the registration procedure
between physicians.

5.6
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Minimally invasive procedures for prostate cancer diagnosis and treatment, including
biopsy and brachytherapy, rely on medical imaging for accurate needle guidance, target
definition, and treatment planning. Efficient utilization of these imaging modalities,
specifically US and MRI, involves challenges such as time-consuming manual
segmentation, poor needle tip visualization, and variable MR-US cognitive fusion. The
work in this thesis seeks to address these challenges through the development and
validation of generalizable and easy-to-implement software- and hardware-based
approaches described in Chapters 2-5. This chapter provides a summary and conclusions
for the described work including a discussion of limitations and potential future work.

6.1
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While the incorporation of 3D TRUS imaging can improve needle guidance for minimally
invasive procedures such as biopsy and brachytherapy, it also necessitates time-consuming
and difficult manual prostate segmentation, which must be completed by the physician in
the operating room environment while the patient is under sedation or anesthetic. Chapter
2 described the development and validation of a deep learning-based automatic prostate
segmentation algorithm for 3D TRUS images, potentially improving workflow efficiency
and reducing procedure time. Our algorithm utilized a modified U-Net architecture1 to
segment 12 radially sampled 2D US images before reconstruction into a 3D surface. The
clinically diverse training dataset consisted of 84 end-fire (biopsy) and 122 side-fire (BT)
3D TRUS images acquired using three different US systems, which was subsequently
resliced to generate 6773 2D TRUS images for training a 2D neural network. Our proposed
algorithm generated 3D surfaces with a median [first quartile (Q1), third quartile (Q3)]
DSC, recall, precision, absolute VPD, MSD, and HD of 94.1 [92.6, 94.9] %, 96.0 [93.1,
98.5] %, 93.2 [88.8, 95.4] %, 5.78 [2.49, 11.5] %, 0.89 [0.73, 1.09] mm, and 2.89 [2.37,
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4.35] mm, respectively, significantly improving performance compared to fully 3D CNNs
including a V-Net, Dense V-Net, and High-resolution 3D-Net trained using the same
dataset. Average total 3D segmentation time of 0.62 s with our proposed method
demonstrated a significant reduction compared to manual segmentation, which can take up
to ten minutes. Our proposed segmentation algorithm demonstrated fast and accurate 3D
segmentation of the prostate across variable TRUS acquisition methods, providing a
generalizable and robust algorithm that has the potential to reduce procedure time in
minimally invasive prostate procedures.
Chapter 2 described a deep learning-based algorithm capable of accurate prostate
segmentation, trained using a large, clinically diverse dataset with variable image quality.
As large clinical datasets are rare, particularly for US imaging, widespread adoption of
deep learning-based segmentation could be facilitated through demonstration of
performance with smaller and less diverse datasets. Chapter 3 examined the impact of the
dataset on segmentation performance using our 2D deep learning plus 3D reconstruction
approach, specifically the effect of dataset size, image quality, and image type. First, endfire and side-fire datasets were generated by splitting the complete dataset of 6761 2D
images, followed by the creation of smaller end-fire, side-fire, and mixed datasets with
1000, 500, 250, and 100 images. A modified U-Net and U-Net++ algorithm were
implemented for this work, as the latter has shown improved performance with small
datasets.2 A 3D TRUS image quality grading was developed based on three factors rated
from 1 to 5: acquisition quality, artifact severity, and boundary visibility. While the U-Net
and U-Net++ showed no difference in performance when trained with the full dataset, the
U-Net++ significantly outperformed the U-Net when trained using only side-fire or only
end-fire images. For the U-Net++ trained using smaller datasets, performance plateaued at
a training dataset of 1000 mixed images with a median DSC of 93.2 [89.7, 94.9] %. For
our testing dataset, image quality showed no significant effect on segmentation
performance for end-fire images but did show a significant effect for side-fire images,
specifically boundary visibility and acquisition quality. The image quality grading scale
specific to 3D TRUS imaging, the first of its kind to our knowledge, may help improve
transparency of published results, easing comparison between algorithms trained on
datasets of different image quality. The demonstrated performance of our algorithm when
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trained with smaller datasets supports the potential for widespread use of deep learning
segmentation methods, even when data is scarce.
Needle tip localization in prostate HDR-BT is typically done using standard Bmode TRUS imaging, which can be limited due to image artifacts, potentially resulting in
deviation from the planned dose. Chapter 4 described the development and validation of
a PD US-based needle tip localization method designed specifically for HDR-BT. Needle
perturbations generated using a custom-built wireless mechanical oscillator could be
detected using PD US, presented as a coloured overlay on the B-mode US image,
potentially improving needle visualization. The mechanical oscillator featured a cylindrical
end piece designed to fit overtop the standard needle mandrins used for HDR-BT,
improving Doppler signal generation. Our PD US needle localization method was
evaluated in tissue equivalent agar phantoms as well as in 5 HDR-BT patients as part of a
prospective feasibility clinical trial. In the phantom, B-mode alone, PD alone, and PD plus
B-mode needle visualization methods demonstrated absolute mean ± standard deviation tip
error of 0.3 ± 0.3 mm, 0.6 ± 0.5 mm, and 0.4 ± 0.2 mm for the mock HDR-BT needle
implant; 0.8 ± 1.7 mm, 0.4 ± 0.6 mm, and 0.3 ± 0.5 mm for the explicit shadowing implant
with plastic needles; and 0.5 ± 0.2 mm, 0.5 ± 0.3 mm, and 0.6 ± 0.2 mm for the explicit
shadowing implant with metal needles, respectively. The averaged absolute tip error for all
five patients in the prospective clinical trial was 0.9 ± 0.7 mm and 0.8 ± 0.5 mm for PD US
and B-mode US needle visualization, respectively. PD US was demonstrated a particular
advantage for needles classified as difficult to see using B-mode US, including providing
the ability to visualize needles previously not visible using standard US alone. Our PD US
method demonstrated equivalent needle tip error for unobstructed needles and reduced tip
error and variation for obstructed needles, potentially increasing treatment accuracy in
HDR-BT. The method is easy-to-implement and requires no modifications to the clinical
workflow, while also being generalizable to other minimally invasive procedures,
described in detail in Section 6.3.3.
Tumour-targeted BT has been proposed to overcome the limitation of conventional
whole-gland BT, motivated by studies which have shown the most likely recurrence site
following therapy is the DIL.3

5

The DIL is not typically visible in US, necessitating the

use of an additional imaging modality such as MRI, and thus challenging and variable
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cognitive fusion of MR-US images is required to utilize the information intraoperatively.
Chapter 5 described the validation and clinical implementation of a surface-based
deformable MR-3D TRUS image registration algorithm for prostate BT. Our DIR
algorithm has two fully automated steps starting with an affine alignment of the prostate
surfaces using the ICP algorithm followed by non-rigid warping using thin plate spline
deformation.6 Validation utilized a deformable prostate phantom and three retrospective
HDR-BT clinical cases with comparison to manual rigid registration and physician
cognitive fusion. When evaluated using phantom images at three deformation levels, the
DIR algorithm significantly improved registration accuracy compared to rigid registration,
demonstrating mean DSC and TRE of 0.74±0.08 and 0.94±0.49 mm compared to
0.64±0.16 and 1.88±1.24 mm for the rigid registrations. The mean CTV and NVB DSC
compared to physician cognitive fusions, averaged for the three retrospective clinical cases,
was 0.53 ± 0.15 for our DIR algorithm, demonstrating reduced variation compared to the
inter-physician variability, which had a DSC of 0.50 ± 0.21. Prospective clinical
implementation of our DIR algorithm allowed for a successful PSMA-PET-MRI GTVtargeted biopsy, confirmed histologically, and facilitated dose escalation to the registered
CTV. Our DIR algorithm allows for the registration and translation of MR-defined target
and organ-at-risk contours into the intraoperative US image, allowing for dose escalation
and dose avoidance while standardizing the registration procedure between physicians,
reducing operator dependence.

6.2
6.2.1

Li i a i
General Limitations

A limitation common to the work described in all Chapters of this thesis is the difficulty
obtaining gold standard comparisons for assessing the accuracy of our proposed methods.
In Chapters 2-3, gold standard manual prostate segmentations were completed by a nonphysician observer, limiting the clinical translation potential as physician contours can
follow different guidelines and will vary physician-to-physician. In Chapters 4-5,
retrospective and prospective clinical validation experiments were conducted, but there
was no way to generate gold standard needle tip locations and MR-US registrations,
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respectively. This necessitated the use of alternative evaluation metrics such as reference
needle-based tip localization error used in Chapter 4 and comparisons to inter-physician
variability as the standard of care in Chapter 5. Contrary to this, phantom experiments in
Chapters 4-5 provided clear gold standards, specifically through CT imaging for the PD
study and through US- and MR-visible landmarks for the registration study.
Another limitation common to each chapter is the difficulty in validating our
proposed methods prospectively. Chapters 2-3 rely solely on retrospective data for training
and evaluation. Prospective clinical implementation and evaluation of our deep learningbased automatic prostate segmentation algorithm would be critical for successful clinical
translation. Among the challenges involved in implementing a deep learning algorithm in
the clinic is the difficulty integrating with the clinical software. In particular, the vendorprovided computers typically do not contain a dedicated GPU with enough memory to
complete the segmentations with the low computation time described in Chapters 2 and 3.
In Chapters 4-5, prospective clinical validation was completed; however, it was limited to
small feasibility studies with 5 and 1 clinical cases for the PD and registration studies,
respectively. As described for Chapters 2-3, prospective studies with additional clinical
cases are critical for demonstrating robustness towards the widespread clinical
implementation of our proposed approaches.

6.2.2

Study-Specific Limitations

Chapter 2: Deep learning segmentation of the prostate in 3D TRUS images
The main limitations of the work described in Chapter 2 relate to the TRUS image dataset
used in the study. While both side-fire and end-fire images were included, acquired using
three different US systems, all images of a certain type were obtained from the same centre.
This limited the generalizability and potential performance of our algorithm when
implemented in a new centre where different US systems or acquisition geometries may be
used. Importantly, all manual gold standard prostate segmentations were completed by one
non-physician observer. While this offered consistency in the segmentation approach, there
was variability in segmentation technique between physicians clinically, making exposure
and robustness to multiple manual segmentation techniques critical for clinical translation.
In addition, inter- and intra-observer segmentation variability was not examined for our

172

dataset, although this has been previously assessed for end-fire7 and side-fire8 3D TRUS
images, with our proposed algorithm demonstrating performance comparable to this
variability. Finally, the dataset was limited to pre-implant 3D TRUS images with minimal
obstructions, disregarding prostate segmentation in post-implant images which is critical
to the HDR-BT workflow.
Beyond the dataset, there were also limitations to our algorithm design and network
comparison implementation. Our algorithm utilized radial slices extracted with a 15° step
angle about the approximate central axis, chosen to balance computation time and
segmentation performance. While performance was excellent with this 15° step angle, no
experiment with varying step angle was completed, so the optimal angle is not known.
When comparing the performance of our proposed method to fully 3D CNNs trained using
the same dataset, hyperparameter optimization was completed for the V-Net, with identical
hyperparameters used for subsequent CNNs (Dense V-Net and High-resolution 3D-Net).
This meant that the performance observed for these two CNNs may not be optimal, as this
would require individual optimization for each architecture. While radial segmentation
approaches have previously demonstrated improved segmentation performance in the base
and apex of the prostate,7 our analysis was limited to whole-gland segmentation
performance. In addition, there was no analysis of the dosimetric impact of segmentation
error.
Chapter 3: Effect of dataset size, image quality, and image type on deep learning
prostate segmentation in 3D TRUS
As the same TRUS dataset was used for the work described in Chapter 2 and Chapter 3,
the same dataset limitations described in the previous section apply to this chapter as well.
Specific to Chapter 3, only one physician observer developed the 3D TRUS image quality
scale and graded the testing dataset. Thus, inter and intra-observer variability in image
quality classification was not assessed. Image quality was only graded for the testing
dataset of 40 3D TRUS images, with no grading completed for the larger training dataset,
which may play a critical role in algorithm performance. While we expect the randomly
sampled testing dataset to be representative of the total dataset, explicit grading of the
training dataset would demonstrate any potential biases. Furthermore, our 3D TRUS
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dataset was shown to be of high quality on average. To improve algorithm generalizability
and further explore the impact of image quality on segmentation performance, an expanded
dataset with a wider range of image qualities, including low quality images, could be used,
ideally from a different centre. While our dataset included TRUS images from multiple
vendors, no experiment was conducted to examine the impact of US machine vendor on
segmentation performance. Such a study would offer a strong assessment of
generalizability, which is critical for widespread clinical translation. Our U-Net++
implementation was limited to only a ResNet CNN backbone. Higher performance may be
achieved through utilization of an ensemble network with results from multiple CNN
backbones combined into one segmentation result using averaging, majority vote, or the
STAPLE method for example.9
Chapter 4: Power Doppler needle localization for interstitial prostate brachytherapy
The main limitation of the work described in Chapter 4 is the evaluation metric used. In
both the phantom and clinical validation, needle tip localization error was computed using
a reference needle calculation, which relied on accurate identification of the reference
needle tip. Although tip error is mitigated by choosing easy to see needles as a reference,
any error contributes to the resulting tip localization error. In addition, the reference needle
calculation utilizes end-length measurements, which assumes there is no bending or
deflection of the needle. While this is a fair assumption in the homogenous phantom, needle
deflection can occur in clinical cases. End-length measurements were also made by hand
using a ruler, limiting accuracy to within 0.5 mm, which may further impact the computed
tip localization error. In the phantom experiments, only one observer identified the needle
tip and landmark locations in US and CT, so no inter-observer variability was computed.
Live US imaging was used for needle tip localization with both B-mode and PD US,
causing needle tips to be identified once, preventing any examination of intra-observer
variability. Specific to the clinical validation, no alternative imaging such as CT or MRI
was used, so there was no proper ground truth to compare to. Another limitation is the time
constraints imposed by the small window in which we completed our study protocol during
the HDR-BT clinical workflow, as we could not extend the procedure time. This resulted
in rushed needle tip localization, which occurred often for the PD US method localization
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as this was completed after the B-mode localizations were done. Finally, both phantom and
clinical validation experiments were limited by their sample size, with only 12-15 needles
per case and a total of 3 phantom cases and 5 clinical cases. In addition, needle visibility
was graded highly on average, with only 11 fully obstructed needles across 5 patients.
Further validation in additional phantom and clinical cases with more variable needle
visibility would allow for a more robust assessment of needle tip localization error.
Chapter 5: Surface-based deformable MRI-3D TRUS image registration algorithm
The main limitation of the surface-based DIR algorithm described in Chapter 5 is its
reliance on accurate and consistent manual prostate contouring. Differences in manual
prostate segmentation technique between MR and US images as well as between and within
observers7,8 would directly impact the registration result and subsequent target and organat-risk contour translation. Implementation of defined prostate contouring guidelines for
both MR and US imaging would help to standardize the contouring process between
different physicians and further reduce operator dependence. The datasets used for
phantom validation and retrospective clinical validation are both small, with 6 and 3 cases
respectively. In addition, clinical implementation was limited to only one prospective
HDR-BT case, including one pre-implant registration and one post-implant registration.
No MR images utilized in this work were acquired with an endorectal coil, which would
result in more deformation than a standard pelvic or body coil. Validation in more
retrospective and prospective cases, including for MR images acquired with endorectal
coils would strengthen the clinical translation potential. Registration accuracy assessment
for the prospective clinical validation case was limited to histological evaluation of the
targeted biopsy result. Quantitative evaluation of our DIR algorithm performance in
prospective patients in terms of DSC or TRE is another critical step towards widespread
implementation.
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6.3
6.3.1

F

eW k
Multi-Institution and Multi-Physician Validation of Deep
Learning
Prostate
Segmentation
Towards
Clinical
Implementation

A 2D deep learning plus 3D reconstruction automatic prostate segmentation algorithm for
3D US images was described in Chapter 2, evaluated using retrospective images acquired
in clinical prostate biopsy and HDR-BT procedures. Future work for this project will be
focused on successful clinical implementation through further clinical validation and
dataset improvements. The dataset used in Chapter 2 and 3 was limited to 3D TRUS images
acquired using three different US systems, all from one centre. Successful clinical
implementation of this algorithm, particularly at a different clinical site, is highly
dependent on the generalizability and robustness of the trained network. A multi-centre
dataset of 3D TRUS images acquired using numerous US systems from different minimally
invasive procedures with varied image quality would result in a more generalizable
segmentation algorithm, improving performance in prospective clinical scenarios. Manual
prostate segmentation also varies between physicians. While our current dataset is limited
to one non-physician observer who provided all ground truth segmentations, the inclusion
of manual segmentations produced by different observers would strengthen the training
dataset and thus algorithm robustness.
Furthermore, in Chapter 2 and 3, algorithm performance evaluation was limited to
segmentation accuracy metrics including DSC, boundary distance metrics, and VPD.
While the performance of our algorithm was strong according to these metrics, the clinical
utility of the segmentation output is related to the physician s confidence in the result. The
prostate contour produced by the algorithm would require manual editing by the physician,
so a study examining how much editing time is required on average would allow for
determination of a clinically relevant total segmentation time. Such a metric may better
reflect the clinical utility of the algorithm. Using multiple physician observers, both
algorithmic and manual physician-defined prostate contours could be provided blindly to
the observer, with the required editing time documented. This would allow for
determination of the average editing time for algorithm-generated contours in addition to
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an evaluation of how this time compares to the editing time for manual contours, effectively
comparing to the current standard-of-care. This multi-center, multi-physician study would
serve to further validate and improve our algorithm s robustness and generalizability as a
critical step towards clinical implementation.
Finally, widespread clinical implementation of deep learning methods in medical
imaging is limited in part by the restricted nature of the proposed models and datasets.
Future work could focus on improving public access to deep learning models and the
datasets used to train and evaluate them. This would increase transparency in the presented
results and would greatly increase access to deep learning methods, accelerating clinical
translation. There are significant challenges in widespread data sharing including the
protection of patient information, restrictions related to research ethics agreements, and the
high cost associated with dataset curation and management.

6.3.2

Automatic Prostate Segmentation in Post-Implant 3D TRUS
Images

The training dataset used in Chapter 2 and 3 was limited to end-fire and side-fire 3D TRUS
acquisition. As described in Section 1.4.2.2, axially reconstructed step-back 3D TRUS
images are commonly used in prostate BT.10

12

Compared to end-fire and side-fire 3D

TRUS acquisitions which utilize transducer rotation, step-back 3D TRUS utilizes
transducer translation in inferior steps, resulting in decreased image resolution in the
sagittal plane. Evaluation and supplemental training of our segmentation algorithm for use
with step-back 3D TRUS images would allow for implementation in any centre where 3D
TRUS is used. In addition, the described dataset is limited to pre-insertion 3D TRUS
images, which have minimal obstructions, presenting a simpler segmentation task. In
HDR-BT procedures, prostate segmentation in post-implant 3D TRUS images is critical
for treatment planning. Segmentation of the prostate in post-implant images presents a
significant challenge due to the hyperechoic artifacts created by the implanted needles
obscuring the prostate boundary. Supplemental training and evaluation of our algorithm
for post-implant 3D TRUS images is a necessary step towards clinical implementation for
HDR-BT. Successful validation in post-implant 3D TRUS would demonstrate a versatile
algorithm that could aid in both pre-implant segmentation for needle guidance and post-
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implant segmentation for treatment planning, greatly reducing procedure time and
standardizing the segmentation procedure.

6.3.3

Power Doppler Needle Localization Extended to other
Minimally Invasive Procedures

Chapter 4 described the development and validation of a PD-based needle tip localization
method for interstitial prostate BT. This method was validated in both phantom and
prospective clinical cases, focusing on simulated and clinical HDR-BT procedures,
respectively. As our PD-based technique demonstrated improved needle tip visibility and
reduced variability compared to standard B-mode US for HDR-BT, future work could
expand our approach to other minimally invasive procedures where needle tip localization
is equally critical. Candidate procedures where PD US may offer potential utility include
LDR-BT, gynecological BT, focal ablation procedures, and hyperthermia procedures. As
our method requires no additions to the clinical equipment or workflow, translation to new
minimally invasive procedures would be smooth, only requiring modification of the end
piece design based on the needle-like tools shape. Each procedure does present new
challenges, however. Focal ablation and hyperthermia procedures commonly require
needle insertion at oblique angles, resulting in needle tip visibility challenges using
standard US,13 and thus a natural application for PD US. In gynecological BT procedures,
needle visibility can be limited by the presence of a vaginal cylinder.14 Validation of PD
US for needle tip identification in other minimally invasive procedures could greatly
increase the clinical translation and potential impact of our method.
As shown in Fig. 4.9, PD US combined with 3D US image acquisition could allow
for the simultaneous identification of all implanted needle tip locations within the 3D US
image. This is particularly relevant for interstitial HDR prostate and gynecological BT
where multiple needles are inserted, including potential use as an initialization for
automatic multi-needle segmentation algorithms.14,15
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6.3.4

Deep Learning-Based
Registration Algorithm

Automatic

MRI-3D

US

Image

Chapter 5 described the validation of a deformable surface-based MRI-3D TRUS
registration algorithm for tumour-targeted prostate BT. Our proposed surface-based
algorithm is limited by its dependence on manual prostate segmentation, which has been
shown to vary within and between observers.7,8 Implementation of deep learning prostate
segmentation as input to the DIR algorithm could improve segmentation consistency and
accuracy compared to standard manual segmentation as well as further reducing procedure
time. 3D TRUS segmentation could utilize the trained networks described in Chapter 2 and
3, requiring no modification.16,17 Prostate segmentation in MR images could utilize the
same algorithm trained with MR data, or a pre-trained MR-specific algorithm could be
implemented.18,19 The underlying registration algorithm could remain unchanged, making
this a natural next step with a large potential impact for reducing operator dependence and
procedure time.
To further improve registration accuracy, the deep learning segmentation
initialization could be augmented with a deep learning-based registration procedure.20

25

A

full deep learning registration procedure would offer significant advantages in terms of
computation time compared to our conventional approach which took approximately two
minutes on average. There are challenges in implementing a full deep learning registration
algorithm, most importantly the difficulty in creating a large dataset of paired 3D TRUS
and MR images with high quality prostate contours.
Image-guided minimally invasive procedures are a powerful tool for prostate
cancer management, while also presenting numerous challenges. This thesis described
several easy-to-implement, generalizable software- and hardware-based approaches
designed specifically for prostate biopsy and brachytherapy. These tools offer the potential
to reduce procedure time and variability, potentially increasing the effectiveness of
minimally invasive procedures towards improved prostate cancer management for men
worldwide.

179

6.4

Refe e ce

1.

Ronneberger O, Fischer P, Brox T. U-net: Convolutional networks for biomedical
image segmentation. In: Lect Notes Comput Sci (including Subser Lect Notes Artif
Intell Lect Notes Bioinformatics). 2015;9351:234-241. doi:10.1007/978-3-31924574-4_28

2.

Zhou Z, Siddiquee MMR, Tajbakhsh N, Liang J. UNet++: A Nested U-Net
Architecture for Medical Image Segmentation. Lect Notes Comput Sci (including
Subser Lect Notes Artif Intell Lect Notes Bioinformatics). 2018;11045:3-11.
http://arxiv.org/abs/1807.10165.

3.

Pucar D, Hricak H, Shukla-Dave A, et al. Clinically Significant Prostate Cancer
Local Recurrence After Radiation Therapy Occurs at the Site of Primary Tumor:
Magnetic Resonance Imaging and Step-Section Pathology Evidence. Int J Radiat
Oncol Biol Phys. 2007;69(1):62-69. doi:10.1016/j.ijrobp.2007.03.065

4.

Arrayeh E, Westphalen AC, Kurhanewicz J, et al. Does local recurrence of prostate
cancer after radiation therapy occur at the site of primary tumor? Results of a
longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012;82(5):e787793. doi:10.1016/j.ijrobp.2011.11.030

5.

Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in
patients treated with hormonal therapy and radiotherapy: implications for conformal
therapy planning. Int J Radiat Oncol Biol Phys. 2002;53(3):595-599.
doi:10.1016/S0360-3016(02)02795-5

6.

Schroeder W, Martin K, Lorensen B. The Visualization Toolkit. 4th Ed. Kitware;
2006.

7.

Qiu W, Yuan J, Ukwatta E, Fenster A. Rotationally resliced 3D prostate TRUS
segmentation using convex optimization with shape priors. Med Phys.
2015;42(2):877-891. doi:10.1118/1.4906129

8.

Tong S, Cardinal HN, McLoughlin RF, Downey DB, Fenster A. Intra- and interobserver variability and reliability of prostate volume measurement via twodimensional and three-dimensional ultrasound imaging. Ultrasound Med Biol.
1998;24(5):673-681. doi:10.1016/S0301-5629(98)00039-8

9.

Warfield SK, Zou KH, Wells WM. Simultaneous truth and performance level
estimation (STAPLE): An algorithm for the validation of image segmentation. IEEE
Trans Med Imaging. 2004;23(7):903-921. doi:10.1109/TMI.2004.828354

10.

Siebert F-A, Hirt M, Niehoff P, Kovács G. Imaging of implant needles for real-time
HDR-brachytherapy prostate treatment using biplane ultrasound transducers. Med
Phys. 2009;36(8):3406-3412. doi:10.1118/1.3157107

180

11.

Schmid M, Crook JM, Batchelar D, et al. A phantom study to assess accuracy of
needle identification in real-time planning of ultrasound-guided high-dose-rate
prostate
implants.
Brachytherapy.
2013;12:56-64.
doi:10.1016/j.brachy.2012.03.002

12.

Batchelar D, Gaztañaga M, Schmid M, Araujo C, Bachand F, Crook J. Validation
study of ultrasound-based high-dose-rate prostate brachytherapy planning compared
with
CT-based
planning.
Brachytherapy.
2014;13(1):75-79.
doi:10.1016/J.BRACHY.2013.08.004

13.

Gillies DJ, Rodgers JR, Gyacskov I, et al. Deep Learning Segmentation of General
Interventional Tools in Two dimensional Ultrasound Images. Med Phys.
2020;47(10):4956-4970. doi:10.1002/mp.14427

14.

Rodgers JR, Hrinivich WT, Surry K, Velker V, D Souza D, Fenster A. A
semiautomatic segmentation method for interstitial needles in intraoperative 3D
transvaginal ultrasound images for high-dose-rate gynecologic brachytherapy of
vaginal
tumors.
Brachytherapy.
2020;19(5):659-668.
doi:10.1016/j.brachy.2020.05.006

15.

Hrinivich WT, Hoover DA, Surry K, et al. Simultaneous automatic segmentation of
multiple needles using 3D ultrasound for high-dose-rate prostate brachytherapy.
Med Phys. 2017;44(4):1234-1245. doi: 10.1002/mp.12148.

16.

Orlando N, Gillies DJ, Gyacskov I, Romagnoli C, D Souza D, Fenster A. Automatic
prostate segmentation using deep learning on clinically diverse 3D transrectal
ultrasound images. Med Phys. 2020;47(6):2413-2426. doi:10.1002/mp.14134

17.

Orlando N, Gyacskov I, Gillies DJ, et al. Effect of dataset size, image quality, and
image type on deep learning-based automatic prostate segmentation in 3D
ultrasound. Phys Med Biol. 2022;67(7):074002. doi:10.1088/1361-6560/AC5A93

18.

Ghavami N, Hu Y, Gibson E, et al. Automatic segmentation of prostate MRI using
convolutional neural networks: Investigating the impact of network architecture on
the accuracy of volume measurement and MRI-ultrasound registration. Med Image
Anal. 2019;58:101558. doi:10.1016/j.media.2019.101558

19.

Litjens G, Toth R, van de Ven W, et al. Evaluation of prostate segmentation
algorithms for MRI: the PROMISE12 challenge. Med Image Anal. 2014;18(2):359373. doi:10.1016/j.media.2013.12.002

20.

Guo H, Kruger M, Xu S, Wood BJ, Yan P. Deep adaptive registration of multimodal prostate images. Comput Med Imaging Graph. 2020;84:101769.
doi:10.1016/J.COMPMEDIMAG.2020.101769

21.

Zeng Q, Fu Y, Tian Z, et al. Label-driven magnetic resonance imaging (MRI)transrectal ultrasound (TRUS) registration using weakly supervised learning for
MRI-guided prostate radiotherapy. Phys Med Biol. 2020;65(13):135002.

181

doi:10.1088/1361-6560/AB8CD6
22.

Chen Y, Xing L, Yu L, et al. MR to ultrasound image registration with
segmentation-based learning for HDR prostate brachytherapy. Med Phys.
2021;48(6):3074-3083. doi:10.1002/MP.14901

23.

Yang X, Fu Y, Lei Y, et al. Deformable MRI-TRUS Registration Using
Biomechanically Constrained Deep Learning Model for Tumor-Targeted Prostate
Brachytherapy. Int J Radiat Oncol Biol Phys. 2020;108(3):e339.
doi:10.1016/J.IJROBP.2020.07.810

24.

Yan P, Xu S, Rastinehad AR, Wood BJ. Adversarial image registration with
application for MR and TRUS image fusion. Lect Notes Comput Sci (including
Subser Lect Notes Artif Intell Lect Notes Bioinformatics). 2018;11046:197-204.
doi:10.1007/978-3-030-00919-9_23/FIGURES/3

25.

Hu Y, Modat M, Gibson E, et al. Weakly-supervised convolutional neural networks
for multimodal image registration. Med Image Anal. 2018;49:1-13.
doi:10.1016/J.MEDIA.2018.07.002

182

APPENDIX A
A.1

Copyright Releases

Permission to reproduce previously published material in

Chapter 2

183

184

185

186

187

188

A.2

Permission to reproduce previously published material in

Chapter 3

189

APPENDIX B

Research Ethics and Health Canada
Approvals

190

191

192

193

194

195

Curriculum Vitae

196

Nathan James Orlando, MSc
Education
2017 – 2022

Doctor of Philosophy in Medical Biophysics
Department of Medical Biophysics
Western University, London, ON, Canada
Supervisors: Aaron Fenster, Ph.D., FCCPM and Douglas Hoover, Ph.D.,
FCCPM
Thesis: Software and Hardware-based Tools for Improving Ultrasound
Guided Prostate Brachytherapy

2017 – 2019

Master of Science in Clinical Medical Biophysics
CAMPEP accredited
Department of Medical Biophysics
Western University, London, ON, Canada

2013 – 2017

Bachelor of Science with Honors: Physics with First Class Honors
Department of Physics
University of Alberta, Edmonton, AB, Canada
Supervisor: Nicola De Zanche, Ph.D., MCCPM
Thesis: SAR Dosimeter for MRI

Publications
Peer-Reviewed Journal Manuscripts (5 First Author, 8 Total)
I. Published (3 First Author, 6 Total)
1. Du Toit C and Orlando N*, Papernick S, Dima R, Gyacskov I, Fenster A. Automatic
femoral articular cartilage segmentation using deep learning in three-dimensional
ultrasound images of the knee. Osteoarthritis and Cartilage Open 4(3), 100290 (2022).
*Co-first Authors.
2. Park C, Xing S, Papernick S, Orlando N, Knull E, Du Toit C, Bax J, Gardi L, Barker K,
Tessier D, Fenster A. Spatially tracked whole-breast 3D ultrasound system toward pointof-care breast cancer screening in high-risk women with dense breasts. Medical Physics
49(6), 3944-3962 (2022).
3. Orlando N, Gyacskov I, Gillies DJ, Guo F, Romagnoli C, D’Souza D, Cool DW, Hoover
DA, Fenster A. Effect of dataset size, image quality, and image type on deep learningbased automatic prostate segmentation in 3D ultrasound. Physics in Medicine and Biology
67(7), 074002 (2022).
4. Zhang C, Hilts M, Batchelar D, Orlando N, Gardi L, Fenster A, Crook J. Characterization
and registration of 3D ultrasound for use in permanent breast seed implant brachytherapy
treatment planning. Brachytherapy 20(1), 248-256 (2021).

197

5. Orlando N and Gillies DJ, Gyacskov I, Romagnoli C, D’Souza D, Fenster A. Automatic
prostate segmentation using deep learning on clinically diverse 3D transrectal ultrasound
images. Medical Physics 47(6), 2413-2426 (2020). (Selected as Editor’s Choice.)
6. Morrish W, West P, Orlando N, Klantsataya E, Gardner K, Lane S, DeCorby R, Francois
A, Meldrum A. Refractometric micro-sensor using a mirrored capillary resonator. Optics
Express 24, 24959-24970 (2016).
II. Under Review (2 First Author, 2 Total)
1. Orlando N, Edirisinghe C, Gyacskov I, Vickress J, Sachdeva R, Gomez JA, D’Souza D,
Velker V, Mendez LC, Bauman G, Fenster A, Hoover DA. Validation of a surface-based
deformable MRI-3D ultrasound image registration algorithm towards clinical
implementation for interstitial prostate brachytherapy. Brachytherapy. Submitted June 15,
2022. Manuscript number BRACHYJOURNAL-D-22-00138.
2. Orlando N, Snir J, Barker K, D’Souza D, Velker V, Mendez LC, Fenster A, Hoover DA.
A power Doppler ultrasound method for improving intraoperative needle tip localization
in interstitial prostate brachytherapy. Medical Physics. Submitted March 28, 2022.
Manuscript number 22-538.

Peer-Reviewed Conference Proceedings (3 First Author, 5 Total)
1. Park C, Papernick S, Orlando N, Jonnalagadda M, Bax J, Gardi L, Barker K, Fenster A.
Toward point-of-care breast cancer diagnosis: validation of a spatially tracked automated
3D ultrasound system. Proc. SPIE 12038, Medical Imaging 2022: Ultrasonic Imaging and
Tomography, 1203804 (2022). (Robert F. Wagner All Conference Best Student Paper
Award runner-up.)
2. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Wireless oscillating device for power
Doppler-based interstitial needle tip identification. Proc. SPIE 11602, Medical Imaging
2021: Ultrasonic Imaging and Tomography, 11602-19 (2021).
3. Papernick S, Orlando N, Park C, Dima R, Gillies DJ, Bax J, Gardi L, Barker K, Appleton
T, Fenster A. Spatially tracked three-dimensional ultrasound imaging for monitoring the
synovial membrane in knee arthritis. Proc. SPIE 11602, Medical Imaging 2021: Ultrasonic
Imaging and Tomography, 11602-13 (2021).
4. Orlando N, Gillies DJ, Gyacskov I, Fenster A. Deep learning-based automatic prostate
segmentation in 3D transrectal ultrasound images from multiple acquisition geometries
and systems. Proc. SPIE 11315, Medical Imaging 2020: Image-Guided Procedures,
Robotic Interventions, and Modeling, 11315-83 (2020).
5. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Power Doppler ultrasound imaging
with mechanical perturbation for improved intraoperative needle tip identification during
prostate brachytherapy: a phantom study. Proc. SPIE 10951, Medical Imaging 2019:
Image-Guided Procedures, Robotic Interventions, and Modeling, 1095131 (2019).

198

News Articles
1. Park C and Orlando N. Improving Internal Radiation Treatment of Cervical Cancer with
3D Imaging. Canadian Cancer Society Research Information Outreach Team (RIOT),
News and Views (2021).

Scholarships
2020-2022

Queen Elizabeth II Graduate Scholarship in Science and Technology
Government of Ontario
Value: $15,000 per year ($30,000 total)

2018-2020

Translational Breast Cancer Research Scholarship
Breast Cancer Society of Canada
Value: $18,000 per year ($36,000 total)

2017-2018

Cancer Research and Technology Transfer (CaRTT) Trainee
CaRTT Strategic Training Program
Value: $18,000

2017-2022

Western Graduate Research Scholarship (WGRS)
Western University
Value: $5,000-$7800 per year ($27,800 total)

2014-2016

Jason Lang Scholarship
Government of Alberta
Value: $1,000 per year ($3,000 total)

2013

University of Alberta Academic Excellence Scholarship
University of Alberta
Value: $2,000

2013

Faculty of Science Academic Excellence Scholarship
University of Alberta
Value: $1,000

2013

Alexander Rutherford Scholarship
Government of Alberta
Value: $2,500

Awards and Honours
2022

First Place Pitch Presentation Award
Imaging Network of Ontario (ImNO) 2022
Imaging for Musculoskeletal Analysis Session
Toronto, ON (Virtual Meeting Due to COVID-19)
Value: $50

199

2022

First Place Pitch Presentation Award
Imaging Network of Ontario (ImNO) 2022
Hardware, Software, and System Development Session
Toronto, ON (Virtual Meeting Due to COVID-19)
Value: $50

2022

Robert F. Wagner All Conference Best Student Paper Award runnerup
SPIE Medical Imaging 2022
San Diego, CA

2021

New Investigator Award Runner-up in Basic Science
New Investigator Scientific Session
Annual Integrative Ultrasound Meeting (AIUM) 2021
Orlando, FL (Virtual Meeting Due to COVID-19)

2021

OICR Rising Stars Poster Award
OICR Translational Research Conference 2021
Toronto, ON (Virtual Meeting Due to COVID-19)
Value: $100

2021

First Place Oral Presentation Award
Imaging Network of Ontario (ImNO) 2021
Machine Learning II Session
Toronto, ON (Virtual Meeting Due to COVID-19)
Value: $250

2020

Second Place in the John R. Cameron - John R. Cunningham Young
Investigators Symposium
2020 Joint AAPM/COMP Meeting
Vancouver, BC (Virtual Meeting Due to COVID-19)
Value: $230

2020

Medical Physics Editor’s Choice
Medical Physics Volume 47, Issue 6, published in June 2020.

2020

Dr. Alfred Jay Award for Translational Research
Department of Medical Biophysics, Western University
Value: $2,000

2019

Selected to present in “Highlights” section for top scoring abstract
submissions
Canadian Organization of Medical Physicists (COMP) Annual Scientific
Meeting
Kelowna, BC

2019

Third Place Oral Presentation Award
London Imaging Discovery Day (LIDD) 2019
London, ON

200

2019

Top Imaging Abstract
Robarts Research Retreat 2019
London, ON
Value: $100

2018

Third Place Poster Award
London Imaging Discovery Day (LIDD) 2018
London, ON

2018

Second Place Poster Award in Advances in structural and
physiological treatment of disease and therapeutic intervention
London Health Research Day (LHRD) 2018
London, ON

2017

The Dean’s Silver Medal in Science
University of Alberta

2016

Departmental Undergraduate Student Research Award (USRA)
University of Alberta
Value: $4,500

2014-2017

Dean’s Honor Roll
University of Alberta

Research Funding
Agency/Program:
Project Title:

Project Role:
Amount:
Funding Period:

London Regional Cancer Program (LRCP) Catalyst Grant for
Translational Cancer Research
Development and Implementation of an Accurate and Efficient MRI-toUltrasound Registration Framework for Focal Dose Escalation in Prostate
Cancer
Co-applicant with Dr. Douglas Hoover (PI), Dr. Lucas Mendez, and Dr.
Aaron Fenster
Value: $10,574
January 1, 2021 - December 31, 2022

Presentations
Invited Presentations (5 First Author, 10 Total)
1. Orlando N. Deep learning prostate segmentation in three-dimensional ultrasound. Invited
oral presentation in the inaugural Institute of Physics (IOP) AI in Medical Physics week
(Virtual). June 20-24, 2022.
2. Fenster A, Park C, Orlando N, Gillies D, Rodgers J. Applications and trends for use of 3D
Ultrasound in image-guided Interventions and point of care diagnostic applications.
Plenary presentation at IEEE International Conference on Imaging Systems & Techniques
(IST), New York, NY, USA (Virtual). August 24-26, 2021.

201

3. Fenster A, Orlando N, Gillies D, Rodgers J. Applications of 3D Ultrasound in Imageguided Prostate and Liver Interventions. Invited presentation at Xidian University, Xi’an,
China. August 23, 2021.
4. Orlando N. A Generalizable and Efficient Deep Learning Algorithm for Automatic
Prostate Segmentation in 3D Ultrasound. 30-minute invited presentation at the Canadian
Association of Physicists (CAP) Congress, Virtual. June 6-11, 2021.
5. Fenster A, Orlando N, Gillies D, Rodgers J. Machine Learning for Improving Ultrasoundguided Interventional Cancer Procedures. Invited oral presentation at 5th International
Caparica Conference on Ultrasonic-based applications from analysis to synthesis,
Caparica, Portugal. May 31-June 3, 2021.
6. Orlando N. Deep Learning Prostate Segmentation in 3D Ultrasound. Invited public oral
presentation in the Machine Learning for Medical Imaging Consortium (MaLMIC) Forum,
Virtual. February 19, 2021.
7. Orlando N. How Artificial Intelligence Can Improve Radiation Therapy for Prostate
Cancer. Invited public oral presentation at RIOT Progress in Cancer Research Symposium,
Virtual. November 14, 2020.
8. Fenster A, Rodgers J, Orlando N, Gillies D, Park C. Development of 3D Ultrasound
Systems for Image-Guided Interventions. Invited oral presentation at 4th International
Caparica Conference on Ultrasonic-based Applications: from analysis to synthesis,
Caparica, Portugal. July 20-23, 2020.
9. Orlando N. Improving Prostate Cancer Radiation Therapy. Invited public oral
presentation at the Kiwanis Club of St. Thomas Golden K, St. Thomas, ON, Canada.
November 26, 2019.
10. Fenster A, Orlando N, Rodgers J, Park C, Gillies DJ. 2D and 3D Ultrasound Devices for
image-guided interventions. Invited oral presentation at BC Cancer Agency Sindi
Ahluwalia Hawkins Centre for the Southern Interior Grand Rounds, Kelowna, BC, Canada.
September 30, 2019. (Group presentation.)

Oral Presentations (15 First Author, 19 Total)
1. Orlando N, Gyacskov I, Gillies DJ, Cool DW, Hoover D, Fenster A. Deep Learning
Prostate Segmentation in 3D Ultrasound and the Impact of Image Quality and Training
Dataset Size. American Association of Physicists in Medicine (AAPM) Annual Meeting,
Washington, DC, USA. July 10-14, 2022.
2. Park C, Papernick S, Orlando N, Jonnalagadda M, Bax J, Gardi L, Barker K, Fenster A.
Toward point-of-care breast cancer diagnosis: Validation of a spatially tracked automated
3D ultrasound system. SPIE Medical Imaging: Ultrasonic Imaging and Tomography, San
Diego, CA, USA. February 20-24, 2022.
3. Orlando N, Snir J, Barker K, Hoover D, Fenster A. A novel wireless mechanical oscillator
for power Doppler-based needle tip identification in brachytherapy. AAPM Annual
Meeting, Virtual. July 25-29, 2021.

202

4. Orlando N, Gillies DJ, Gyacskov I, Romagnoli C, D’Souza D, Hoover D, Fenster A. Deep
learning-based prostate segmentation in 3D ultrasound: a study of dataset size and its
effect on performance. COMP Annual Scientific Meeting, Virtual. June 22-25, 2021.
5. Park C, Papernick S, Orlando N, Jonnalagadda M, Bax J, Gardi L, Barker K, Fenster A.
Development of a spatially tracked three-dimensional ultrasound system for whole-breast
imaging. COMP Annual Scientific Meeting, Virtual. June 22-25, 2021.
6. Orlando N, Gillies DJ, Gyacskov I, Romagnoli C, D'Souza D, Fenster A. An Efficient
Deep Learning Algorithm for Automatic Prostate Segmentation in Three-Dimensional
Ultrasound. Annual Integrative Ultrasound Meeting (AIUM), Orlando, FL, USA (Virtual).
April 10-14, 2021. (Runner-up award for basic science category in New Investigator
Scientific Session.)
7. Orlando N, Gillies DJ, Gyacskov I, Romagnoli C, D'Souza D, Hoover D, Fenster A. Effect
of dataset size and acquisition type on deep learning segmentation of the prostate in 3D
ultrasound. Imaging Network of Ontario (ImNO), Toronto, ON, Canada (Virtual). March
23-24, 2021. (Received award for oral presentation.)
8. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Wireless oscillating device for power
Doppler-based interstitial needle tip identification. SPIE Medical Imaging: Ultrasonic
Imaging and Tomography, San Diego, CA, USA (Virtual). February 14-18, 2021
9. Papernick S, Orlando N, Park C, Dima R, Gillies DJ, Bax J, Gardi L, Barker K, Appleton
T, Fenster A. Spatially tracked three-dimensional ultrasound imaging for monitoring the
synovial membrane in knee arthritis. SPIE Medical Imaging: Ultrasonic Imaging and
Tomography, San Diego, CA, USA (Virtual). February 14-18, 2021
10. Orlando N, Gillies DJ, Gyacskov I, Romagnoli C, D’Souza D, Fenster A. rmU-Net: A
Generalizable Deep Learning Approach for Automatic Prostate Segmentation in 3D
Ultrasound Images. American Association of Physicists in Medicine (AAPM) and
Canadian Organization of Medical Physicists (COMP) Joint Meeting, Vancouver, BC,
Canada (Virtual). July 12-16, 2020. (Second place in the J.R. Cameron - J.R.
Cunningham Young Investigator Symposium.)
11. Orlando N and Gillies DJ, Gyacskov I, Romagnoli C, D’Souza D, Fenster A. A Deep
Learning-based Method for Generalized Prostate Segmentation in 3D Ultrasound.
Imaging Network of Ontario (ImNO), Toronto, ON, Canada (Virtual). March 26-27, 2020.
12. Orlando N, Gillies DJ, Gyacskov I, Romagnoli C, D’Souza D, Fenster A. A Deep Learning
Approach for Automatic Prostate Segmentation in Clinically Diverse 3D Ultrasound
Images. Western Research Forum (WRF), London, ON, Canada. March 19, 2020
(Cancelled due to COVID-19.)
13. Orlando N, Gillies DJ, Gyacskov I, Fenster A. A generalizable deep learning-based
method for automatic prostate segmentation on 3D ultrasound. SPIE Medical Imaging:
Ultrasonic Imaging and Tomography, Houston, TX, USA. February 15-20, 2020.
14. Orlando N, Snir J, Barker K, Hoover D, Fenster A. A power Doppler ultrasound-based
intraoperative needle tip identification method for interstitial brachytherapy. Canadian
Organization of Medical Physicists (COMP) Annual Scientific Meeting, Kelowna, BC,
Canada. September 24-27, 2019.

203

15. Zhang C, Hilts M, Batchelar D, Orlando N, Fenster A, Crook J. Rigid Registration of
Computed Tomography Images and 3D Ultrasound Images for Permanent Breast Seed
Implant Planning Procedure. Canadian Organization of Medical Physicists (COMP)
Annual Scientific Meeting, Kelowna, BC, Canada. September 24-27, 2019. (Selected to
present in “Highlights” section for top scoring abstract submissions.)
16. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Development and validation of a power
Doppler ultrasound method for improved intraoperative needle tip visualization during
high-dose-rate brachytherapy. American Association of Physicists in Medicine (AAPM)
Annual Meeting, San Antonio, TX, USA. July 14-18, 2019.
17. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Use of needle-vibrating device and
power Doppler ultrasound for improved intraoperative needle tip localization. London
Imaging Discovery Day (LIDD), London, ON, Canada. June 12, 2019. (Received award
for oral presentation.)
18. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Development of a power Doppler
ultrasound method for improved intraoperative needle tip localization during interstitial
brachytherapy. Robarts Research Retreat, London, ON, Canada. June 7, 2019.
19. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Power Doppler ultrasound for
improved needle tip visualization during prostate brachytherapy. Western Canadian
Medical Physics Meeting (WesCan), Edmonton, AB, Canada. March 28-30, 2019.

Poster Presentations (19 First Author, 24 Total)
1. Orlando N, Snir J, Barker K, D’Souza D, Velker V, Mendez LC, Fenster A, Hoover D.
Clinical validation of a power Doppler-based needle visualization method in high-doserate prostate brachytherapy procedures. Canadian Organization of Medical Physicists
(COMP) Annual Scientific Meeting, Quebec City, QC, Canada. June 22-25, 2022.
2. Orlando N, Tessier D, Hoover D, Fenster A. Needle Tip Identification in Clinical Power
Doppler Ultrasound Using Induced Vibrations by an Innovative Mechanical Oscillator.
Canadian Association of Physicists (CAP) Congress, Hamilton, ON, Canada. June 5-10,
2022.
3. Orlando N, Du Toit C, Papernick S, Dima R, Gyacskov I, Fenster A. A deep learning
algorithm for automatic cartilage segmentation in three-dimensional ultrasound images of
healthy participants. Imaging Network of Ontario (ImNO), Toronto, ON, Canada
(Virtual). March 22-24, 2022. (Received award for pitch presentation.)
4. Park C, Xing S, Papernick S, Orlando N, Bax J, Gardi L, Barker K, Tessier D, Fenster A.
Spatially tracked whole-breast three-dimensional ultrasound system toward point-of-care
breast cancer screening in women with dense breasts. Imaging Network of Ontario
(ImNO), Toronto, ON, Canada (Virtual). March 22-24, 2022. (Received award for pitch
presentation.)
5. Orlando N, Gyacskov I, Gillies DJ, Romagnoli C, D’Souza D, Hoover D, Fenster A. Deep
learning prostate segmentation in three-dimensional ultrasound: the role of dataset size.
Image-guided Therapeutics & Diagnostics Symposium, University of British Columbia,
Virtual. November 17-18, 2021.

204

6. Park CK, Xing S, Papernick S, Orlando N, Bax J, Gardi L, Barker K, Tessier D, Fenster
A. Whole-breast phantom validation of a spatially tracked 3D ultrasound system for pointof-care breast cancer imaging. Image-guided Therapeutics & Diagnostics Symposium,
University of British Columbia, Virtual. November 17-18, 2021.
7. Park CK, Papernick S, Orlando N, Jonnalagadda M, Bax J, Gardi L, Barker K, Fenster A.
Automatic Spatial Registration System for Whole-Breast Three-Dimensional Ultrasound.
ePoster and live discussion session at AAPM Annual Meeting, Virtual. July 25-29, 2021.
(Interactive ePoster Session for high-scoring abstracts.)
8. Orlando N, Gyacskov I, Gillies DJ, Romagnoli C, D’Souza D, Hoover D, Fenster A. How
does dataset size and diversity influence prostate segmentation performance in 3D
ultrasound? Robarts Research Retreat, Virtual. June 17, 2021.
9. Park CK, Papernick S, Orlando N, Jonnalagadda M, Bax J, Gardi L, Barker K, Fenster A.
Spatially-tracked 3DUS system for whole-breast imaging. Robarts Research Retreat,
Virtual. June 17, 2021.
10. Orlando N, Snir J, Barker K, Hoover D, Fenster A. A wireless oscillator for power
Doppler ultrasound-based needle identification in brachytherapy. Oncology Research and
Education Day, Virtual. June 14-18, 2021.
11. Orlando N, Gillies DJ, Gyacskov I, Romagnoli C, D’Souza D, Hoover D, Fenster A. A
Robust and Efficient Deep Learning Prostate Segmentation Algorithm for 3D Transrectal
Ultrasound Images. London Health Research Day 2021, London, ON, Canada (Virtual).
May 11, 2021.
12. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Power Doppler Ultrasound: A Method
for Improving Needle Tip Identification in Brachytherapy. OICR Translational Research
Conference (TRC), Toronto, ON, Canada (Virtual). March 25-26, 2021. (Received award
for e-poster presentation.)
13. Orlando N and Gillies DJ, Gyacskov I, Fenster A. Deep learning-based automatic prostate
segmentation in 3D transrectal ultrasound images from multiple acquisition geometries
and systems. SPIE Medical Imaging: Image-Guided Procedures, Robotic Interventions,
and Modeling, Houston, TX, USA. February 15-20, 2020.
14. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Improved needle tip visualization in
interstitial brachytherapy using needle vibration. Oncology Research and Education Day,
London, ON, Canada. June 14, 2019.
15. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Power Doppler ultrasound for
improved intraoperative needle tip visualization during prostate brachytherapy. London
Health Research Day (LHRD), London, ON, Canada. April 30, 2019.
16. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Improved Intraoperative Needle Tip
Identification Using Power Doppler Ultrasound. Imaging Network of Ontario (ImNO),
London, ON, Canada. March 28-29, 2019.
17. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Improving needle tip localization in
interstitial prostate brachytherapy using power Doppler imaging. OICR Translational
Research Conference, Toronto, ON, Canada. March 21-22, 2019.

205

18. Orlando N, Snir J, Barker K, Hoover D, Fenster A. Power Doppler ultrasound imaging
with mechanical perturbation for improved intraoperative needle tip identification during
prostate brachytherapy: a phantom study. SPIE Medical Imaging, San Diego, CA, USA.
February 16-21, 2019.
19. Orlando N, Hoover D, Edirisinghe C, D’Souza D, Wong E, Fenster A. An examination of
needle deflection in high dose rate prostate cancer brachytherapy. CARO-COMPCAMRT Joint Scientific Meeting, Montreal, QC, Canada. September 12-15, 2018.
20. Snir J, Orlando N, Patrick J, Surry K, Velker V, Hoover D. Mechanical perturbation
enhanced power Doppler ultrasound imaging for improved intra-operative localization of
interstitial brachytherapy needles. CARO-COMP-CAMRT Joint Scientific Meeting,
Montreal, QC, Canada. September 12-15, 2018.
21. Orlando N, Hoover D, Edirisinghe C, D’Souza D, Wong E, Fenster A. Needle deflection
in high dose rate prostate cancer brachytherapy. Eight-minute e-poster presentation at
London Imaging Discovery Day (LIDD), London, ON, Canada. June 14, 2018. (Received
award for poster presentation.)
22. Orlando N, Hoover D, Edirisinghe C, D’Souza D, Wong E, Fenster A. An examination of
needle deflection in high dose rate prostate cancer brachytherapy. Oncology Research and
Education Day, London, ON, Canada. June 8, 2018.
23. Orlando N, Hoover D, Edirisinghe C, D’Souza D, Wong E, Fenster A. An examination of
needle deflection in high dose rate prostate cancer brachytherapy. Robarts Research
Retreat, London, ON, Canada. June 1, 2018.
24. Orlando N, Hoover D, Edirisinghe C, Wong E, Fenster A. Quantifying needle deflection
in high dose rate prostate cancer brachytherapy. London Health Research Day (LHRD),
London, ON, Canada. May 10, 2018. (Received award for poster presentation.)

Leadership Experience and Academic Service
09/2021 – 04/2022

Co-supervisor – Engineering Co-op Student
Summary: Co-supervised 8-month research co-op at the London Regional
Cancer Program focusing on deep learning prostate segmentation.

09/2021 – 04/2022

CAMPEP Mentor – Medical Biophysics Academic Mentorship
Program
Summary: Responsible for mentoring a one-year CAMPEP MSc student
in the Department of Medical Biophysics.

11/2021 – 12/2021

Organizer – Robarts Professional Development Miniseries
Summary: Part of the organizing committee for a three-part professional
development series featuring Dr. Aaron Fenster.

06/2021

J.R. Cunningham Young Investigator Symposium Co-moderator
COMP 2021
Summary: Co-moderated this marquee session at the COMP 2021
Annual Scientific Meeting.

206

03/2021

Pitch Presentation Co-chair and Judge
ImNO 2021
Summary: Responsible for chairing and judging two pitch presentation
sessions at ImNO 2021.

09/2020 – 08/2021

Mentor - Medical Biophysics Academic Mentorship Program
Summary: Responsible for mentoring a first-year MSc student in the
Department of Medical Biophysics.

01/2020 – 07/2022

Deep Learning Club – Organizing Committee Founding Member
Summary: Founding member of this committee which built and connected
a network of students interested in AI from across Western University.

07/2019 – 07/2021

Robarts Association of Trainees Committee Member
Summary: Elected committee which represents, connects, and advocates
for trainees at the Robarts Research Institute.

01/2019 – 04/2019
12/2019 – 04/2020
02/2021 – 04/2021

Founding member and Academic Coordinator - Medical Biophysics
Undergraduate Research Day Planning Committee
Summary: Helped organize the first three annual Medical Biophysics
undergraduate research conference at Western University.

09/2018 – 08/2021

CAMPEP Student Representative
Summary: One of two peer-elected student members on the CAMPEP
steering Committee.

Teaching Experience
09/2020 – 04/2021
09/2021 – 04/2022

Teaching Assistant – Practical Radiotherapy Physics - BIOPHYS
9672
Course Instructor: Kathleen Surry, Ph.D., MCCPM
Western University

02/2021

Invited Guest Lecturer - Biomedical Applications of Neural
Networks - BIOPHYS 9709
Western University

01/2020 – 05/2020

Pedagogy in Biophysics – BIOPHYS 9674B
Summary: Contributed to the development of a graduate-level course
curriculum titled “Biomedical Applications of Neural Networks”.

10/03/2020

An Introduction to Deep Learning with Keras Tutorial
Summary: 30-minute tutorial introducing deep learning with Keras.

Clinical Experience
05/2018 – 09/2018
09/2019 – 01/2020

Linear Accelerator Mechanical and Output Quality Assurance
London Regional Cancer Program, London, ON, Canada
Supervisor: Rob Barnett, Ph.D., FCCPM
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Independently performed routine mechanical and output quality assurance
measurements for Varian Clinac iX and TrueBeam linear accelerators.

Undergraduate Research Experience
09/2016 – 12/2016

Undergraduate Honors Thesis Project
Title: SAR Dosimeter for MRI
Supervisor: Nicola De Zanche, Ph.D., MCCPM
Summary: Designed and built a dosimeter to independently verify
Specific Absorption Rate (SAR) levels of an MRI system.

05/2016 – 08/2016

Undergraduate Research Assistant
Department of Physics, University of Alberta, Edmonton, AB, Canada
Supervisor: Alkiviathes Meldrum, Ph.D.
Summary: Assisted with the development of a refractometric liquid and
gas sensor using both polymer and silver coated microcapillaries.

Professional Development Experience
09/2017 – 06/2022

Own Your Future Trainee
Summary: Curriculum-based professional development program at
Western University designed specifically for doctoral students.

09/2017 – 08/2018

Cancer Research and Technology Transfer (CaRTT) Trainee
Summary: Training program in cancer biology and treatment which aims
to development partnerships between basic and clinical researchers.

Professional Memberships
2019 – Present

American Association of Physicists in Medicine (AAPM)
Student Member

2018 – Present

Canadian Organization of Medical Physicists (COMP)
Student Member

2021 – 2022

Canadian Association of Physicists (CAP)
Student Member

2019 – 2022

Society of Photo-Optical Instrumentation Engineers (SPIE)
Student Member

